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The Developmental Origins of Health and Disease hypothesis (DOHaD) states that the 
propensity for the eventual development of poor metabolic outcomes can originate in response 
to external influences experienced by the developing fetus in utero. The developmental 
plasticity and subsequent modification of metabolism in response to external factors is believed 
to be both mediated and reflected through epigenetic phenomena such as DNA methylation. In 
line with this general hypothesis, we investigated two prenatal factors - one non-modifiable 
(firstborn status); another modifiable (glucose tolerance) with the DNA methylome within the 
infant birth tissue, umbilical cord, on participants within the GUSTO birth cohort - a unique 
Singaporean sample populace from the three largest Asian ethnic groups (Chinese, Malay and 
Indian). For the first objective, we found parity to be strongly associated with higher maternal 
age, lower socioeconomic status, ethnicity, suboptimal micronutrient status, and increased 
gestational weight gain. An interrogation of the downstream influence of first vs. subsequent 
pregnancies on perinatal methylation identified significant CGI hypomethylation in firstborn 
neonates. In the second objective we found that while both fasting plasma glucose (FPG) and 
2hr post glucose challenge (2hPG) associate with common prenatal factors (maternal age, 
ppBMI, blood pressure), they also correlated with several unique covariates. We also found 
significant differences in the DNA methylation of the genomic locations impacted by FPG as 
opposed to 2hPG. This strongly suggests that the FPG vs. 2hPG dichotomy seen in Type 2 
Diabetes is also reflected in Gestational diabetes (GDM), and can lead to different metabolic 
trajectories in neonates post exposure. Together, the findings from both parity and maternal 
hyperglycemia studies provide global insight into potential epigenetic phenomena which may 
play significant roles within the DOHaD hypothesis.
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can be detected from limited starting material. Infinium 450K methylation array is the most popular 
platform for high-throughput profiling of this mark in clinical samples, as it is cost-effective and requires 
small amounts of DNA. However, this method suffers from low genome coverage and errors introduced 
by probe cross-hybridization. Whole-genome bisulfite sequencing can overcome these limitations but 
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solution to increase the methylome coverage in large sample sets. Here we first demonstrate that MC 
Seq can be employed using DNA amounts comparable to the amounts used for Infinium 450K. Second, 
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Seq and Infinium 450K in terms of coverage, technical variation, and concordance of methylation calls 
in clinical samples. Last, since the focus in EWAS is to study interindividual variation, we demonstrate 
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Abstract 
Prenatal environments and genetic polymorphisms can have a lasting impact on offspring’s metabolic 
function by perturbing its epigenome. We report neonatal epigenome wide association study (EWAS) 
in an Asian mother-offspring cohort (N=987) that interrogates the effects of prenatal environment 
variables, umbilical cord DNA methylation and genetic risk score on birth weight and adiposity up to 4 
years of age. We found 11 prenatal environments including maternal adiposity, height, blood glucose 
and plasma unsaturated fatty acid levels to influence birth weight. We also found an association of birth 
weight with genetic risk scores previously derived from adult weight and BMI measures. Methylation 
levels at 50 CpGs were associated with birth weight, and a subset of these were located in genes and 
miRNA known to be involved in metabolic pathways/disorders in humans and animal model systems. 
Upon interrogation of the influence of environment and genetic factors on these CpGs: 24 CpGs (48%) 
were associated with only environment, 3 CpGs (6%) associated with genotype alone, and 16 CpGs 
(32%) were associated with both environment and genotype. SNPs associated with CpGs were located 
in cis, however the variation in methylation at these CpGs was independent of the genetic risk score. 
Environmental factors associated with variation in methylation at birth were predominantly maternal 
adiposity related (pre-pregnancy BMI, gestational weight gain and maternal glucose levels). Methylation 
levels at half of these CpGs were also associated with offspring size and adiposity in early childhood 
This study provides further evidence that developmental pathways to childhood adiposity begin before 
birth and are influenced by genetic, epigenetic and environmental factors. 
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OBJECTIVE: We investigated the influence of mid-pregnancy maternal glycemia, measured using 
fasting and 2h post 75g oral glucose tolerance test (OGTT), on the fetal DNA methylome. 
 
RESEARCH DESIGN AND METHODS: We conducted an epigenome-wide association study (EWAS) 
with respect to DNA methylation, on the umbilical cords of term, singleton infants from the Growing Up 
in Singapore Towards healthy Outcomes (GUSTO) birth cohort in Singapore. Fasting maternal plasma 
(FPG) glucose concentrations and 2h post 75g OGTT (2-hPG) were collected at 26 weeks gestation. 
Linear regression was used for data analysis with plasma glucose taken as a continuous variable. 
 
RESULTS: The study cohort had 901 eligible mother-infant dyad pairs. While FPG and 2-hPG share 
many similar general covariates (maternal age, ppBMI, BP), they are also correlated with several unique 
(univariate) covariates. After adjusting for potential confounders, we found significant differences 
between the genomic locations impacted by FPG as opposed to 2hPG. Furthermore, within the top 500 
CpGs significantly differentially methylated, only 16 CpGs were shared between FPG and 2-hPG. We 
also managed to replicate significance in several diabetes-related EWAS. 
 
CONCLUSIONS: The findings suggest these two traditionally used indices of gestational diabetes 
reflect unique metabolic trajectories post exposure. 
 
In this paper, I was involved in the analysis and interpretation of data. 
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1.  INTRODUCTION 
1.1 Defining Epigenetics 
Coined in 1942 by Conrad Hal Waddington, epigenetics describes the study of ‘causal mechanisms by 
which the genes of the genotype bring about phenotypic effects’ – or the study of ‘how the genotype 
connects to the phenotype in relation to developmental biology’ (Waddington 1942). Waddington 
illustrates epigenetics with the different phenotypic outcomes of Drosophila melanogaster wing 
morphology, introducing how environmental influences (momentary thermal heat shock) during early 
(pupal) development can lead to phenotypic changes (Waddington 1953). This understanding 
cumulated with the famous Waddington’s landscape (Figure 1.1), a metaphorical illustration of how 
genetic regulation can lead to the markedly different phenotypic outcomes of cellular development. 
Specifically, as cells differentiate, they roll down Waddington’s landscape, commit to separate paths 
based on the various contours along the landscape, ultimately arriving at particular troughs upon 
reaching a fully differentiated state (Waddington 1957). In essence, epigenetic phenomena can be 
described as a change in phenotype without an underlying change in the organism’s genetic sequence. 
 
 





Heritability of epigenetically derived phenotypes beyond a single organismal generation was first 
discovered by Royal Alexander Brink through a series of cross-breeding experiments in Zea mays 
(Brink 1956). Brink found inheritance of pigment colour aleurone (purple or red) in corn kernels to 
violate Mendelian laws of inheritance1, a phenomenon he later termed ‘paramutation’ (Brink 1958). 
Interestingly, though paramutation is rarely described since its discovery and largely limited to plants 
(Chandler and Stam 2004) paramutation-like2 phenomena are beginning to be found in mammalian 
systems in recent years (Rassoulzadegan, Grandjean et al. 2006). Common between Waddington’s flies 
and Brink’s maize was phenotypic changes achieved through either an external environmental factor or 
internal molecular mechanisms did not involve a change in the underlying genetic sequence – epigenetic 
phenomena. 
Exemplifying epigenetic phenomena, one looks to Robert Briggs and Thomas King and  the first 
successful cloning of frogs – Rana pipiens (Briggs and King 1952). The duo transplanted donor nuclei 
from frog eggs at very early (18h post-fertilization) stages of development into activated3 but enucleated 
host eggs resulting in viable frogs. This was followed by another paper demonstrating the increasingly 
unsuccessful transplantability of donor nuclei as time progresses after post-fertilization (King and 
Briggs 1954) suggesting the act of cellular differentiation depressed the potential for successful cloning. 
This technique, somatic cell nuclear transfer (SCNT), is now one of the most famous techniques in 
developmental biology. It becomes obvious that despite identical genetic composition, experimental 
success varied depending on innate mechanisms within the cell, tied to time since fertilization, or 
differentiation status of the cell. 
Following the successful demonstration of increasing post-fertilization failure in donor nuclei 
transplantability by Briggs and King, John Bertrand Gurdon replicated their results on another 
amphibian species, Xenopus laevis (Gurdon, Elsdale et al. 1958), expanding the repertoire of donor 
 
1
 Or as he elegantly describes, ‘departures from the law (of Mendelian heredity)’. 
2
 Classical paramutation involves the direct physical interaction between chromatin arms, Rassoulzadegan et al. 
2006 demonstrates said epigenetic phenomena mediated by RNA, hence, paramutation-like. 
3
 Activated eggs are egg cells which have been previously fertilized by a sperm cell and subsequently enucleated. 
Unfertilized egg cells are not viable and hence not ‘activated’ - .i.e. complete nuclei transferred into an enucleated 
unfertilized egg cell will not develop. 


nuclear differentiation stage and cell types on resultant clone viability ((Gurdon 1960), comparing with 
similar follow-up on Rana pipiens (Briggs and King 1957), (Gurdon 1962)). To allay suspicions that 
the resultant clonal frogs were indeed from the donor nuclei and not a product of failed removal of host 
nuclei, Gurdon used mutant donor nuclei on non-mutant host cells (Gurdon 1962). Gurdon’s work on 
the African clawed toad (Rana pipiens) using SCNT techniques eventually won him the Nobel Prize 
for Medicine in 20124. By the transplantation of adult somatic toad cells into unfertilised egg cells, 
Gurdon managed to push fully differentiated cells from the bottom of Waddington’s landscape, all the 
way back to the top, where they can then fully develop into a toad again. 
Wherein the work of Waddington, Brink and Gurdon demonstrate how certain factors, both intrinsic 
and extrinsic, influence the phenotype through epigenetic mechanisms – context-dependent epigenetic 
modifications, organisms also can inherit phenotypes from parental origins epigenetically. One form of 
such an epigenetic inheritance is genomic imprinting. The importance of parent-of-origin sources of 
germ cells was pioneered by Azim Surani5, postulating the mechanism in which this could be mediated 
– DNA methylation (Barton, Surani et al. 1984, Surani, Barton et al. 1984, Reik, Collick et al. 1987, 
Surani, Barton et al. 1987). In essence, because the offspring receives two copies (alleles) of the genome 
(one from each parent), imprinting serves to ensure only one allele gets expressed (dosage 
compensation) in a parent-specific manner. Genomic imprinting, although lying within a distinct 
category of germline-dependent epigenetic modification – whereby the epigenetic modification is 
incorporated into the germline distinct from imprinting mechanisms (Crews and Gore 2014). 
 
4
 While it is interesting to speculate the Nobel Committee’s decision to award Gurdon with the Nobel Prize in 
2012 for his work on ‘the discovery that mature cells can be reprogrammed to become pluripotent’, it is worth 
noting that both Briggs and King passed away in the year 1983 and 2000 respectively. Nobel Prizes are not 
awarded posthumously.  
5
 Incidentally Azim’s PhD supervisor was Robert Edwards – who did a post-doctoral stint in Conrad Waddington’s 




Figure 1.2 Extent of intergenerational environmental influence. Environmental exposure on the F0 generation (a 
pregnant female organism or parental male) can directly influence up to two subsequent generations (F1: sex cells 
of the F0 and fetus of the pregnant F0 female; and F2: sex cells in the fetus of the pregnant F0 female). Hence, only 
environmental influences on the F0 which lead to phenotypic changes extending beyond the F2 for females and F1 
for males (after restoration F1 and beyond) can be considered transgenerational. Images modified from 
healthline.com 
 
Beyond the parental organism, epigenetic inheritance via genomic imprinting can conceivably result in 
direct phenotypic changes from the F0 generation to the F1 generation, however, intergenerational 
epigenetic effects due to environmental influences are less obviously reflected (Figure 1.2). Through 
the female, events which influence mammalian pregnancies in the F0 can directly influence the F1 (fetus 
within the mother) as well as the F2 generation (germ cells of the fetus within the mother). Through the 
male, environmental influence extends only to the F1 generation through the germ cells of the F1 
mammal developing within the F0 uterus. Hence, environmental influences affecting phenotypes 
extending to the F2 generation via the female, of F1 generation via the male can only be termed 
intergenerational. Truly transgenerational6 propagation of non-genetic-based phenotypes has to traverse 
beyond the immediate intergenerational successions, F2 in the female lineage; F1 in the male lineage 
(Heard and Martienssen 2014). Hence for context-dependent epigenetic modifications to extend beyond 

6
 ‘Trans-‘ is a prefix meaning “beyond” and “changing thoroughly”. So it seems more appropriate to define it as 
such. Some books/papers define transgenerational as “effects passing from one generation to the immediate 
successive generation” – this seems inappropriate. 
	

intergenerational effects, repeat exposures becomes necessary. Alternatively, removal of the 
environmental influence should restore the resultant phenotype beyond intergenerational successions. 
It is thus argued that only germline-dependent epigenetic modifications have the potential for 
transgenerational inheritance whereas context-dependent epigenetic modifications can only have 
intergenerational influences (Crews and Gore 2014).  
 
1.2 Aetiology of Epigenetic Inheritance 
1.2.1 Transgenerational Inheritance  
Very few cases of bona fide transgenerational epigenetic inheritance found in animals to date, most 
found within the model organism Caenorhabditis elegans. Loss of fertility is inherited in the spr-5 C. 
elegans strain, a mutant which lost the lysine-specific histone demethylase 1A (LSD1/KDM1) enzyme 
– losing the ability to demethylate a specific histone modification, histone 3 lysine 4 dimethyl 
(H3K4me2). Such double knock-out mutants produce progressively diminishing brood sizes with 
increasing generation number as well as exhibiting increasing degrees of sterility within their offspring, 
significant7 after approximately the 20th generation (Katz, Edwards et al. 2009). Indeed, H3K4me2 
marks do accumulate progressively in such mutants (Nottke, Beese-Sims et al. 2011), which was 
attributed to misregulation of genes associated with germline development. Interestingly the 
deteriorating phenotype was rescued upon introduction of a single wild type copy (generation 28), 
reverting the organism back to its usual fertility after just one generation thereafter (Katz, Edwards et 
al. 2009). Notably, such genetic mutants act through histone modifications (accumulation of H3K4me2 
marks) within the germline cells, thus can properly be classified as a germline-dependent epigenetic 
event. 
Less persistent yet equally impressive is the inheritance of longevity within wdr-5(ok1417) and set-
2(ok952) mutants – both wdr-5 and set-2, together with ash-2 form a lysine-specific histone 
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methyltransferase, converting H3K4me2 to H3K4me3. Introduction of ash-2 RNAi in the F0 generation 
to these C. elegans mutants resulted in increased longevity which lasted until the F3 generation (Greer, 
Maures et al. 2011). Similar to the male mammalian system, C. elegans possess primordial germ cells 
existing concurrently with somatic daughter cells during embryogenesis, but do not further extend its 
influence on subsequent generations thereafter, hence transgenerational effects are those which extend 
beyond the F1 generation. Expectedly such mutations are shown to act through the germline (Greer, 
Maures et al. 2011), intriguingly through similar epigenetic but dissimilar gene expression pathways 
from that of Katz et al. (2009). 
Environmental stress such as heat or osmotic shock during early embryogenesis have also been shown 
to induce transgenerational inheritance of certain phenotypic traits. In Drosophila melanogaster, such 
stress resulted in modified eye colour (differing pigment production) and wing morphologies lasting up 
to F5 (Seong, Li et al. 2011)8. Both types of stress were shown to induce the phosphorylation of 
drosophila activation transcription factor 2 (dATF-2), releasing it from heterochromatin. This disrupted 
heterochromatin resulted in phenotypes which were heritable across generations, its effect weakening 
with progressive successions, corresponding to the state of chromatin in those generations. Seong et al. 
also established that both timing and strength of environmental insult is critical to achieve the desired 
phenotypic result although concede that the exact mechanisms establishing this critical window of 
development remains elusive. 
Evidence of transgenerational epigenetic inheritance in vertebrates is even scarcer, with perhaps the 
exposure of the fungicide vinclozolin to rats in utero (Anway, Cupp et al. 2005) being the most well 
documented. Introduction to such an environmental toxin during the critical period of development in 
gonadal sex determination of pregnant Sprague-Dawley and Fisher rats was shown to reduce 
spermatogenic capacity in subsequent male offspring9. However the same effect was not observed when 
Wistar and Long-Evans rats were used (Schneider, Kaufmann et al. 2008). Although Schneider et al. 
(2008) concede genetic variation could have resulted in different susceptibilities to the toxin, they pretty 
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much heavily critiqued both result and methodology of Anway et al. (2005), casting many doubts on 
the validity of their results. Notably10, Schneider et al.’s paper was funded by a chemical company 
producing vinclozolin (BASF) and Anway et al. produced an erratum in 2010 clarifying certain 
experimental protocols but to date Anway et al.’s article and its scientific conclusions still stand. 
1.2.2 Human Cohorts  
There are no cases of transgenerational epigenetic modification-induced phenotypes definitively shown 
in humans. Most obviously, human experimentation is unethical. Secondly, limited to observational 
studies, the most well-studied environmental modification-induced phenotype would be prenatal famine 
exposure (Lumey, Stein et al. 2011). Such studies suffer from two major limitations; first, just as many 
observational studies claim to demonstrate transgenerational epigenetic effects only to fail this thesis’ 
criteria for transgenerational, most human cohorts also lack the successive depth to show phenotypic 
effects beyond the intergenerational. Secondly, those human cohorts which do possess historical depth, 
lack the numerical power and depth of phenotypic data to definitively support their claims. The most 
prolific historical human cohort studied to date has to be the Dutch Hunger Famine Cohort (Lumey, 
Stein et al. 2007). People residing within western Netherlands under Nazi occupation during the last six 
months of World War II (October 1944 – May 1945), were subject to harsh food restrictions in response 
to their support for the allies during the war. Although many populations and communities suffered 
severe famine during times of hardship, the Dutch cohort of 1944-45 were the preferred case study for 
researchers as many dimensions of the famine were elaborately documented – including official food 
rations allotted to the residents, as well as government records of health and birth records encompassing 
measures of fetal growth and cause-specific infant mortality statistics. Moreover, this population had a 
natural control – the other half of the country not exposed to the famine, liberated by the Allied forces 
prior to the Winter of 1944 (Stein, Susser et al. 1975).  
Nevertheless, even within the context of the Dutch Hunger Famine Cohort, studies rarely evaluate 
dietary restriction during embryonic development on its effect beyond the F1 generation. Nevertheless, 
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this singular event generated studies showing altered physiologies and metabolisms in affected 
individuals – and that both the timing of exposure in context of gestation, and gender of the infant were 
relevant. In females, instead of a usually increasing relationship between birthweight and parity (Karn 
and Penrose 1951), in utero famine exposure resulted in F1 mothers producing children with decreasing 
birthweight with increasing parity (Lumey and Stein 1997). Differences also were observed in body fat 
deposition by the age of 59 but only in affected females but not males (Stein, Kahn et al. 2006). This 
change in metabolism was also reflected by elevated serum total cholesterol and triglyceride levels, 
again only in affected females (Lumey, Stein et al. 2009). In males, exposure in the last trimester of 
gestation and first few months of life resulted in significantly reduced obesity in F1 19-year-old men, 
but significantly elevated obesity rates if the men were exposed to the famine within the first two 
trimesters of gestation (Ravelli, Stein et al. 1976)11.  Males also had slightly elevated risk of developing 
hypertension upon middle-age, but in utero exposure increased the odds in both genders as compared 
to their siblings and the general population (Stein, Zybert et al. 2006). Notably both genders had had 
differences in energy balances and diet preferences as compared to non-affected siblings, however the 
extent (significance) of such differences varied depending on the reference population used (Stein, 
Rundle et al. 2009). Also notable were the lack of relationships found between prenatally exposed 
individuals with cognitive ability (Groot, Stein et al. 2011), cardiovascular risk (Lumey, Martini et al. 
2012) and DNA methylation in repeat elements (Lumey, Terry et al. 2012)12.  
Complementing the Dutch Hunger Famine Studies is the Overkalix cohort studies – investigating the 
effects of both food abundance and poor harvests on subsequent mortality. Utilising historical records 
and statistical estimates of harvests, food availability, mortality and childhood circumstances from a 
local community in northern Sweden, Lars Olov Bygren and his collaborators investigated the effects 
of food supply on subsequent generations’ mortality. These studies found a positive correlation between 
paternal grandfather’s food abundance and shortage during mid-childhood (age 9-12) and grandson (F2) 
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 Despite a title claiming “global DNA methylation”, analysis was restricted to LINE-1 (long interspersed 
nucleotide element 1) and Sat2 (satellite 2 DNA sequence).  
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general mortality risk13, paternal grandmother’s food abundance during mid-childhood (age 8-10) and 
granddaughter (F2) general mortality risk (Pembrey, Bygren et al. 2006). In particular, there were 
positive correlation between paternal grandfather’s/father’s (but not through the maternal lineage) food 
abundance during mid-childhood (age 9-12 for boys, 8-10 for girls) and F1/F2 cardiovascular and 
diabetes-linked mortality (Kaati, Bygren et al. 2002). Large fluctuations in food supply within this mid-
childhood period further aggravated the risk of cardiovascular mortality, but this association was only 
demonstrated in F2 females through their paternal grandmothers (Bygren, Tinghog et al. 2014). Further 
studies reinforced the links between paternal mid-childhood food shortage and reflected novel 
associations with maternal mid-childhood food abundance and a reduction in the immediate subsequent 
generation’s (F1) cardiovascular mortality risk (Bygren, Kaati et al. 2006, Kaati, Bygren et al. 2007). 
Despite very small sample sizes (approximate 100 individuals) Bygren’s studies are unique in that they 
are the only studies on human cohorts to date that suggest genuine transgenerational environment-








 1.3 Heterokairy 
The malleability of an organism’s physiological response to heterokariotic events adds complexity to 
the aetiology of epigenetic inheritance. Coined in 2002, heterokairy is derived from the greek root words 
‘Hetero’ (meaning different) and ‘Kairosis’ (at the right time) (Spicer and Burggren 2003). It is defined 
as ‘plasticity in the timing of the onset of developmental events at the level of an individual during its 
development14’. Formulated to distinguish the processes of heterochrony – a term used in evolutionary 
biology describing developmental events across generations, against processes of developmental 
plasticity within a single generation, phenotypic changes in direct response to the exposome fall 
squarely under this definition. A straightforward example of this is the presence of a predator 
(exposome) stimulating the accelerated hatching of red-eyed tree frogs (phenotypic response within a 
single generation) at the expense of delayed gill regression (developmental process) (Warkentin 2007). 
In the article coining heterokairy, Spicer and Burggren used the example of how a particular abiotic 
exposure can influence the development of Artemia, or brine shrimp. Brine shrimp develop respiratory 
regulation mechanisms, which allow the maintenance of oxygen uptake within a sizable oxygen tension 
(hypoxic) bandwidth, concurrently with the formation of functional gills and heart (Varo, Taylor et al. 
1991). Exposure to hypoxic environments (exposome) prior to this development however, accelerated 
the development of this respiratory regulation (as measured from oxygen intake) before the formation 
of functional gills and heart, at the expense of individual lifetime reproductive output (Spicer and El-
Gamal 1999)15.  
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Figure 1.3 Effects of various hormone supplements (agent) at specific exposure intervals during pregnancy (week 
of gestation) and the corresponding reported degree of hypospadias (position of meatus). Adapted from 
(Gluckman and Hanson 2005)16. 
 
Heterokairy alludes to a greater concept known as ‘critical windows of development’ very briefly 
mentioned earlier. First defined in context of embryology, ‘critical windows of development’ refer to 
specific timeframes within an organism’s ontogenesis, for example, the initial development of a certain 
organ, which when perturbed, result in ‘decided injuries to this particular organ, while only slight or 
no ill effects may be suffered by the embryo in general’ (Stockard 1921). In particular, heterokairotic 
responses to the exposome during critical windows of development can be graded (Figure 1.3). For 
example, during embryonic development, all human fetuses are by default morphologically female. 
However, seven weeks into gestation, the male fetal testis secretes testosterone which directs the 
development of the fetus’ penis. This stimulates the maturation of the male penis – a process which is 
completed by the twelfth week of gestation (Moore 1985). Mothers exposed to progestogenic steroids 
(usually prescribed by gynaecologists as a drug to reduce the risk of miscarriages) increase the risk of 
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their male offspring’s of developing hypospadias, or the opening of the urethra under the penis rather 
than at the tip. Figure 1.2 illustrates the relationship between the exposure during gestation to the 
ultimate degree of hypospadias in the male offspring – the earlier the reported drug exposure, the nearer 
the urethral opening ends up to the base of the penis. Here, Gluckman and Hanson also note that drug 
exposure after a certain window (in this case the twelfth week of gestation) would have no effect on 
penile development anymore (Gluckman and Hanson 2005). 
Since most critical windows of development occur during embryogenesis, severe changes in the fetal 
exposome can result in permanent alteration of the fetal physiological trajectory. Examples of such 
severe changes include antenatal nutrient deprivation of the Dutch Hunger Famine Cohort or antenatal 
nutrient abundance of the Overkalix Cohort previously mentioned (Section 1.2.2). Graded phenotypic 
responses to changes in the exposome (in this case antenatal nutrient deprivation) is especially evident 
in the Dutch Hunger Famine Cohort, where different famine exposures with respect to pregnancy 
trimesters result in varying susceptibilities to obesity (Ravelli, Stein et al. 1976), diseases such as 
hypertension (Stein, Zybert et al. 2006) and even metabolic responses (Stein, Kahn et al. 2006, Lumey, 
Stein et al. 2007). The importance of the antenatal environment on the future growth trajectory of the 
offspring lead to the “fetal origins of disease” hypothesis wherein “process(es) whereby a stimulus or 
insult at a critical period of development has lasting or lifelong effects” is described as “fetal 
programming” (Barker 2000). Successive impactful heterokairotic events thus, can conceivably drive 





Figure 1.4 Hypothesis of how the timing of environmental stressors (exposome) potentially influences the growth 
trajectories of a developing embryo with respect to stage of development. Adapted from (Burggen and Reyna 
2011). 
 
Singular heterokariotic responses however, do not necessitate permanent physiological consequences. 
Changes in the exposome is both time and dosage specific to any particular critical window of 
development to elicit significant changes in the organism’s growth trajectory (Figure 1.4) – it follows 
that the inherent phenotypic plasticity of an organism to specific exposomic changes is simply reduced 
during critical windows of development. In other words, organisms are more sensitive to exposomic 
change during critical windows of development, which mostly reside within embryonic development. 
Chickens exposed to transient hypoxic environments from day 6 to 19 of incubation17 had significantly 
reduced body weight than control chickens 3-4 weeks post-hatching, as well as endothelial dysfunction 
(Ruijtenbeek, Kessels et al. 2003). The same group then published another paper showing no significant 
changes morality, body weight at hatching or up to 15 weeks post-hatching using the same chronic 
moderate hypoxia treatment on a separate set of chickens (Ruijtenbeek, Kessels et al. 2003). A third 
paper establishes that there is indeed significant body weight differences upon hypoxic treatment at 
embryonic day 19 (Villamor, Kessels et al. 2004). They attribute the non-significant body weight 
difference at hatching to catch up growth in the last two days of normoxia, pointing out that 
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physiological changes in arterial development does not necessitate a reduction in birth weight 
(Ruijtenbeek, Kessels et al. 2003). This phenotypic plasticity within heterokaryotic responses is 
reminiscent of the catch up growth phenomena in humans, whereby infants born smaller experience 
accelerated growth parameters within the first 2 years of life and eventually ‘catch-up’ in terms of 
weight to their normal birthweight counterparts (Ong, Preece et al. 2002).  
 
1.4 DNA Methylation 
Wherein the organism’s genome govern the malleability of phenotypic plasticity, the ultimate 
phenotypic manifestation in response to the organism’s exposome is strongly suggested to be directed 
by epigenetic mechanisms (Bird 2002). As can be inferred from the thesis so far, there are four major 
molecular mechanisms governing epigenetics: chromatin interactions (e.g. paramutation), RNA, 
histone modifications and DNA methylation (Naumova and Dekker 2010). Through these molecular 
mechanisms, individual cells progress down Waddington’s landscape, each possessing increasingly 
unique gene expression profiles as they differentiate into various cell lineages. Although cross-talk is 
frequent between various mechanisms (Zhang and Pradhan 2014), to simplify discussions, this thesis 
shall focus on DNA methylation as the medium for epigenetic phenomena. 
DNA methylation typically refers to the covalent attachment of a methyl group from S-adenyl 
methionine (SAM) to the fifth carbon of the cytosine residue on the DNA nucleoside of an organism’s 
genome (5mC), mediated by DNA methyltransferase enzymes (Wu and Santi 1985). In vertebrates, 
majority of the chemically modified nucleotide is succeeded by a guanine nucleotide, or in CpG sites 
(Ehrlich, Gama-Sosa et al. 1982). The phenotype-modifying effects of DNA methylation were first 
discovered in bacteria by McCarty and Avery (McCarty and Avery 1946) but only chemically identified 
two years later by Rollin Hotchkiss (Hotchkiss 1948). However, its role in mammalian systems 
regulating gene expression and cell differentiation was only demonstrated almost 30 years after its 
discovery (Holliday and Pugh 1975, Compere and Palmiter 1981). That is perhaps unsurprising 
considering both model organisms used in early epigenetic research, Caenorhabditis elegans (Simpson, 
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Johnson et al. 1986) and Drosophila melanogaster (Urieli-Shoval, Gruenbaum et al. 1982), lack 
detectable18 levels of cytosine (CpG) methylation. However, whilst the C. elegans genome does not 
encode conventional DNA methyltransferase (Hung, Karthikeyan et al. 1999), Drosophila possess 
DNA-methyltransferase-like genes (Tweedie, Ng et al. 1999) and DNA methylation exists mostly in 
CpT rather than CpG (Lyko, Ramsahoye et al. 2000). Vertebrates on the other hand, have the highest 
levels of methylated cytosines in the animal kingdom (Bird 2002). 
1.4.1 Genomic Characteristics 
CpG dinucleotides represent just under a percent of all nucleotides within the human genome19, with 
70-80% of CpG dinucleotides methylated in relatively stable patterns (Bird 2002). Only 21.8% of 
autosomal CpGs are dynamically regulated within normal development and most of which are distal to 
transcription start sites (Ziller, Gu et al. 2013). High 5mC levels found within gene bodies are associated 
with increased gene expression, first discovered in the active X-chromosome (Hellman and Chess 
2007), then in mitotically-active cells (Ball, Li et al. 2009). Notably this association was not found in 
slow or non-dividing cells (Xie, Barr et al. 2012). Interestingly, 5mC possess elevated mutagenic 
potential compared to unmodified nucleotides, capable of spontaneously deaminating to thymine 
(Coulondre, Miller et al. 1978). Cytosines can also be methylated in non-CpG sites in mammalian 
systems (Ramsahoye, Biniszkiewicz et al. 2000), mostly in CpA, which can be found in significant 
proportions in mouse and human embryonic stem cells but are lost in mature tissues (Lister, Pelizzola 
et al. 2009) except in murine frontal cortex (Xie, Barr et al. 2012). Unlike in gene bodies, most CpG 
methylation elsewhere in the genome however, is mainly associated with gene silencing (Holliday and 
Pugh 1975). This association holds true in promoters and even up to the first exon (Brenet, Moh et al. 
2011). Of particular interest are CpG islands, or CGIs – regions of about 1 kilobases in length within 
the genome with higher CpG densities but are usually unmethylated (Bird, Taggart et al. 1985) – and 
its immediate nearby flanking regions. 
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Specifically, CpGs within CGIs are defined to be ‘Individual CpGs that lie in regions of DNA at least 
200bp in length, having a GC ratio > 50% and an observed-to-expected CpG ratio > 60%’ wherein the 
‘observed-to-expected CpG ratio’ is calculated by the population of CpGs divided by the product of the 
number of cytosines and guanines, multiplied by the total number of nucleotides in the genome 
(Gardiner-Garden and Frommer 1987). These genomic regions are usually unmethylated at all stages 
of development in all tissue types (Antequera and Bird 1993), positioned at the 5’ ends of many genes 
(Bird 1987), with approximately 70% of known gene promoters lying within CGI regions (Saxonov, 
Berg et al. 2006). In fact, about half of CGI regions contain known transcription start sites, yet lack 
other promoter elements such as TATA boxes (Carninci, Sandelin et al. 2006). CGIs also contain less 
nucleosomes than other regions of the genome (Tazi and Bird 1990). Unsurprisingly, CGI sequences, 
especially those associated with promoters, are highly conserved in mammalian systems (Illingworth, 
Gruenewald-Schneider et al. 2010). Nevertheless, a small but significant proportion of CGIs do undergo 
differential methylation during gametogenesis and early embryonic development (Caspary, Cleary et 
al. 1998), including regions associated with imprinting (Kantor, Kaufman et al. 2004). CGIs have tissue-
specific patterns of DNA methylation, and methylation usually results in stable silencing of associated 
genes (Mohn, Weber et al. 2008).  
Flanking CGIs are CpG Shores, regions 0-2 kilobases (kb) from CGIs (Irizarry, Ladd-Acosta et al. 
2009). Although methylation of CpG shores, as with CGIs, correlate strongly with gene silencing, CpG 
shores have highly conserved tissue-specific DNA methylation patterns – unlike the uniform nature of 
CGIs (Irizarry, Ladd-Acosta et al. 2009). Expectedly, they are also the most variably methylated 
genomic regions (Ziller, Gu et al. 2013). The superficially arbitrary boundary delimited by Irizarry et 
al. in a biologically relevant region in the genome so variably methylated probably resulted in the 
mushrooming plethora of nomenclature in nearby or related regions. Chronologically, ‘CpG Shelves’, 
regions 2-4 kb from CGIs (Bibikova, Barnes et al. 2011, Sandoval, Heyn et al. 2011)20; ‘open sea’, 
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Naming rights of CpG shelves was then claimed by Bibikova et al. (2011), who published (and submitted) later 
than Sandoval et al. (2011). 
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regions which are not CGIs, shores or shelves (Sandoval, Heyn et al. 2011); ‘CpG Valleys’, 
hypomethylated regions at least 5 kb long21 with an average methylation of 30% or less (Xie, Schultz 
et al. 2013) – which may or may not contain CGIs22; ‘CpG Canyons’, also hypomethylated regions, 
regions at least 3.5 kb in length with an average methylation of  10% (Jeong, Sun et al. 2014) – 90% 
of which contain CGIs and their concomitant shores; and the latest to the collection, ‘CpG Ravines’, 
‘ultrastable’ CGIs which are consistently hypomethylated flanked by hypermethylated shores and 
shelves (Edgar, Tan et al. 2014). Unsurprisingly, most of these ascribed regions (valleys, canyons, 
ravines) were enriched in genes for transcription regulation, homeobox proteins and development, and 
have high sequence conservation across mammals23 – as do CGIs (Carninci, Sandelin et al. 2006, 
Saxonov, Berg et al. 2006). Since the determination of valleys, canyons and ravines possess an 
experimental component (through cell lines no less) and overlap with CGIs, shores and shelves to 
various degrees, until further establishment of their definitions, this thesis shall adopt more well-defined 




 Comparison for hypomethylation was done between a human embryonic stem cell (hESC) line and 
differentiated cell lines from the original hESC. More importantly, determination of precise regions (much less 
exact definition) was not elaborated within the paper beyond ‘by examining all continuous hypomethylated 
regions’. 
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1.4.2 Molecular Function 
As DNA methylation is mostly associated with gene silencing, 5mC are thought to repress irrelevant 
transcription, mainly from retroviral elements (Bird 1995). Such genomic parasites can replicate and 
randomly insert copies of themselves into the genome, causing potentially harmful mutations (Wu, 
Rinchik et al. 1997). Unsurprisingly, reduced DNA methylation within such elements resulted in 
increased expression (of Long Interspersed Nuclear Elements – LINEs (Woodcock, Lawler et al. 1997) 
and Short Interspersed Nuclear Elements – SINEs (Liu, Maraia et al. 1994)). Another retroviral element, 
intracisternal A particle (IAP) – the most aggressive retrovirus in the murine genome, is heavily 
methylated throughout the lifespan of the mouse. It is thus hypothesized that DNA methylation acts to 
silence these elements, or even mutate them due to deamination of 5mC, deactivating them permanently 
(Walsh, Chaillet et al. 1998). However, demonstrating the importance of other epigenetic mechanisms, 
repression might not be achieved solely through DNA methylation. Alu elements – the most abundant 
subset of the SINE family (Smit 1999), can be activated by stress without a change in DNA methylation 
levels (Liu, Chu et al. 1995). Moreover during murine development, retroviral elements become 
unmethylated during gonadal proliferation (Walsh, Chaillet et al. 1998), resulting in them becoming 
transcriptionally active (Bird 1997). 
Apart from retroviral elements (Walsh, Chaillet et al. 1998), other genomic features exhibit higher 
tendencies for de novo establishment of 5mC such as high GC content (Scrable and Stambrook 1997)24, 
high copy numbers (Garrick, Fiering et al. 1998) and repetitive elements (Mummaneni, Bishop et al. 
1993). Short TpA-rich genomic segments have also been shown to induce methylation albeit only in a 
fungal system (Neurospora) (Miao, Freitag et al. 2000). In the case of imprinted genes, imprinting boxes 
recruit non-coding RNAs which then leads to DNA methylation (Tremblay, Duran et al. 1997, Shemer, 
Hershko et al. 2000).  
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of CGIs remain unmethylated. 
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Another theory regarding the function of 5mC is to maintain the silencing of genes which have been 
previously silenced by other epigenetic mechanisms. Several examples of gene silencing preceding 
DNA methylation exist. Experimentally, Gautsch and Wilson observed repression of retroviral 
transcription in tetracarcinoma cells two days after infection but de novo methylation of the genome 
was only seen 15 days later (Gautsch and Wilson 1983). In the X chromosome, not only does the 
activation of the Xist gene and X inactivation precede CGI methylation by several days (Keohane, 
O'Neill et al. 1996), genes on the X-chromosome such as phosphoglycerate kinase are silent before its 
CGI promoters are methylated (Lock, Takagi et al. 1987). These suggest a mechanism prior to DNA 
methylation marking a particular genomic region for silencing, following which leads to establishment 
of 5mC in that region. In 2000, Wutz and Jaenisch demonstrated X inactivation resulting from 
expression of Xist transgene in embryonic stem cells can be reversed when the Xist gene is inactivated. 
However, if Xist was inactivated three days after X inactivation, X inactivation becomes irreversible 
(Wutz and Jaenisch 2000), attributed to all layers of epigenetic regulation – RNA, histone modifications 
and DNA methylation (Csankovszki, Nagy et al. 2001). Hence, Adrian Bird25 postulates that the failure 
of gene transcription promotes de novo methylation in associated genomic regions (Bird 2002). 
Developmentally, cellular lineages are postulated to be established from the loss or lack of 5mC in 
select genomic regions, leading to proper activation of lineage-specific genes (Walsh and Bestor 1999). 
Premature activation of genes during development can occur if Dnmt1, the enzyme responsible for 
methylating cytosines, is inhibited (Stancheva and Meehan 2000). Unsurprisingly, Dnmt1 deletion 
(murine somatic cell lines) leads to widespread gene activation – including genes only normally 
expressed in terminally differentiated cells (Jackson-Grusby, Beard et al. 2001). The capacity of the 
genome to delay 5mC suggests the presence of other genetic (Siegfred, Eden et al. 1999) and epigenetic 
machineries initialising cell-specific lineages, whilst DNA methylation perpetuates the silenced 




 Discoverer of CGIs, and author of many papers on DNA methylation. 
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1.4.3 Mammalian Embryogenesis 
The DNA methylome during the inception of embryogenesis (preimplantation) has been investigated 
in several mammalian systems such as cows, rats and pigs (Dean, Santos et al. 2001), but the evolution 
of this methylome across embryonic development has been most comprehensively investigated only 
within the murine animal model (excellently reviewed in (Seisenberger, Peat et al. 2013), and 
(Messerschmidt, Knowles et al. 2014)26). Presumably for ethical and technical limitations, there does 
not seem to be studies on how the DNA methylome of humans evolve throughout embryonic 
development. Although differences in distribution exist, the DNA of mature mammalian sperm cells 
are highly methylated ((Howlett and Reik 1991), (Wermann, Stoop et al. 2010)27. However, wherein 
mice oocytes have a slightly under 50% global methylation (Smallwood, Tomizawa et al. 2011), human 
oocytes have near baseline global methylation levels28 (Wermann, Stoop et al. 2010). Due to limited 
knowledge on other animal models (as well as in humans), henceforth this section discusses events 
known in the murine system unless otherwise stated. 
Incipient to zygotic formation, the paternal genome is subjected to two rounds of active, global 
demethylation. The first occurs before DNA replication (Mayer, Niveleau et al. 2000); the second starts 
concurrently but finishes prior to the completion of DNA replication (Wossidlo, Arand et al. 2010). 
Specifically, Wossidlo et al.’s high resolution staged bisulphite analysis demonstrated noticeable 
demethylation pre-replication but significant demethylation during S-phase. Since no direct 
demethylase enzyme has been found, active demethylation is suggested to be due to 5mC conversion 
to 5-hydromethylcytosine (5hmC) by a TET (Ten-eleven translocation) enzyme (Tahiliani, Koh et al. 
2009). TET enzymes can also catalyse the conversion to 5hmC to 5-formylcytosine (5fC) and 5-
 
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 Obviously several excellent reviews exist. Here two of the more comprehensive reviews are highlighted – the 
first from Wolf Reik’s laboratory – Reik was a PhD student under Rudolf Jaenisch, then post-doc under Azim 
Surani, now head of the Epigenetics Programme in Cambridge, UK; the second from Daniel Messerschmidt – a 
young scientist who has published several high-impact papers on imprinting, epigenetic reprogramming during 
preimplantation. The latter currently works as a junior Principle Investigator in IMCB under A*STAR Singapore. 
27
 Caveat being for most papers claiming mammalian representation of DNA methylome development, they 
merely refer to the murine system. Also, even in context of mice, most papers cited refer to repeat elements. Hence 
here, I cite the earliest known mouse study on DNA methylation in sperm and the corresponding first human 
study. 
28
 Something most papers claiming mammalian representation somehow fail to address. 
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carboxylcytosine (5caC) and finally to cytosine (Ito, Shen et al. 2011). However, since bisulfite 
conversion cannot distinguish 5mC and 5hmC (Nestor, Ruzov et al. 2010), subsequent 
immunoflorescence experiment reveals Tet3 to be responsible for the second round of paternal 
demethylation (Wossidlo, Nakamura et al. 2011)29. The maternal genome seems to be protected against 
active demethylation by a protein complex PGC7/Dppa3/Stella (Wossidlo, Nakamura et al. 2011). It is 
also proposed that since Dnmt1 is absent in the zygotic nucleus, methylation marks on the maternal 
genome is passively demethylated over subsequent cellular divisions instead (Howell, Bestor et al. 
2001).  
Parental-specific demethylation (active sperm DNA demethylation, passive oocyte demethylation) 
seems to be consistent across other mammalian models (cows, rats, pigs) (Dean, Santos et al. 2001). 
Interestingly, this is not conserved across phylogeny as zebrafish exhibit an inverse parental-
demethylation relationship (Jiang, Zhang et al. 2013) and frogs (Xenopus laevis) do not seem to exhibit 
DNA demethylation immediately after fertilization (Stancheva and Meehan 2000). This phylogenic 
discrepancy is probably due to different mechanisms of embryonic cellular differentiation – either 
through the inheritance of germ plasma or inductive signalling (reviewed in (Strome and Lehmann 
2007)). In most invertebrates, and in fish and frogs, the first few divisions of the embryo segregates 
various maternal cytoplasmic organelles and material – the resulting cellular composition determining 
subsequent cell fate. In mice however (and by extrapolation – mammals), specific signals received from 
neighbouring cells influence the cell lineage trajectories. Of particular interest, are the primordial germ 
cells. 
Primordial germ cells (PGCs) are cellular precursors of gametes which differentiate and develop from 
the zygote early during mammalian embryogenesis. Since PGCs are the only cells in the organism 
capable of transmitting genetic information to the next generation, intuitively, examples of 
transgenerational inheritance due to an organism’s exposome during early embryogenesis is most likely 
to have influenced PGC development, probably during the critical period of development. In mice, 
 
29
 Also shown for cows and rabbits. 
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global demethylation is completed by E3.5 all cells in the inner cell mass (ICM) of the preimplantation 
embryo are largely unmethylated (Evans and Kaufman 1981). De novo methylation then is initiated and 
completed by E6.5, corresponding to the earliest known PGC precursor cells (Felici 2009). PGCs then 
start a new phase of global demethylation which is completed around E12.5 (Seki, Hayashi et al. 2005). 
Notably, although most of the genome in PGCs are demethylated in this phase (including repeat 
elements), some IAP can escape demethylation, potentially allowing for transgenerational epigenetic 
inheritance (Lane, Dean et al. 2003). In humans, PGCs were first detected 21 days post fertilization in 
the cellular location anatomically analogous to the mouse zygote (Fuss 1911) and human PGC precursor 
cells are hypothesized to segregate from the early ICM 12-14 days post fertilization (Felici 2012). PGC 
then migrate into the gonadal ridges five weeks into gestation (Witschi 1948) and subsequently mature 
into embryonic germ cells at approximately nine weeks (Shamblott, Axelman et al. 1998). Notably, 
wherein the murine PGC development (and DNA methylome remodelling) spans a fifth of gestation 
(E6.5 to E12.5), human PGC development (especially DNA methylome remodelling) is relatively 
unknown. Imprinted regions are removed during PGC development and re-established in gametogenesis 
during embryogenesis, however, when this demethylation occurs is not known in humans. Since PGC 
migration into gonadal ridges correspond to the critical window of development for penile development 
(Section 1.3), it is not unreasonable to assume that human PGCs mature by the twelfth week of gestation 




1.5 Interrogating DNA methylation 
Unlike genomic haplotypes wherein an individual either has a certain characteristic haplotype or 
another, DNA methylation is graded – a single nucleotide within a specific genomic locus can possess 
anywhere between 0% to 100% methylation. Within somatic diploid cells, the presence of two alleles 
permits three methylation states – 0%, where both nucleotides on each allele are not methylated; 50%, 
where one CpG on an allele is methylated and the other is not; 100%, where both CpGs on both alleles 
are methylated. The larger the cell population within the sample, the more precise the methylation value 
of the sample.30 Overall, this allows the degree of exposome’s influence on the DNA methylome to be 
quantified by the degree at which DNA methylation differences are observed between case and control. 
However, this model is independent of whether DNA methylation is causal to phenotypic change or 
responsive to an environmental influence. It has to be stressed however, that unlike in cases of cancer, 
where hypermethylation often implies complete (or near complete) methylation of a general genomic 
region (usually CGI) which was previously not associated with methylation (Esteller, Corn et al. 2001), 
or in imprinting, where DNA methylation differences between maternal and paternally derived alleles  
would expected be somewhat bimodally distributed (at 0% and 100%), physiological change-
induced/inducing methylation changes are more subtle. As such, investigative techniques have to 
interrogate DNA methylation levels in smaller genomic loci and to greater precision. Today, DNA 
methylation is surveyed using two major technologies – Next Generation Sequencing (NGS)-based and 





 Methylation is also heavily influenced by heterogeneous cell composition within a sample as DNA methylation 
is tissue-specific. This will be addressed in chapter 2. 
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
1.5.1 Bisulfite Conversion 
Regardless of technology employed to probe DNA methylation, most modern technologies have a 
bisulfite conversion step31. Bisulfite ions (HSO3-) generated from the reaction between a strong alkali 
(usually NaOH) and a bisulfite salt (usually NaHSO3) in the presence of hydroquinone react with single 
stranded unmethylated cytosines, deaminating them into uracil (Frommer, McDonald et al. 1992). Most 
notably in this reaction, is that methylated cytosines are not converted into uracils32. Hence, after 
bisulfite treatment, and subsequent sample amplification by polymerase chain reaction (PCR), sites 
which possessed methylated cytosines remain cytosines whereas sites which possessed unmethylated 
cytosines would be converted into thymines – allowing for the distinguishing DNA methylation states. 
The relative proportion of thymines and cytosines in a specific loci would then reflect the original 
methylation status of that genomic position. Nevertheless, as bisulfite treatment is a chemically harsh 
one, excessive or prolonged temperatures during desulfonation can lead to damage, such as by 
introducing breaks into the single stranded DNA sample (Ehrich, Zoll et al. 2007). Since specific 
technologies have differing requirements in DNA fragment length for the interrogation of DNA 
methylation, the longer the DNA fragment length required, the less viable DNA samples remaining 
after bisulfite treatment. Even upon successful optimizations (achieving 99.7% cytosine conversion), it 
is estimated that 84-96% of total DNA is degraded during bisulfite treatment (Grunau, Clark et al. 
2001). Unfortunately, despite its limitations, bisulfite conversion remains the most effective (and 




 Notable exceptions include affinity enrichments (MBD, MeDIP-Seq) and HPLC techniques. 
32
 The first paper to report this reaction had a >96% cytosine conversion rate and 2-3% 5mC conversion to 
thymine. Wang et al. (1980) Nucleic Acids Res. 8(20): 4777–4790. Today’s bisulfite conversion kits claim >99% 
cytosine conversion efficiency (see Section 2.4.2). 
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1.5.2 Next Generation Sequencing 
The first sequencing technique was developed in 1972 by Ray Wu, relying on consecutive primer 
extensions and labelled nucleotides to determine the underlying DNA sequence of samples (Wu 1972). 
This was improved upon by Sanger and colleagues by the adoption of chain-terminating inhibitors 
instead of normal labelled nucleotides which increased both the accuracy and efficiency of sequencing 
(Sanger, Nicklen et al. 1977)33. Nevertheless, Sanger sequencing was limited in the length and speed at 
which it can sequence samples. Next generation sequencing, aims to increase the throughput and 
efficiency of sequencing. This was facilitated with the development of mapping algorithms which 
enabled the piecing together of multiple small DNA fragments into a larger genome map based on 
individual fragment overlaps. The parallel sequencing of these multiple fragments from one genome 
birth the first iterations of NGS – and have since diversified to encompass several variants including 
pyrosequencing (removing the electrophoresis step (Ronaghi, Karamohamed et al. 1996)), Sequencing 
by Oligonucleotide Ligation and Detection (SOLiD) (Shendure, Porreca et al. 2005), Reversible 
terminator chemistry (Illumina sequencing)34 (Bentley, Balasubramanian et al. 2008) and Ion Torrent 
(Rusk 2011)35.  
Unique to each sequencing platform is the optimal length of sample DNA fragment inputs as well as 
the method in which they are generated. Random shearing of DNA (usually via sonication) is preferred 
in unbiased surveys of the genome such as Whole Genome Bisulfite Sequencing but is generally 
regarded as costly and inefficient – not only does the genome contain large expanses of regions without 
CpGs (Ziller, Gu et al. 2013)36, the large genome coverage comes at the expense of individual CpG 
resolution37 (Ziller, Hansen et al. 2015). Targeted enrichments of genomic regions known to be 
 
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 Despite the multitude of research groups which started DNA sequencing optimization, Sanger et al. improved 
the chemical efficiency of sequencing to such an extent that his name is synonymous with first generation 
sequencing techniques – i.e. Sanger Sequencing. 
34
 A combination of Sanger-like sequencing, on microarray-like clusters, amplified in parallel, optically detected 
and interpreted. Originally called Solexa sequencing until the company was acquired by Illumina in 2007.  
35
 Instead of optical detection, Ion Torrent utilizes detection of H+ ions generated from polymerization during 
sequencing by ion-sensitive field-effect transistor sensors. 
36
 About 65% of their 101-bp reads had no CpGs. 
37
 Single nucleotide coverage of 5x is equivalent to a methylation resolution of 20%. This may be acceptable in 
oncology, but subtle methylation differences in metabolic disease or determination of inter-individual variation 




associated with gene expression or regulation is largely preferred – achieved through methylation-
specific restriction enzyme digest or affinity enrichment.  
Restriction enzymes are enzymes which cut nucleic acids (usually DNA) at specific recognition motifs 
– methylation-specific restriction enzymes do so only when the recognition motifs contain methylated 
cytosines. The differential DNA digestion products of a methylated and unmethylated DNA sample (i.e. 
after bisulfite treatment) after restriction enzyme digest allows for an estimate of the amount of DNA 
methylation within the original sample (Singer-Sam, LeBon et al. 1990). A combination of methylation-
specific restriction enzymes allows for the survey of up to a third of all CpGs in the human genome 
(Schumacher, Kapranov et al. 2006). Reduced Representation Bisulfite Sequencing (RRBS), bisulfite 
sequencing after restriction enzyme digest, achieves high CpG coverage with low genome coverage 
(approximate 1% of the entire genome), enriching for CpG dense regions such as gene promoters and 
repeat regions (Meissner, Gnirke et al. 2005).  
Affinity enrichment techniques utilize either antibodies specific against methylated cytosines 
(methylated DNA immunoprecipitation – MeDIP) (Weber, Davies et al. 2005) or methyl-binding 
proteins (methylated CpG island recovery assay – MIRA) (Rauch and Pfeifer 2005) to enrich for 
genomic regions with methylated cytosines (usually additionally labelled with Cy3 dye). This is 
compared against the input control (usually labelled with Cy5 dye) and the differential dye intensities 
provides the DNA methylation level. This technology is incompatible with bisulfite sequencing thus 
not only is it unable to provide single nucleotide resolution, it can only provide comparative methylation 
differences. However, absolute methylation levels can be estimated using algorithms such as CHARM 
(Comprehensive high-throughput arrays for relative methylation) (Irizarry, Ladd-Acosta et al. 2008) or 
Batman (Bayesian tool for methylation analysis) (Down, Rakyan et al. 2008). The newest variant of 
NGS is methylCapture sequencing (methylC-Seq) (Lister, O’Malley et al. 2009), combining affinity 
purification in the form of tagged-RNA baits to genomic regions of interest  and bisulfite sequencing. 
methylC-Seq is capable of single nucleotide resolution, targeted genomic investigations, as well as off-




1.5.3 Microarray-based Technologies 
DNA Microarray technology exploited the complementary of nucleic acids to bind, isolate and quantify 
genomic regions of interest using complementary bait-pair sequences (Maskos and Southern 1992). 
Originally used to quantify gene expression (Schena, Shalon et al. 1995), it has been adopted for SNP 
identification (Gunderson, Steemers et al. 2005) and subsequently DNA methylation quantification 
(Ordway, Bedell et al. 2006). The production DNA methylation microarrays was subsequently 
commercialized (Bibikova, Lin et al. 2006) with increasing probe specificities and densities (Bibikova, 
Le et al. 2009) cumulating with the Illumina HumanMethylation450 BeadChip (Infinium 450K) 
(Sandoval, Heyn et al. 2011)38. The Infinium 450K claims 98.9% gene coverage (17.2 probes per gene), 
as well as 96%, 94% and 86% coverage of all CpG islands, shores and shelves respectively (5.6, 2.8 
and 2.1 probes per loci respectively) (Bibikova, Barnes et al. 2011). DNA methylation measured on 
Infinium 450K also achieves high correlations with other platforms such as WGBS (Bibikova, Barnes 




 Ordway et al. (2006) designed 21,294 unique probes. Illumina started producing DNA methylation 
quantification microarrays shortly after in 2006 (GoldenGate) with a mere 1,505 unique probes independent of 
Ordway’s. This was increased in 2009 to 27,578 unique probes. Illumina’s probe repertoire was expanded again 
to 485,577 unique probes with the HumanMethylation450 BeadChip in 2011. 
39
 0.95 for normal cell lines, 0.96 for tumour cell lines; 10-120x coverage. 
40
 0.93 for human clinical samples, after quantile normalization 4x coverage. 
41




Figure 1.5 Infinium assay overview. Illustrating the differential chemistries between (A) Infinium I and (B) 
Infinium II assays on the HumanMethylation450 BeadChip (Dedeurwaeder et al.,2011). Legend – M: methylated; 
U: unmethylated cytosines. 
 
Notably, Infinium 450K employs two distinct chemistries in the determination of DNA methylation – 
Infinium I assay and Infinium II assay (Dedeurwaerder, Defrance et al. 2011). The first utilizes two 
separate sets of probes ligated to two beads – one to survey methylated sites (cytosines) and the other 
to survey unmethylated (thymines) sites (Figure 1.5A). The second has a uniquely different set of probes 
on the same bead which allows for the binding of either methylated or unmethylated targets (Figure 
1.5B). Infinium I assays share the same colour channel (red), their distinct physical locations on the 
microarray allow for the differentiation and calculation of , which is a representation of sample DNA 
methylation levels. Infinium II assays on the other hand, share the same physical location on the 
microarray hence require a two colour channel readout (green for methylated sites, red for unmethylated 
sites) for  calculation. The differential chemistries within the same microarray chip leads to systematic 

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biases which require chemistry-based peak intensity normalizations (Dedeurwaerder, Defrance et al. 
2011) as the intensities of Infinium II assays are typically lower than those of Infinium I42. Moreover, a 
small percentage of probes were later found to cross-hybridize to more than one genomic locus – 
potentially resulting in false positive results (Chen, Lemire et al. 2013, Price, Cotton et al. 2013)43. 
Hence, appropriate normalizations and probe omissions have to be executed to ensure accurate 
representation of DNA methylation quantifications when using this technology. 
 
 1.6 Paving the gaps  
From literature, we observe increased propensities for detrimental metabolic disease outcomes upon 
exposure to extreme prenatal environments (Section 1.2.2) with potentially inter- as well as 
transgeneration effects (Section 1.2.1). Mechanistically, such outcomes maybe driven by misaligned 
adaptive responses which were sensitized by exposome’s influence during ‘critical windows of 
development’ (Section 1.3). Such heterokairotic responses are strongly suggested to manifest through 
epigenetic phenomena (Section 1.1) – the most well-known of which is DNA methylation (Section 1.4). 
Notably, just as the DNA methylome can reflect external influences, it can also serve to drive 
phenotypic change (Section 1.4.2). Despite extensive knowledge of the evolution of the DNA 
methylome in context of other mammalian models (Section 1.4.3), how the DNA methylome evolves 
in human embryogenesis and early life is very much unexplored. Moreover, beyond the critical window 
of development within PGCs, heterokairotic response to exposome influence during other windows 
may play significant roles in altering the phenotypic trajectory of the offspring. This is due to the unique 
mammalian situation wherein the metabolism of female members sensitize two subsequent generations 
within her uterus during pregnancy. Even if altered heterokairotic phenotypes are not targeted at PGCs, 
the change in metabolic pathways can indirectly induce heterokairotic response in germ cell maturation 
 
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 Inituitively so – Infinium II assays detect two variants of the same locus within a single space whereas Infinium 
I assays do so on two physical locations. Both bead sizes equal, the range of Infinium I assays would theoretically 
be double that of Infinium II assays. 
43
 First found to produce false positives on sex chromosomes by Chen et al., the list of cross-hybridizing probes 
was further expanded to the rest of the autosomes by Price et al. 
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– thereby propagating transgenerational effects. Ostensibly, a myriad of DNA repair and epigenetic 
maintenance mechanisms ensure transient changes in exposomic exposure do not typically result in 
drastic phenotypic changes (Section 1.3, Section 1.4.2). Nevertheless, because fetal development 
possesses numerous critical windows of development for various homeostatic mechanisms, it becomes 
especially vulnerable to environmental insults. This forms the notion of the Developmental Origins of 
Health and Disease (DOHaD) hypothesis wherein the propensity to develop detrimental heath outcomes 
in an adult is largely influenced by antenatal events. 
Based on the DOHaD hypothesis, we wish to investigate two environmental exposomes on fetal 
development – one non-modifiable (parity) and another modifiable (plasma glucose levels) on how they 
can influence the phenotypic trajectory of the offspring. To assess this altered trajectory, we compare 
the DNA methylome of infant umbilical cords using a well-established analytical technique, 
Infinium450K, as a surrogate indicator of the overall fetal epigenetic landscape. 


2. GUSTO COHORT 
2.1 Background of the GUSTO Cohort 
Singapore has seen a rapid socioeconomic transition from ‘third world’ to ‘first’ in under fifty years 
(Lee 2000), during which the Gross Domestic Product (GDP) per capita increased more than 100-fold 
from 1965 to 2013 (Group 2015)1. Intuitively food consumption (both quality and quantity) increases 
as a function of increasing affluence (Gerbens-Leenes, Nonhebel et al. 2010), but this rapid transition 
has correlated strongly with an equally rapid increase in the prevalence of Non-Communicable Diseases 
(NCDs) including obesity (Foo, Vijaya et al. 2013), type 2 diabetes (Lee 2000), heart disease (Ounpuu 
and Yusuf 2003), asthma (Lee, Chew et al. 1997) and osteoporosis (Koh, Saw et al. 2001). Concomitant 
improvements in the healthcare capacities and policies aimed specifically to improve healthy living in 
Singapore served to significantly dampen the rise in mortality from more severe NCDs such as stroke 
(Venketasubramanian 1998). These efforts also seem to have some effect in reducing recent prevalence 
in select groups for some NCDs such as obesity (Foo, Vijaya et al. 2013) and dementia (Kua and Ko 
1995, Sahadevan, Saw et al. 2008). Nevertheless all the various examples reflect differential prevalence, 
hence susceptibilities to their respective NCDs. The differential disease susceptibilities correlating to 
the change in socioeconomic environment can be explained through altered in utero and early life 
heterokariotic response to the exposome under the DOHaD hypothesis (Section 1.5).  
 
Singapore is also unique in that she possesses three genetically (Teo, Sim et al. 2009), 
socioeconomically (Lee 2004) and culturally (Chen, Low et al. 2014) distinct populations Chinese, 
Malay and Indian – within a small geographical location. An elegant study in 2014 identified the SNPs2 
across 73 sub-populations stratified both ethnically and geographically across Asia (with two non-Asian 
controls) and clustered them accordingly (Liu, Saw et al. 2014). The principal component analysis alone 
resulted in the clustering of individual subpopulations resembling very closely to their geographical 
regions (Figure 2.1A, B). Notably, Liu  et al. confirmed previous studies claiming that Singaporean  
 
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 Singapore’s GDP per capita was US$516.29 in 1965 and US$55,182.48 in 2013 – a >100-fold increase over 47 
years. 
2




Figure 2.1: Clustering of populations based on SNPs (Liu et al. 2014). (A) Legend of which subpopulations study 
individuals belonged to geographically. (B) Principal Component Analysis clustering of all subjects who were 




Chinese were relatively homogeneous3 and comparable genetically to select Chinese populations in 
China (Chen, Zheng et al. 2009); and Singaporean Indians were more heterogeneous than Chinese 
counterparts, and genetically comparable to South Indians (Ali, Liu et al. 2013)4. Moreover, the 
dendrogram subpopulation clustering also suggests that the three unique ethnicities within Singapore 
are representative of three large sub-divisions: Singapore Chinese with East Asian Chinese including 
Taiwanese, Japanese and Koreans; Singapore Malays with indigenous South-east and East Asian 
populations; and Singapore Indians with the general Indian sub-continent. Given the rapidly improving 
socioeconomic conditions in China, India as well as the rest of the ASEAN region – very similar the 
early rise of Singapore (Group 2015), an investigation into how an evolving early life exposome 
translates into adult phenotypes and disease in Singapore across all three major ethnicities would be 
very useful in predicting and managing economically pernicious NCDs across most of the entire Asian 
continent. Hence, against this backdrop, the GUSTO (Growing Up in Singapore Towards healthy 
Outcomes) birth cohort study was formulated. 
The GUSTO study was primarily concerned with how prenatal exposures influenced the subsequent 
generation’s propensity in developing obesity and metabolic disease. However, the complexity of gene-
environment-epigenetic interactions necessitated extensive record keeping of phenotype, genotype and 
epigenomic information. This also allowed for the probing of other specific exposome-epigenome 
relationships. Specifically, this thesis shall cover how one example of a non-modifiable phenotype – 





 Evident from the minimal spread of SG-CH points within Figure 2.1B 
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2.2 GUSTO Study Demographics 
GUSTO study participants were recruited from two Singapore hospitals – National University Hospital 
(NUH) and Kandang Kerbau Women’s and Children’s Hospital (KKH) between June 2009 and 
September 2010. They consist of women who were at least 18 years or above, attending their first 
trimester antenatal dating ultrasound scan. Subjects had to be of homogenous F
-2 ethnicity5, delivering 
in NUH or KKH, and intend to reside in Singapore for the next five years to facilitate follow-up. 
Subjects also had to consent to donation of birth tissues including umbilical cord, cord blood and 
placenta. Subjects who were undergoing chemotherapy, or under psychotrophic medication, or who 
suffered from type I diabetes were excluded from the study. Selected subjects gave informed written 
consent to indicate interest in participation (Soh, Tint et al. 2014). Recruitment and subject follow up, 
sample processing, data management and analysis were done by a collaboration of independent teams.  
Phenotypic data collected pertaining to this thesis included maternal age at birth, subject ethnicity, 
maternal height and weight, infant gender, birth order, infant gestation, infant birthweight, maternal 
obstetric history and maternal Oral Glucose Tolerance Test at 26 weeks gestation (OGTT – fasting and 




 Both sets of grandparents as well as both parents had to be of the same ethnicity to ensure genetic coherence 




Figure 2.2: Flowchart of subject recruitment and progression in GUSTO (Soh, Tint et al. 2014). This thesis, only 
antenatal maternal phenotypic data and postpartum umbilical cord tissue are used in subsequent analysis. 








2.2.1 Comparability to Other Study Populations 












Filipinos  Cebu Longitudinal Health and Nutrition Survey. 
Enrolment: Original cohort – 1983-1984, there were 8 
additional surveys done postpartum, most recently in 
2009. Originally to investigate infant-feeding 
patterns, now the study encompasses several 
objectives including developmental origins of young 
adult disease risk. Study includes original cohort 
women, their offspring and subsequently, the third 
generation starting 2007. 
(Adair, Popkin 
et al. 2011) 
COCOA 1364  
(on-going) 
Korean Cohort for Childhood Origin of Asthma and allergic 
diseases. Enrolment: Nov 2007-Dec 2015. Determine 
gene-environment interaction on pediatric 
susceptibility to allergic diseases. Study includes 
father, mother and child from under 26 weeks 
gestation to 10 years postpartum. 
(Yang, Lee et 
al. 2014) 
JECS 100,000 (?) Japanese Japan Environment and Children Study: Enrolment: 
Jan 2011-Dec 2013. Determine environmental factors 
which influence childhood health and development. 
Study includes father, mother and child from as early 
periconceptually as possible to 13 years postpartum. 
9,819 were recruited within the first year (Michikawa, 
Nitta et al. 2015). 
(Kawamoto, 
Nitta et al. 
2014) 
LWBC 773 (252) Han 
Chinese 
LaizhouWan Birth Cohort. Enrolment: Sep 2010-Dec 
2013. Determine environmental pollution with health 
outcomes of mother and child. Study includes mother 
and child from under 28 weeks gestation to 2 years 
postpartum. 





Indian   The South Asian Birth Cohort Study. Enrolment: not 
stated. Determine impact of intrauterine gene-
environment on infant adiposity. Study intends to 
recruit mother and child from three geographic 
locations including rural and urban India as well as 





TEC 1264 (730) Taiwanese Taiwan Early-Life Cohort. Enrolment: Jul 2001-Jul 
2005. Determine prenatal biomarkers to predict 
development of atopic dermatitis in childhood. Study 
includes mother and child from during the third 
trimester to 2 years postpartum.  
(Wen, Wang et 
al. 2011) 
USM 153 Malay Universiti Sains Malaysia Birth Cohort Study. 
Enrolment: May 2010-Jun 2011. Determine influence 
of prenatal nutrition and oxidative stress exposure on 
postpartum and infant obesity. Study includes mother 
and child from under 24 weeks gestation to 1 year 
postpartum. 





ABC 106,370  
(on-going) 
Danish Aarhas Birth Cohort. Enrolment: 1990- today. Create 
a database, and subsequently a biobank to address 
fetal programming hypotheses, its website (www.ab-
biobank.dk) claims storage of over 4,500 samples 
with the highest subject figure reference stated on the 
right. 
(Pembrey, 




Swedish All Babies in Southeast Sweden. Enrolment: Oct 
1997-Oct 1999. Primarily to determine immune-
mediated diseases such as type 1 diabetes and coeliac 
disease, the study has expanded to include nutrition, 
obesity, smoking, vaccination and psycho-social 
factors. Study includes mother and child from first 






British Avon Longitudinal Study of Parents and Children. 
Enrolment: Apr 1991-Dec 1993. Determine prenatal 
gene-environment interactions on eventual health, 
behaviour and development of the child. Study 
includes mother and child from under 10 weeks 
gestation, and intends to conduct lifelong follow-up. 
Currently investigating up to 17 years postpartum 
(www.bristol.ac.uk/alspac). 
(Golding, 
Pembrey et al. 
2001) 
ELFE 20,000 (?) French Etude Longitudinale Francaise depuis l'Enfance. 
Enrolment: Apr 2011-Dec 2011. Determine child’s 
cognitive and motor development in relation to 
prenatal environmental exposures, nutrition and 
socioeconomic factors. Study includes mother and 
child from first trimester gestation to 14 years 
postpartum. This study has yet to publish results based 
solely on its own cohort. 
(Vandentorren, 










Generation R. Enrolment: Apr 2002-Jan 2006. 
Lifelong follow-up cohort, study aims to determine 
causal pathways to growth and development 
throughout life. Study includes father, mother and 
child from under 18 weeks gestation and is currently 
assessing up to 7 years postpartum. 
(Jaddoe, Duijn 





Portuguese  Birth Cohort Geração XXI. Enrolment: Apr 2005-Sep 
2006. Estimate pre-pregnancy prevalence of 
cardiovascular risk factors and relate them to 
offspring obesogenicity and later life health outcomes. 
Study includes mother and child recruited at birth up 
to 7 years postpartum with intention to extend 
indefinitely. 
(Alves, 




Norwegian Norwegian Mothers and Babies. Enrolment: mid 
1999-end 2005. No specific research hypothesis. To 
collect as much phenotypic information and 
biological samples as possible. Lifelong cohort, study 
includes mother and child from 17 weeks gestation, 
currently up to 7 years postpartum.  
(Magnus, 
Irgens et al. 
2006) 
* Studies have to collect both phenotypic information from both mother and child as well as intention of birth tissue sample 
collection to be included. In cases where a country has more than one study, the study with the largest sample size would be 




Epidemiological findings based on historical population cohorts (Section 1.2.2) lead to the natural 
transition of targeted birth cohorts investigating the causative mechanisms under the DOHaD 
hypothesis. Beyond epidemiological associations, the collection of biological samples is essential to 
extend knowledge with respect to intergenerational (much less transgenerational) phenotypic 
inheritance. In this regard, the European scientific communities have had a significant head start over 
Asia (Table 2.1), facilitated by superbly organised health records and historical impetus. On that note, 
recently, the United Kingdom initiated a drive to establish a birth cohort of 80,000 (Pearson 2015) – 
this was not included in Table 2.2 as the study has yet to publish, whereas other studies with intent have 
published their intended collection protocols (such as (Anand, Vasudevan et al. 2013) and 
(Vandentorren, Bois et al. 2009)). This is significant as the British study was announced two weeks 
after a similarly large birth cohort in the US was scrapped (US National Children’s Study (Reardon 
2014)). The US National Children’s Study was initiated in 2000, starting with a pilot recruitment cohort 
of 5,000 and was slated to increase that to 100,000 – unfortunately, a combination of poor study design, 
infrastructure, mismanagement and a federal budget cut cumulated in its cancellation. Given that the 
US has the highest increase in obesity prevalence across all age and genders (GBD 2014)6, the demise 
of a promising study specific to the US, which aimed to provide a representative depiction of how 
prenatal environmental influences postnatal growth and health outcomes is a scientific disappointment. 
Within Asia, many countries are spearheading their own prospective birth cohorts to address the 
DOHaD hypothesis, with Japan leading the scientific front7. The CLHNS cohort in Philippines has 
three-generation representation, but does not possess biological samples from the F1 generation. 
However, CLHNS has extensive biosampling across the F2 and F3 generations, providing fertile ground 
for intergenerational epigenetic studies – which it has yet to conduct (Adair, Popkin et al. 2011). 
Intriguingly, despite epigenetic phenomena being touted as the medium which transgenerational effects 
affect, most of these birth cohorts publish associations and correlations based on genetic, biochemical 
metabolites and/or biometric measurements with growth, childhood obesity parameters and/or allergy-
 
6
 Almost three quarters of the population are overweight (74%). 
7
 The first large scale birth cohort looking into fetal origins of health and disease began recruitment in 2002 with 
an eventual cohort population of >20,000 participants. 
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related diseases. Notable exceptions include ALSPAC, the Princess Ann Hospital (PAH) study 
(Godfrey, Barker et al. 1997) and Southampton’s Women Survey (SWS) (Inskip, Godfrey et al. 2006) 
– all of which are located in Britain.  
GUSTO may be a relatively new prospective birth cohort in the DOHaD research scene but it has made 
significant contributions to understanding how epigenetic phenomena may reflect in utero gene-
environment interactions (Teh, Pan et al. 2014) and correlate with changes in gene expression in concert 
with growth parameters (Lim, Ng et al. 2012, Cheong, Chng et al. 2014) shortly since its inception. 
Lacking numerical superiority over some studies, GUSTO possesses depth and breadth of phenotypic 
data and biological sample analysis combined with ethnic diversity, tracking maternal and fetal 
anthropometry (including biospecimen collection, questionnaires, and clinic examinations) up to four 
times prior to delivery and eight times post-delivery rivalling many regional and even large-scale 
European studies. This is also complemented with antenatal and postpartum maternal nutrition – the 
combination of data and sample collected arguably most comprehensive amongst all birth cohorts 
established thus far. A small subset also underwent infant MRI to determine precise body composition 
measurements – the first study to do so on healthy infants. Even the evolving microbiome of the infant 
is monitored in the first three years of life. For a full list of phenotypes and biospecimens collected, see 
supplementary information of (Soh, Tint et al. 2014). With respect to this thesis, no paper8 has reported 
the DNA methylome difference between firstborns and non-firstborns, as well as how it correlates to 




 To the best of our knowledge, at the date of thesis submission. 
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2.3 Infant tissue at birth – Umbilical cord  
 
Figure 2.3 Histological sample of a stained umbilical cord obtained postpartum. Image adapted from 
www.pinterest.com/source/i-heart-histo.tumblr.com  
 
One of the biospecimens collected in GUSTO was infant umbilical cords – the sampling of which allows 
the surveying of fetal DNA methylome. Staging of embryonic development was historically chronicled 
by a series of histological analysis of human embryos in what is today known as the Carnegie Collection 
(O'Rahilly and Muller 1987). Within the Collection, the origins of the umbilical cord was observed to 
have emerged from the mesodermic9 layer by 13 days post-fertilization through the connecting stalk 
(Hertig, Rock et al. 1956). Histologically, the umbilical cord is simply the conduit between the fetus 
and placenta. Following embryogenesis, the allantois and yolk sacs – which came from the hypoblast10, 
regress, remnants of which remain embedded in the umbilical cord residing closer to the fetus. The 
expansion of amniotic epithelium also encloses the umbilical cord, forming its eventual epithelial layer. 
Blood islands containing primitive erythroblasts, hematopoigenic and mesenchymal11 cells can be 
observed within the cord 18 days post-fertilization (Bloom and Bartelmez 1940) but can only be 

9
 Hertig et al. refers this as the ‘mesoblast’. Mesoderm, they argue, can only be ascribed to this layer at day 20 
post-fertilization, after gastrulation proper. 
10
 As opposed to the germ layers (ectoderm, mesoderm and endoderm) – they arose from the epiblast. Both of 
which came from the inner cell mass.  
11
 Here, Bloom and Bartelmez described cells which appeared mesenchymal in nature – they did not attribute 
stem-ness to such cells. Stem-cell nature of mesenchymal cells found in umbilical cord was discovered decades 
later, in Campagnoli et al. 2001, Blood, 98, 2396-2402. 
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properly ascribed as blood vessels 20 days post-fertilization with concomitant vascular components. 
Also, contained within the umbilical cord, is the Wharton’s Jelly – first described postpartum by 
Thomas Wharton (Wharton 1659), Wharton’s Jelly comprises a matrix of gelatinous substance and 
fibroblasts which envelope the blood vessels (two arteries and a vein) perivascularly within the 
amnionic epithelium. This substance was later identified to be mucopolysaccharides (Levina 1949), a 
compound comprising of mostly hyaluronic acid and chondroitin sulfate – believed to provide 
mechanical support to the umbilical cord (Baeurle, Kiselev et al. 2009). Mucopolysaccharide 
production is observed to increase 8 weeks into gestation with small mast cell populations visible 13 
weeks into gestation (Vinogradov 1958). Prior to parturition, the umbilical cord experiences 
myxomatous12, hypothesized to assist closure of blood vessels within (Figure 2.3). 
2.3.1 DNA Extraction 
Umbilical cords (UC) were harvested after birth by trained clinicians. In summary, UC was obtained 
from the mid-region of each human umbilical cord sample and washed well in sterile (phosphate 
buffered saline) PBS. Cord tissue was also gently squeezed to remove any blood. Each cord then was 
cut into smaller pieces and stored in 4°C for up to 4h before subsequent processing.  
The high concentration of hyaluronidase within the extracellular matrix of umbilical cords can interfere 
with subsequent downstream analysis. Hence, the UC tissue was powdered via mortar and pestle in the 
presence of liquid nitrogen. Between 250-300 mg of powdered UC was extracted and brought to room 
temperature before being submersed in 500L of 1 mg/mL hyaluronidase enzyme solution in PBS. 
Samples were then incubated at 37°C for 30 minutes with shaking.  
After hyaluronidase removal, 500L of TNES13 buffer was added to sample UCs and was homogenized 
using Xiril Dispomix Homogeniser. 10L of Proteinase K (20mg/mL) was added to the homogenised 
tissue and the mixture was incubated at 55 °C overnight. If lumps of tissue was still observed after 
 
12
 The process of infusion of connective tissue within the umbilical cord. 
13
 50mM Tris pH 7.5, 400mM NaCl, 100mM EDTA, 0.5% SDS 
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overnight incubation, another 10L of Proteinase K was added and incubated until no visible tissue was 
observed. 
To precipitate and extract genomic DNA from the homogenized UCs, 500L 5.0 M NaCl was mixed 
thoroughly into the lysate. Subsequently the mixture was centrifuged at 13,200 rpm for 20 mins at room 
temperature and the supernatant was extracted. An equal volume of pure ethanol kept prior at -80°C 
was introduced to the supernatant and gently inverted to precipitate DNA. The solution was allowed to 
stand at -80°C for 10 mins. Precipitated DNA was spooled into 500L H2O containing RNase A 
(100g/mL) and incubated at 55°C for 30 minutes or until the pellet dissolves. 
Purification of DNA was done using phenol/chloroform. An equal volume of phenol/chloroform 
solution was added into the samples and the mixture gently inverted before centrifugation at 13,200 
rpm for 10 mins at 4°C. The top aqueous layer was carefully extracted without disturbing the middle 
protein layer. The phenol/chloroform wash was repeated and supernatant transferred to a new tube. A 
tenth of the volume of 3 M NaAc pH 5.2 and 2 volumes of pure ethanol kept prior at -80°C was added 
to the sample. The mixture was allowed to stand for 10 mins in -80°C to precipitate DNA. Subsequently 
the mixture was centrifuged at 13,200 rpm for 10 mins at room temperature. The supernatant was 
removed and the DNA pellet was washed with 70% ethanol, spun down again and supernatant was 
again removed. The DNA pellet was then air dried for approximately 15 mins or until the side of the 
pellet just turns translucent. The DNA pellet was then resuspended in 100L H2O and incubated at 55°C 
for 30 mins, then left overnight at 4°C to allow complete dissolution of DNA.  
To assess the quantity and quality of DNA extracted, 2L of each sample was measured on NanoDrop 
(Thermo Scientific) and were above 1.5 for both 260/280 and 260/230 ratios. This process yielded 5-
10g of DNA per 100mg of frozen powdered UC tissue. 500ng of each sample was then ran on 0.8% 




2.4 Infinium Human Methylation 450 BeadChip  
The DNA methylome of GUSTO subject infant umbilical cords was primarily surveyed using the 
InfiniumHumanMethylation450 BeadChip (Infinium450K). Validated in 2011, the Infinium450K 
BeadChip is a DNA methylation microarray technology with annotated probes which serves to sample 
a fraction of potentially interesting regions in the genome at a significant fraction of time14 and cost of 
other sequencing techniques (Sandoval, Heyn et al. 2011). However, a significant proportion of the 
probes were later found to be cross-hybridizing (Chen, Lemire et al. 2013, Price, Cotton et al. 2013) – 
affecting the accuracy of the methylation calls. Hence, such probes were removed. Since both male and 
female infant umbilical cords were sequenced, probes corresponding to sex chromosomes were also 
removed leaving a total of 374,650 probes remaining. To ensure robustness, we additionally require 
that probes be present in at least 90% of the samples per study (section 2.4.1) and have a methylation 
range of 10% to observe differential DNA methylation with respect to the investigated phenotype. 
This results in a final CpG list of 244,815 probes for the Parity study and 231,281 for the GDM study. 
Notably, as Infinium450K provides single nucleotide DNA methylation resolution across a large 
number of CpGs, results of which would provide increased precision (over technologies as such 
Pyrosequencing), genomic coverage and greater throughput (over technologies such as GoldenGate in 
ALSPAC (Relton, Groom et al. 2012), or Sequenom MassARRAY in PAH and SWS (Godfrey, 
Sheppard et al. 2011)) in the genomic loci potentially influenced by the phenotypes investigated over 
other measurement techniques employed within the other birth cohort studies. 
2.4.1 Sample Selection 
From the 1,176 successful deliveries, subjects who delivered preterm (gestation under 37 weeks) and/or 
had incomplete phenotypic data were removed from subsequent analysis. Genotypic analysis using 
Illumina Omniexpress + exome array revealed a few subjects of questionable self-reported ethnicity – 
they were also removed to prevent confounding effects. Population linkage analyses were separately 
conducted on the SNPs discovered within the GUSTO cohort outside this thesis using the Pi-hat module 
 
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 Here, the processing time for one batch of 48 samples on the Infinium 450K platform is five days as compared 
to two weeks for one batch of seven samples on RRBS – more than 20 times faster. 
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of PLINK (Purcell, Neale et al. 2007). Genetic relationships suggestive of consanguineous unions15 or 
infants who might be related to each other16 were also removed as infants were assumed to be 
genetically independent, and borne to genetically independent parents during statistical analysis. Only 
singleton deliveries were considered. This translates to a total of 958 subjects remaining for the Parity 
Study and 901 subjects in the GDM Study. 
2.4.2 Sample Preparation (Microarray) 
1g of good quality genomic DNA was bisulfite converted according to the manufacturer’s 
recommendations (EZ DNA methylation kit. Zymo Research. Cat. No. D5005). Bisulfite converted 
genomic DNA was prepared according to the manufacturer’s recommendations (Illumina Infinium HD 
Methylation protocol). In summary, a whole genome amplification was done at 37°C for 22 hours, end-
point fragmented enzymatically, purified via precipitation, resuspended before hybridization on an 
Infinium HumanMethylation450 BeadChip (Cat. No. WD-314–1002, Illumina Inc.) at 48°C for 18 
hours. The BeadChip was then washed to remove unhybridized and non-specifically hybridized DNA. 
Single nucleotide extension followed using the hybridized bisulfite converted DNA as template. 
Incorporated nucleotides were labelled with biotin (cytidine and guanine) and 2,4-dinitrophenol 
(adenine and thymine). Staining was done using a combination of antibodies fixed with fluorophores 
which could differentiate the four nucleotides. Lastly, the BeadChip was washed to remove the original 
hybridized DNA, protected and scanned using the Illumina HiScan SQ scanner. 
The Illumina iScan SQ scanner instrument has a two-colour laser fluorescent scanner (532/580 nm, 0.53 
m spatial resolution) which excites the fluorophores fixed during the above staining procedure. These 
signals generate image intensities which were then captured using the GenomeStudio Methylation 
module software (.idat files), and translated into methylation scores for each CpG – represented as a -




 Defined to be parents related up to the extent of second degree cousins. 
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2.4.3 Statistical Analysis Methods 
Probes with signal detection p values above 0.05 or provided signal from fewer than three beads were 
removed, leaving 476,359 remaining probes – 129,236 Type I and 347,123 Type II probes. Type I and 
Type II probes were scaled as recommended (Dedeurwaerder, Defrance et al. 2011)17. In essence, raw 
-values were converted into M-values – the log2 ratio between the signal intensity from the methylated 
probe against the unmethylated probe (Du, Zhang et al. 2010). M-values obtained from Type I and Type 
II probes were then independently processed to obtain their respective density peaks. Subsequently 
Type II probes were scaled using Type I density peak and range as reference. Adjusted M-values were 
used to correct for batch effects by quantile normalization followed by ComBat – an R package which 
utilizes empirical Bayes method to normalize variations across experimental batches (Johnson, 
Rabinovic et al. 2007). Adjusted M-values were finally reconverted to -values for further analysis. 
Conversion from -values to M-values makes methylation distributions Gaussian and homoscedastic 
(Du, Zhang et al. 2010). As -values range from 0 (non-methylated) to 1 (fully methylated), it represents 
a biologically intuitive paradigm to interpret data. However, being bounded, -values are not Gaussian 
– which interferes with the statistical principles used in many methods (including normalization). 
Furthermore, as most DNA methylation distributions exhibit significant heteroscedasticity – usually 
with very low mean and standard deviations near 0% and 100%. Although M-value distributions are 
also bimodal, both mean and standard deviations across the M-value distributions are relatively 
constant. Hence, in context of an unfiltered genomic dataset, analysis using M-values is more 
statistically robust. 
Nevertheless, reconversion to -values facilitates biological replication. For example, even if a CpG 
has highly significant methylation difference between two phenotypes using M-value – if the 
methylation range is within a narrow band at the extreme methylation values of 0 or 100%, this absolute 
methylation difference challenging to replicate. It follows that a methylation range filter has to be 
imposed for CpG selection. Here, we used the methylation of the 95th percentile subtracted with the 5th 
 
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percentile of at least 10% (M95 – M5  10%), permitting a small percentage of samples possessing 
extreme methylation profiles18. CpGs also had to be present in at least 90% of the subjects – resulting 
in a total of 244,815 probes. -values reported were normalized (mean = 0, standard deviation = 1)19. 
To circumvent the impact of a small number of extreme methylation outliers driving the significance of 
any particular CpG, probes with 2x interquartile range (IQR) under 10% were removed, leaving 174,211 
probes for analysis. 
DNA methylomes surveyed via the Infinium 450K were primarily analysed using linear regression 
against fixed covariates (Parity Study: infant gender, ethnicity and gestation; GDM study: birth order, 
infant gender, ethnicity and gestation) and cell type (Section 2.4.4) using R (x64 v3.1.2).  
In genomic studies, there often is inflation of p-values due to multiple testing. Several methods have 
been developed to mitigate this, the more prevalent being Bonferroni-correction (Bonferroni 1936), 
False Discovery Rate correction (FDR) (Yoav and Yosef 1995) and genomic control correction (Devlin 
and Roeder 1999). Bonferroni-correction is the simplest and most conservative, which goes as follows: 
 if 
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for 1  i  n 
then, 
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Where n = number of tests (T); Ti = ith test (1  i  n); Ho = all hypotheses Hi are false;  = alpha value  
In other words, the Bonferroni-corrected p-value of any individual CpG = raw p-value divided by the 
number of tests (in this case, CpGs). The Benjamini-Hochberg FDR correction is slightly more 
complicated, where there are H1 to Hm null hypotheses corresponding to P1 to Pm p-values. For any 
given , the largest k such that P(k)    


 is determined and all H(i) for I = 1 to k are rejected. 
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 Keeping in mind at all our subjects were physiologically healthy and hence not expected to carry starkly 
different methylation profiles. 
19
 Normalization of -values makes comparison on the effect size comparable between the CpGs but does not 
change the p-value. 
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Essentially this method is less stringent over Bonferroni-correction, gaining statistical power at the 
expense of increased Type I error rates.  
A further quality control technique employed during analysis was the use of setting the methylation 
outlier values to within 2x interquartile range (IQR) of the median/removing the methylation outlier 
values outside 2x interquartile range (IQR) of the median. Here, we stress that this is a quality control 
technique used to filter out CpG hits which are primarily driven by outlier values and not the main 
criteria used to select significant CpG hits (methylation outlier correction). If a significant CpG was 
still found to be significant using this quality control technique, this would reflect that this particular 
CpG possesses stronger potential to be correlated to the phenotype investigated. 
2.4.4 Cell Type Correction 
Several tissue types can be utilized in the surveying of infant DNA methylome. In this thesis, we used 
umbilical cord tissue (Section 2.3). Other non-invasive tissue types include placenta, umbilical cord 
blood and infant buccal swabs. Regardless of biospecimen(s) chosen, surveying the DNA methylome 
inherently encounters the problem of cellular heterogeneity – which serves to increase the DNA 
methylation variation. Histologically, placental tissue is the most heterogeneous of the available options 
– making both clinical extraction and biological analysis challenging. This is also reflected in the large 
variation within reported DNA methylation results from placental samples over other tissue types 
(Ollikainen, Smith et al. 2010, Gordon, Joo et al. 2012, Armstrong, Lesseur et al. 2014). On the other 
hand, cord blood, umbilical cord and buccal swabs exhibited comparable ranges within DNA 
methylation variation (Ollikainen, Smith et al. 2010, Armstrong, Lesseur et al. 2014). Notably, the 
different tissue types had their own unique DNA methylation profile – concordant to that seen from 
multiple human cell lines (Shoemaker, Deng et al. 2010)20. Umbilical cord however, provides 
significantly more biological material than would blood or buccal swabs.  
 
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 Armstrong et al. (2014) found a weakly significant correlation between cord blood and placental tissue for 




Umbilical cords contain several cell types, the most abundant being Wharton’s Jelly mesenchymal cells 
– specialized fibroblast-like cells embedded in a matrix of hyaluronic acid, proteoglycans and mucus 
connective tissue (Can and Karahuseyinoglu 2007). Other minor cell types include mast cells and blood 
vessel cells (umbilical cords contain two arteries and a vein) containing endothelial and smooth muscle 
cells. Notably, umbilical cord blood not fully removed during processing can result in minor21 white 
blood cell contamination. Hence, a Houseman’s algorithm (Houseman, Accomando et al. 2012) was 
used with an umbilical cord specific reference dataset (Gutierrez-Arcelus, Lappalainen et al. 2013) to 
estimate the cellular proportions of various cell types within each sample’s DNA methylation profile. 
The F statistic of the top 1000 maximum informativeness CpG sites between fibroblasts, 
lymphoblastoid cells and T-cells was calculated for 244,312 probes and was used to estimate cell type 
fraction within 1,148 GUSTO samples.  
2.4.5 Gene Ontology Analysis 
To identify genes or pathways which may be enriched, gene ontology analysis can be conducted 
(Ashburner, Ball et al. 2000). Essentially, assuming all genes are of equal length, represented equally 
on the genome, and surveyed on a platform with equal representation (same number of probes per gene), 
then the extent of enrichment for any gene ontology term can be evaluated by the hypergeometric 
distribution: 






,-  , 
where Prob(X  b) refers to the probability of having b terms from an ontology cluster with B terms, N 
refers to the total number of genes in the genome, B – the total number of genes associated with a 
specific gene ontology term, n – the number of genes in the dataset to query, b – the number of genes 
common between B and n, and the enrichment value being (b/n) / (B/N) (Tavazoie, Hughes et al. 
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 The proportion of white blood cells in blood is about 0.1% of formed elements (red blood cells, white blood 
cells and platelets). Even with significant blood contamination of UC samples, the DNA contribution from white 




1999).22 This premise is the method of calculation for many gene ontology packages and calculators 
available today. However, intuitively, omitting a background reference set or relying on external 
background sources is problematic as No (global background reference in HGT(b, N, B, n)) would be 
substantially different from the true NA (background reference specific to the platform or analysis data 
subset used)23. Although some gene ontology programmes circumvent that by allowing user input 
background references, gene and probe representation remains problematic because intuitively, 
		./0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< =	/>?@AB . Indeed it has been shown that 
omission of the background reference leads to significantly different results and conclusions (Geeleher, 
Hartnett et al. 2013, Harper, Peters et al. 2013). Fortunately, newer tools recognise this problem and 
have begun to incorporate probe representation into their calculations. For example, GOseq assigns 
each gene with a probability weightage based on probe representation, and further adopts a modified 
hypergeometric test to compensate for over-representation in certain genes within each gene ontology 
category (Young, Wakefield et al. 2010). Here, we used the R package missMethyl – which adopts the 
statistical approaches of GOseq but designed specifically for the Infinium450K array for the 
calculations of gene ontology enrichments (Phipson, Maksimovic et al. 2016). Lastly, as gene ontology 
results are usually populated with many terms, multi-layered, and many times redundant – we used 
REVIGO to condense and collapse the gene ontology results into easily interpretable conclusions. 
REVIGO takes all the gene ontology terms and associated p-values and clusters the data based on 
semantic similarity measures (Supek, Bošnjak et al. 2011). Here, we used the default similarity settings 
(0.7 – medium), Homo sapien database, Sim Rel semantic similarity and input gene ontology terms 





 Other statistical methods to calculate enrichment include the binomial, chi-square and Fisher exact test – 
reviewed in Rivals et al. 2007, Bioinformatics, 23, 401-407. 
23
 This point extends beyond the statistical method as all tests make similar assumptions. 
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 2.5 GUSTO Sub-Study Characteristics 
2.5.1 Demography 
Table 2.2 Phenotypic information of all full term GUSTO Study participants 









































1,100 (0.0094)     
536 (0.0046) 
 Average 
(Standard deviation) Range Sample Size 
Maternal pre-pregnancy BMI 
(self-reported) 26.3 (4.5) 26.8 1061 
Maternal age at birth (years) 31.3 (5.1) 28.0 1088 
Gestation (days) 272.6 (6.9) 31.0 1088 
Birthweight (g) 3141 (396) 3770 1088 
OGTT (fasting) (mmol/L) 4.3 (0.5) 5.0 884 
OGTT (2h) (mmol/L) 6.5 (1.4) 10.5 884 
*Compiled from the years of active GUSTO deliveries (2009-2011), data taken from the Yearbook of Statistics Singapore 
2015. Ethnicity and infant gender proportions calculated after removal of ‘others’. Birth Order proportions include all 
ethnicities as the census did not provide ethnicity breakdowns within birth order. 
 
The GUSTO study cohort is not representative of the entire Singapore population (Table 2.2)24. To 
achieve greater statistical power within the two minority ethnicities, Malay and Indian subjects were 
intentionally over sampled in proportion to the Chinese – 25.55% Malays and 18.20% Indians within 
the GUSTO cohort as compared to 16.95% Malays and 12.47% Indians in the Singapore Population 
Census between 2009 and 2011. Nevertheless, the proportions of infant gender ratios as well as infant 
birth order appears to be very similar to the prevailing trends – 52.67% infants born in GUSTO are 
 
24
 No statistical comparison was conducted as the data from the Singapore population census is not concordant 
with the GUSTO study parameters (e.g. participants were of homogeneous ethnicity in GUSTO and not 
necessarily in the Singapore census). 
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males as compared to 51.72% amongst Singapore citizens and permanent residents; 45.40% infants in 
GUSTO are firstborn as compared to 47.58% in the Population Census. 
2.5.2 Infinium450K Genome Coverage 
 
Figure 2.4 Overview of genomic coverage by Infinium450K. (A) Distribution of CpGs with respect to CpG 
Islands, shores, shelves and open sea; (B) Genomic features; and (C) chromosomes. Blue bar reflects 
representation from all Infinium450K probes, the orange bar reflects autosomal probes which have been filtered 
for cross-hybridization effects (1st Filter) and the grey bar reflects autosomal probes which additionally are found 
in at least 90% of the cohort as well as have a DNA methylation range of above 10%.  
 
Infinium450K was designed to target up to 485,577 unique probes, of which 30.9%, 23.1%, 9.7% and 
36.3% belonged to CpG islands, shores, shelves and open seas respectively (Figure 2.3A); 29.1%, 2.0%, 
9.1%, 31.9%, 2.8%, 2.1% and 23.0% belonged to promoters, 5’ untranslated regions (UTR), exons, 
introns, 3’ UTRs, transcription termination sites (TTS) and intergenic regions respectively (Figure 
2.3B). Reduction in genomic representation was fairly uniform across all genomic features upon the 
removal of cross-hybridizing probes (1st Filter) but impacted CGIs and promoters more significantly 
when the second filter (requiring  90% sample presence and larger DNA methylation range amongst 
	

all samples > 10%; Parity study results shown.). The two step filter did not reflect significant bias within 
normalized distribution of CpG populations across the chromosomes, save the sex chromosomes X and 
Y (Figure 2.3C). It does however reflect the comparatively low coverage on certain chromosomes such 





3. PARITY STUDY 
3.1 Biology of Parity (non-modifiable phenotype) 
3.1.1 Nomenclature  
Parity suffers from a fluid definition – in the UK, parity is defined as ‘the number of times a woman has 
given birth to a fetus with a gestational age of 24 weeks or more, regardless of whether the child was 
born alive or stillborn’ (Borton 2014); in the US, this window shifts from anywhere within 20 to 24 
weeks depending on the attending clinician (Creinin and Simhan 2009); in Singapore, most papers 
either do not define parity, or simply disregard the chunk in bold and consider parity to be equivalent 
to the number of children born to a woman, excluding stillbirths (Lim, Wong et al. 2012, Mueller, 
Mueller et al. 2013, Chen, Wu et al. 2014). Although there are significant implications to the biology 
of parity for a currently pregnant women, should she have had carried an infant but suffered a natural 
or induced abortion or stillbirth as compared to a truly nulliparous1 woman. However, for the sake of 
consistency, parity is defined in this thesis (and within the GUSTO study) as “the number of times a 
woman has given birth to a live baby”. Hence, the birth order of a live infant to a GUSTO subject, 
would be equivalent to the GUSTO subject’s parity plus one. 
Not to be confused with to parity, is ‘gravidity’ – which refers to ‘the number of times a woman has 
been pregnant, irrespective of the pregnancy outcome’ (Borton 2014). Due to the nomenclature within 
GUSTO, the subtraction of gravid and para2 data provides the number of times a woman has 






 A nulliparous woman is one who has never carried a pregnancy beyond 24 weeks (UK definition). She who has 
given birth once before is known as a primiparous woman and she who has given birth twice or more, a 
multiparous woman.  
2
 Number of abortions = Gravid – (Para + 1) 
	

3.1.2 Birth Outcomes with respect to Parity 
The higher the parity, the larger the newborn – firstborn infants are usually the lightest, having the most 
pronounced birthweight difference in between birth orders (Swamy, Edwards et al. 2012). Surprisingly, 
parity remains an independent determinant of birthweight up to the tenth delivery (Juntunen, Laara et 
al. 1997). Firstborns also possess the highest risk of prenatal complications and neonatal morbidity, as 
well as antenatal delivery complications (Bai, Wong et al. 2002). Firstborns are also predisposed to 
“catch-up growth” – a phenomenon characterised by increased rates of weight and height gains during 
infancy – eventually being heavier and taller than non-firstborn counterparts at childhood (Ong, Preece 
et al. 2002). Interestingly, the risk of childhood obesity is elevated in firstborn individuals (Celi, Bini 
et al. 2003), suggesting a greater “catch-up” in weight than height – separating the two heterokairotic 
mechanisms. Moreover, the general reduction in mean birthweight among firstborn who eventually 
become mothers was not observed in the next generation (Nordtveit, Melve et al. 2009), suggesting a 
restoration of the phenotypic norm3. 
3.1.3 Physiology  
Epidemiologically, the older the woman has her first child, the longer she is expected to live 
(Westendorp and Kirkwood 1998). However, this relationship does not extend to the number of progeny 
– both men and women exhibit an inverted-U relationship between age at death and mean number of 
progency (Westendorp and Kirkwood 1998). Moreover, female fertility drops as a function of maternal 
age regardless of socioeconomic factors (O'Connor, Holman et al. 1998), reflective of the natural 
attrition in oocytes, decline in neuroendocrine and uterine function upon ageing (Fitzgerald, Zimon et 
al. 1998). Parity, or a pregnancy event, also seems to be protective of breast cancer the earlier the woman 
experiences her first pregnancy (Meier-Abt and Bentire-Alj 2014). The elevated hormonal levels as 
such prolactin (Yu, Gerkins et al. 1981) and estrogen (Bernstein, Pike et al. 1985) experienced during 
pregnancy is believed to contribute to the protective effect of parity on breast cancer. Induction of 
differentiation of naïve mammary glandular structures upon a parous event leads to changes in cellular 
 
3
 Although the authors attribute this to socioeconomic factors. 
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composition (Medina 2005) and extracellular matrix (Maller, Hansen et al. 2013) which appear to 
impede tumour growth and progression. Nevertheless, wherein a successful pregnancy is associated 
with a reduction in mortality rates in women, mortality rates increase upon spontaneous or induced 
abortions (Gissler, Berg et al. 2004). 
The paradoxical relationship between a declining fertility and decreased propensity for detrimental birth 
outcomes upon subsequent pregnancies is attributed to various physiological factors including a smaller 
nulliparous placenta (Zalud and Shaha 2008), less vascularization (Khong, Adema et al. 2003), poorer 
cardiovascular dynamics (Clapp and Capeleas 1997) and reduced nutrient transfer efficiency as 
compared to subsequent pregnancies (Town, Patterson et al. 2005). This leads to a reduced nutrient 
supply in the nulliparous placenta biologically similar to pathological conditions such as pre-eclampsia. 
However, their pathophysiologies in the development of smaller infants is different. For example, in 
preeclampsia, there are significant increases in plasma leptin concentrations (Mise, Sagawa et al. 1998) 
whereas plasma leptin is significantly lower in nulliparous mothers during late gestation and firstborn 
infants at delivery (Ong, Preece et al. 2002). Leptin is an appetite-regulating hormone, presence of 
which decreases appetite and hence weight gain (Brennan and Mantzoros 2006). Other adipokines such 
as glucocorticoid receptor (GR), uncoupling protein 2 (UCP2), 11-hydroxysteroid dehydrogenase 
(HSD11B), insulin receptor and insulin-like growth factor 1 receptor (IGF1R) are also upregulated in 
firstborn offspring, independent of other factors of energy balance (Hyatt, Keisler et al. 2010). This 
altered adipogenic endocrine condition of firstborns is concordant to observed elevated childhood 





3.1.4 Adjusting the HPA (Hypothalamus-Pituitary-Adrenal) Axis 
HPA refers to three major endocrine glands within vertebrate physiology – Hypothalamus, Pituitary 
gland and the Adrenal gland. Highly conserved across organisms (Denver 2009)4, these organs interact 
via hormonal secretions to regulate internal homeostasis of systems as diverse as metabolism (Dallman, 
Strack et al. 1993), stress (Tsigos and Chrousos 2002) and immune response (Webster, Tonelli et al. 
2002). Establishment of the sensitivity of fetal HPA axis appears to be a late gestation event. 
Physiologically, although the fetal adrenal gland can be first identified at four weeks gestation and is 
capable of steroid-production by the eighth week of gestation (Mesiano and Jaffe 1997), the 
hypothalamus and pituitary appear to only be functionalised only at 21 weeks of gestation (Koutcherov, 
Mai et al. 2002)5. Moreover, given that the exposome would have little influence outside the critical 
window of development (Section 1.3), extremely preterm infants (under 28 weeks gestation) possess 
dysregulated stress hormone (cortisol) irrespective of the actual environmental stress received (Hanna, 
Jett et al. 1997) – suggesting the critical window of development for HPA sensitivity to lie within the 
third trimester of pregnancy and beyond6. Nevertheless, in context of placental insufficiency (be it from 
maternal nutrient deprivation (Bell and Ehrhardt 2002), very early or closely-spaced pregnancies (King 
2003), or simply a smaller nulliparous placenta (Zalud and Shaha 2008)), permanent or residual effects 
early on during pregnancy may go on to effect the development of HPA sensitivity.   
Stress leads to production of various stress-related hormones such as adrenocorticotrophic hormone 
(ACTH), corticotrophin-releasing hormone (CRH) and cortisol. Whilst the first two are impermeable 
to the placenta (Murphy 1979), the placenta protects the developing fetus from excessive cortisol 
influence by the secretion of HSD11B which converts active cortisol into inactive cortisone (Sun, Yang 
et al. 1998). Decreased HSD11B production increases fetal exposure to maternal stress hormones and 
 
4
 Reviewed in Denver 2009, hormone analogues which govern growth and development are present in other 
kingdoms such as plants and fungi. 
5
 The cells which ultimately become these various organs can be identified very early during gestation, but 
functionalization is only observed mid-second trimester. 
6
 See also Section 1.2.2, comparing against epidemiological observations of Ravelli et al 1976 – HPA influence 
on stress response and metabolism appear distinct as infants exposed to famine during the third trimester are less 
likely to be obese, rather famine exposure within the first two trimesters leads to significantly elevated obesity 
rates. This suggests the driving force behind metabolic sensitivity lies outside the HPA axis. 
	
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hence is associated with low birth weight in humans (Steward, Rogerson et al. 1995), and more 
drastically, permanent hypertension (Lindsay, Lindsay et al. 1996) and insulin resistance in rats 
(Lindsay, Lindsay et al. 1996). Elevated stress-hormones (CRH and cortisol) detected during the second 
trimester is also suggestive of preterm risk (Sandman, Glynn et al. 2006). Notably nulliparous mothers 
are perceived to be more stressed than parous counterparts – whilst their cortisol levels are higher, it 
remains non-significantly so (Conde and Figueiredo 2014). Nevertheless, intuitively maternal stress 
peaks approaching parturition (Meinlschmidt, Martin et al. 2010), and given the increased risk of 
prolonged labour amongst other obstetric complications for a nulliparous mother (Bai, Wong et al. 
2002), a possibly prolonged stressful labour/delivery episode in the critical window of development of 
fetal HPA sensitivity may lead to an altered infant metabolic trajectory for a first born infant.7    
 
3.2 Materials and Methods 
958 subjects with full phenotypic information with respect to the covariates adjusted for were selected 
to have the infant umbilical cord samples be surveyed via Infinium450K (Table 3.1). The -values 
(Section 2.4.2) were batch-corrected using ComBat (Johnson, Rabinovic et al. 2007), analysed using 
linear regression (Section 2.4.3), corrected for predominant covariates and cell types (Section 2.4.4). In 
context of the Parity study, these were gestation (in days), infant gender, ethnicity, cell type 
composition, the interaction between ethnicity and cell type composition, and bisulfite conversion 
batch. 244,815 autosomal, non-hybridizing probes had data from at least 90% of the subjects and a 
DNA methylation range of above 10%. 174,211 probes had 2xIQR methylation ranges of at least 10%. 
After the p-values of the probes were calculated, those which were no longer significant after outlier 




 Wherein maternal stress before and during pregnancy is strongly associated with a myriad of negative offspring 
outcomes, it has to be noted that parity does not seem to negatively influence the HPA stress response in normal 
women themselves after the pregnancy.  
	

Table 3.1 Characteristics of the study sample: N = 958 GUSTO Mother-infant dyads in GUSTO/Parity Study 
 Firstborns (n = 440) Non-Firstborns (n = 518)  
 Mean (SD) Range N Mean (SD) Range N p-value* 
Maternal Age at birth 
(years) 30.0 (4.8) 22.2 440 32.6 (4.9) 27.7 518 5.71 x 10
-18 
Maternal pre-pregnancy 
BMI (self-reported) 22.1 (4.2) 25.7 405 23.2 (4.6) 26.4 470 0.1362 
Gestation (days) 273.3 (7.0) 29.0 440 272.0 (6.8) 31.0 518 0.0243 
OGTT (fasting) (mmol/L) 4.3 (0.5) 5.8 408 4.4 (0.5) 4.5 486 0.3512 
OGTT (2h) (mmol/L) 6.5 (1.5) 11.9 408 6.6 (1.4) 10.8 486 0.2884 
Systolic blood pressure  
(26 weeks gestation) 
(mmHg) 
114.2 
(12.9) 89.0 361 
112.7 
(12.4) 65.0 428 7.72 x 10
-3 
Diastolic blood pressure 
(26 weeks gestation) 
(mmHg) 
65.6 (8.6) 61.0 361 64.1 (8.5) 50.0 428 3.71 x 10-4 
































2.73 x 10-6 
3.35 x 10-4 
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*P-value of univariate analysis (general linear model) of firstborn status with the corresponding covariate, 
adjusted for ethnicity and maternal age. 




3.3 Results  
3.3.1 Genomic Characteristics 
 
Figure 3.1 Distribution of Infinium450K probe p-values with respect to firstborn status. (A) Cumulative 
histogram; (B) Manhattan plot. The red line represents the threshold for significance using the Bonferroni-
corrected p-value (6.542). (C) Volcano plot of normalized regression  values (x-axis) against its negative 
logarithmic (base 10) p-values. Large black dots (n = 250) were randomly plotted to approximate the distribution 
within the scatterplot cloud. 
 
From a total of 174,211 autosomal, non-crosshybrid Infinium450K probes, 55 had significantly 
differentiated DNA methylation levels between firstborns and non-firstborns with a p-value < 10-4 
(Figure 3.1A). These probes are represented in a Manhattan plot (Figure 3.1B) with none above the 
Bonferroni p-value threshold of 2.870 x 10-7 (in red). After probes within 10bp of known SNPs were 
removed8, 11,392 probes had p-value under 0.05 and remained significant after outlier correction. The 
larger cloud density on the positive end of the normalized regression beta values suggest 
hypomethylation in the umbilical cords of firstborn infants (Figure 3.1C; ratio of probes with positive 
normalized beta versus negative normalized beta: all probes – 1.327, probes with p-value <0.05 – 
1.566). The top CpG and clusters of significant CpGs are discussed in Appendix I and II respectively. 

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A) Firstborn Status – Genomic Association 
  
B) Firstborn Status – CGI 
 
 
Figure 3.2 Relative enrichment of probes significant within firstborns with respect to methylation Interquartile 
Range (IQR), regression beta direction, p-value significance; segregated by (A) gene association and (B) CpG 
Island association. The left half of the figures represent probes which have negative beta values (i.e. 
hypermethylated in firstborns) whereas the right half represents probes which have positive beta values (i.e. 
hypomethylated in firstborns). Each figure is further divided to represent probes which have relatively conserved 
methylation values (i.e. IQR  20%) and those which display large inter-individual variation (i.e. IQR > 20%). 
The significance of relative enrichments was calculated using a chi-square test and the p-values of the enrichment 




By dividing the probes with respect to DNA methylation range, most probes significantly associated 
with firstborn status and displaying high variation (IQR > 20%) were not particularly enriched in any 
genomic association region, and suggestively under-represented in CGIs but potentially enriched in 
genomic regions of Open Seas (Figure 3.2). Probes which exhibit less variation (IQR  20%) on the 
other hand, seem to be enriched in intergenic regions. This suggests that firstborns tend to possess DNA 
methylation differences in intergenic/non-CGI regions as compared to non-firsborns. The depletion in 
differentially methylated genebody regions (hypermethylated exons and hypomethylated 3’ UTR)9, 
suggest most genomic regions around genes themselves have very similar DNA methylation profiles 
between firstborns and non-firstborns. Intriguingly, the enrichment distributions within CGIs and Open 





 Parity variable is coded 1 (firstborn) and 2 (non-firstborn) – so a negative beta reflects higher methylation in 




3.3.2 Impact of Different Parity Models on Infant DNA Methylation 
 
Figure 3.3 Heatmap of the normalized beta coefficients from three different models. Parity represents the initial 
parity model (methylation regressed against firstborn status, gestation, infant gender, ethnicity, cell type, the 
interaction between ethnicity and cell type, and bisulfite conversion batch); Parity adj. represents the initial parity 
model additionally adjusted for maternal age at birth; Age represents the initial model with maternal age at birth 
replacing firstborn-status. The heatmap takes the top 200 most significant CpGs as per the first model (parity) 
and compares them against the same CpG of the other two models. Beta coefficients are represented from blue 
(hypomethylated in firstborns) to yellow to red (hypermethylated in firstborns). CpGs with p-value > 0.1 are 
represented as blanks. Significance of CpGs per model are represented as follows: no * with colour – 0.1  p  
0.05, * - 0.01  p < 0.05, ** - 0.001  p < 0.01, *** - 10-4  p < 0.001, **** - 10-5  p < 10-4, ***** - 10-6  p < 




Table 3.2 Trends for CpGs most significantly methylated in firstborns across different models 










50 9.561 x 10-5 33:17 37:13 17:0 
100 1.645 x 10-4 55:45 77:23 29:0 
200 4.150 x 10-4 100:100 155:45 54:0 
500 1.225 x 10-3 265:235 388:112 123:1 
1000 2.723 x 10-3 556:444 752:248 239:11 
5000 1.881 x 10-2 2952:2048 3530:1470 867:192 
Parity, Parity adj. and Age represent different models as described in Figure 3.3. Parity Hypo:Hyper charts the 
number of CpGs found to be hypomethylated against those found to be hypermethylated within the limits of the 
top n CpGs. Parity adj. less:more sig. charts the number of CpGs found to be either less or more significant in the 
Parity adj. model comparing the same CpG in the Parity model with that in the Parity adj. model. The number on 
the left of the Age sig:more sig. charts the number of CpGs which were originally in the top Parity model and 
then were also found to be significant in the Age model. The number on the right compares the significance of the 
same CpG between Parity and Age and describes those which were more significant in the Age model. 
 
Since maternal age at birth is inevitably tied to parity-based outcomes, we wanted to investigate whether 
the differential methylation observed was driven by this one major covariate. As such, we compared 
the most significant CpGs within the initial model with a second model further adjusting for maternal 
age at birth and a third model with maternal age at birth but without parity (Figure 3.3, Table 3.2). There 
seems to be an approximately equal distribution between significantly hypomethylated and 
hypermethylated CpGs, and further adjusting for maternal age decreases the significance of the CpG in 
approximately three out of four instances. However, further adjusting for maternal age did not 
significantly reduce the number of CpGs which were originally found to be significant in the first model. 
While a small fraction of CpGs are also found to be significantly associated with maternal age (without 
adjusting for parity), they are mostly less significant than parity (without adjusting for maternal age) 







3.3.3 Impact of Parity on Infant DNA Methylation Stratified by Ethnicity 
 
Figure 3.4 Heatmap of the normalized beta coefficients from six different analysis. All represents the initial parity 
model (methylation regressed against firstborn status, gestation, infant gender, ethnicity, cell type, the interaction 
between ethnicity and cell type, and bisulfite conversion batch) with all 958 subjects. C, M and I represents the 
same model but with only subjects of Chinese ethnicity (n = 558), Malay ethnicity (n = 234) and Indian ethnicity 
(n = 166) respectively. PxM and PxI represents the results from interaction term of firstborn status and ethnicity 
of methylation regressed against the interaction between firstborn status and ethnicity, firstborn status, gestation, 
infant gender, ethnicity, cell type, the interaction between ethnicity and cell type, and bisulfite conversion batch. 
The heatmap takes the top 200 most significant CpGs as per the first model (parity) and compares them against 
the same CpG of the other models. Beta coefficients are represented from blue (hypomethylated in firstborns) to 
yellow to red (hypermethylated in firstborns). CpGs with p-value > 0.1 are represented as blanks. Significance of 
CpGs per model are represented as follows: no * with colour – 0.1  p  0.05, * - 0.01  p < 0.05, ** - 0.001  p 




Table 3.3 Trends for CpGs most significantly methylated in firstborns stratified by ethnicity 








# sig. PxM 
(lowest p) 
# sig. PxI 
(lowest p) 
50 50 23 22 1  (0.01790) 
2  
(9.616 x 10-4) 
100 99 42 41 1  (0.01790) 
5  
(9.616 x 10-4) 
200 193 73 88 2  (0.01790) 
8  
(4.000 x 10-4) 
500 463 151 199 6  (0.01790) 
16  
(4.000 x 10-4) 
1000 874 228 361 23  (1.588 x 10-3) 
45  
(2.741 x 10-4) 
5000 3113 695 1302 162  (6.543 x 10-4) 
226  
(2.741 x 10-4) 
Sig. in Chinese, Malay and Indians only represent the number of CpGs which possess p <0.05 within each ethnic-
sub-population. # sig. PxM and # sig. PxI represent the number of CpGs found to have significant association (p 
< 0.05) between firstborn-status and ethnicity. The numbers within the brackets report the lowest p value from 
these CpGs with the numbers in bold-faced red indicative of a significance that passes multiple testing.  
 
Another covariate which was found to be significantly different between firstborns and non-firstborns 
was ethnicity (Table 3.1). Hence, we compared the significance of interaction between ethnicity and 
firstborn-status and also ran the same linear regression model individually within the three ethnic sub-
populations (Figure 3.4, Table 3.4). Reflective of the numerical composition of the GUSTO cohort, 
CpGs found to be significant in the whole cohort is likely to be significant among the Chinese but only 
approximately one-third of which will be significant among the Malays and Indians. Although there 
was suggestive evidence of some interaction between the indian-subpopulation with parity within the 
top 50 CpGs, this may be isolated as there is little evidence of significant ethnicity interactions beyond 






3.3.4 Potential Genetic Networks Associated with Parity 
Table 3.4 Number of CpGs found to have tissue-specific functionality by GenoSkyline 
Tissue Type 















































































































CpGs that fulfil the CpG criteria are indicated in square brackets in the first column. CpGs that fall in each tissue-specific category are represented in absolute numbers as 
well as percentages of the total CpG population which fulfil the CpG criteria in brackets. Legend: ESC – embryonic stem cells; G.I. – gastrointestinal 
 
As parity is representative of many other pregnancy-related covariates, similarly, DNA methylome changes observed could have functional implications in 
different tissue types. Notably, the correlation between birth tissue and other tissue types has not been well investigated – and recent studies suggest this 
correlation may be relatively weak (Huang, Chu et al. 2016). Hence, to investigate CpGs which are more likely to have similar changes in DNA methylation, 
we employed a tissue-specific functional annotation software – GenoSkyline (Lu, Powles et al. 2016) to identify such CpGs (Table 3.5). GenoSkyline is a data 
resource that condenses epigenetic marks from seven different histone tracks and DNAseI hypersensitivity sites in 73 out of the 111 available tissue types 




entire human genome (hg19) is assigned a probability score per tissue/cell category with respect to its potential functionality in that tissue category. Gene 
ontologies using tissue-specific CpGs are furbished in Appendix III, suggesting enrichments of cardiac and nervous functions across the tissue-types. 
 
Table 3.5 Relative methylation specific to different CpGs of tissue-specific functionality  
Tissue Type 















































































































CpGs that fulfil the CpG criteria are indicated in square brackets in the first column. The ratios represent the numbers of hypermethylated CpGs:hypomethylated CpGs within 
each category with the number of hypomethylated CpGs divided by the number of hypermethylated CpGs represented in the brackets. Legend: ESC – embryonic stem cells; 








Figure 3.5 Heatmap of the normalized beta coefficients across different tissue-specific CpGs as identified by 
GenoSkyline. This heatmap represents the top 200 most significant CpGs in the parity model and stratifies it 
across the different tissue-specific CpGs identified. Beta coefficients are represented from blue (hypomethylated 





Figure 3.6 Histogram of number of tissues in which CpGs are functional. Only the seven tissue types described 
in Lu et al.’s original paper was plotted – ESC, Fetal and Breast were omitted.  
 
 
Table 3.6 Most representative Gene Ontology with respect to Parity (Biological Process) 
Top 500 CpGs 
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Headers of each column in bold represent the criteria and the numbers in the brackets represent the number of 
CpGs used as input into missMethyl – a gene ontology enrichment software. The gene ontologies flagged as 
significant (p < 0.05) by missMethyl was then input into a gene ontology visualisation/consolidation software 
Revigo. The table lists the top five most representative gene ontologies (biological process) for each input criteria 
from Revigo with the numbers in square brackets indicative of the number of significant gene ontologies which 
the representative gene ontology represents. 

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To benchmark our discussions, we pegged comparisons using the top 500 CpGs. We note that this 
threshold (p = 1.225 x 10-3) is representative of genome-wide borderline significance and also represents 
the data relatively well (Table 3.6, Figure 3.5, 3.6). Moreover, adopting a more stringent criteria limits 
the number of CpGs which can be used for gene ontology analyses – which may either produce non-
results or biased results. Conversely, adopting a more lenient threshold may result in too many CpGs 
significant by chance – which may lead to false observations and conclusions (Table 3.7). Specifically, 
using the top 500 CpGs separated across different tissue-types, the top gene ontology obtained was the 
following: atrial septum morphogenesis/development (blood, epithelium, ESC), cardiac atrium 
development (heart), atrial-ventrical node cell to bundle of His cell communication (Fetal), regulation 
of dendrite development (lung, muscle), regulation of cell projection organization (gastrointestinal) and 
regulation of circadian sleep/wake cycle (brain). 
Relative differential methylation within each tissue-type appears consistent (Table 3.6) with CpGs 
functionally associated with muscle, epithelium, lung and blood reflecting the greatest degree of 
hypomethylation in firstborns. Interestingly, in Lu et al’s original paper, they described the major 
proportion of the human genome being not functionally associated with any tissue type1. However, only 
a fifth of all significant CpGs were not associated with any tissue type – and approximately a sixth of 
all significant CpGs were associated with a single tissue type (Figure 3.5, 3.6). Notably, the histogram 
distribution of all CpGs analysed within our Infinium450K dataset is very similar to the other 
distributions (Figure 3.6) suggesting an enrichment of tissue-specific functional CpGs within the initial 





 Their paper discussed the seven main tissue types – blood, brain, epithelium, GI, heart, lung and muscle. Tissues 
from fetal origins – fetal and ESC were discussed separately. Breast tissue was not discussed but available for 
download on their website. In their paper, 77.8% of human genomic loci had no functional association with any 




Globally, well developed countries are experiencing a general decline in birth rates and fertility 
(Caldwell and Schindlmayr 2003) – Singapore is no exception. The latest Population in Brief report by 
the Singapore Department of Statistics reveal a slow but annual decline in total fertility rates with the 
exception of the latest Dragon Year in 2012. This is concordant with the gradual increase in proportion 
of both resident and citizen who are firstborns (NPTD 2014)2. The association of adverse health 
outcomes to people who are firstborn hence will affect increasing proportions of the population. In this 
chapter, we observe methylation differences in the DNA methylome of 440 firstborns as compared to 
518 non-firstborn infant umbilical cords. These differences suggest slight hypomethylation in firstborns 
across CpGs associated with tissues spanning all three embryonic origins (endoderm, mesoderm and 
ectoderm) suggesting potential altered developmental trajectories resulting from this non-modifiable 
phenotype. Nevertheless, we note no single genomic loci attaining Bonferroni-corrected p-value 
significance, which is expected – despite the subtle physiological differences between firstborns and 
non-firstborns, all subjects were physically healthy infants born to physiologically healthy mothers. 
Parity encapsulates a large range of socio-economic, biological and environmental influences. This is 
reflected in the univariate analysis results between firstborn status and the other 
phenotypes/environments collected within GUSTO (Table 3.1). While we observed expected 
differences in covariates such as ethnicity, maternal age, education and work experience, blood 
pressures and IVF status; we also unexpectedly did not observe significant differences in well-
established epidemiological observations such as birthweight and smoking or alcohol exposures. As 
such, it would seem prudent not to over-correct for any covariate in our subsequent regression model 
testing the effect of parity on infant DNA methylation. Hence, we only corrected for covariates which 
are known to significantly impact DNA methylation – infant gender, gestation, ethnicity and cell type. 
 
2
 Testament to successful government policies, there is a marked decrease in citizen proportion coinciding with 
‘post-war baby boomers’ (mode), the implementation of Singapore’s “Stop at two” policy in 1970; and a 
subsequent increase when the policy was removed in 1987. Intriguingly, the second population mode corresponds 
to just before the 1997 Asian Financial Crisis. 


Notably, maternal age was identified as the most significant pre-pregnancy/antenatal environment 
associated with parity. Nevertheless, adjusting for maternal age did not significantly reduce the 
significance of our CpGs in the original model – and in many cases (>1 in 5) increased the significance 
of individual CpGs. Furthermore, we note that a model using maternal age alone (without parity) did 
not reflect significances of similar magnitudes with respect to the CpGs most significantly associated 
with parity. This suggests that other covariates encapsulated by the parity phenotype collectively play 
a larger role in the influence of the infant DNA methylome than maternal age alone.  
The impact of parity on infant DNA methylation is also suggestively independent of ethnicity. Analysis 
of separate models testing for the interaction between ethnicity and parity did not suggest significant 
interactions between Malays or Indians (as compared to Chinese) and firstborn status. Interestingly, 
running the original parity model on individual ethnic sub-populations did result in different proportions 
of the top CpGs present remaining significant (as opposed to using the full dataset). This difference 
resembles the different proportions of Chinese, Malays and Indians used in the analysis with the Malays 
and Indians retaining significance in about two-fifths of the top n CpGs. Intriguingly, restricting the top 
n CpGs to n = 50 did suggest a difference between Chinese and Indians – two ethnicities most 
genetically distinct from each other (Section 2.1). 
Despite the methylation differences observed, the methylation changes we observed were not large, and 
using the strictest genome-wide significance threshold, none of the CpGs would be significant 
(Appendix II). Nevertheless, the most significant CpG within the Parity study is cg24125648, just shy 
of Bonferroni significance (2.870 x 107) at p = 3.61 x 107. This CpG resides on the promoter region of 
the Huntingtin Interacting Protein K (HYPK) gene and has a beta-value of 0.320 – every standard 
deviation increase in methylation in cg24125648 increases the odds of not being a firstborn by 0.320. 
As the name suggests, HYPK can interact with Huntingtin and other neural peptides, displaying 
chaperone-like activity to reduce neural aggregates (Raychaudhuri, Sinha et al. 2008). Interestingly, 
while Huntington is a genetic disorder, the rate of disease onset has yet to be investigated with respect 
to birth order. Notably, the mean absolute difference between the methylation of firstborns and non-
firstborns in this CpG is a mere 0.805%. Since firstborn children are typically phenotypically healthy, 
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there is little reason to suspect a drastic epigenetic change in their DNA methylome. Concomitantly, 
this also suggests that in order for substantial significance to be identified in individual CpGs, a much 
larger sample size is necessary. However, unlike in GWAS studies identifying SNPs, CNVs or 
haplotypes, DNA methylation exists as a range between 0 to 100 (or 0 to 1). Hence, even if substantial 
significances are identified, the methylation differences have to be above the sensitivity of validation 
instruments (such as Sequenom or Pyrosequencing) – which is typically 5% (or 0.05).  
Despite the general methylation pattern of being approximately equally hypomethylated and 
hypermethylated in firstborns, CpGs with tissue-specific associations appear mostly more 
hypomethylated than hypermethylated. Here, we annotated CpGs with tissue-specific associations 
using GenoSkyline – a database which incorporated epigenomic data from the Epigenome Roadmap. 
The Epigenome Roadmap is a large public database of 111 distinct tissue types with epigenetic 
information encompassing histone ChIP-seq, RNA-seq, DNaseI hypersensitivity sites (HS) and DNA 
methylation data. GenoSkyline utilises the histone and DNase I HS data from 73 of these tissue types 
to generate probability scores for different genomic loci specific to general tissue types as outlined in 
Section 3.3.4. Interestingly, despite all tissue groups reflecting hypomethylation in firstborns – the 
hypomethylation trends do not seem to cluster by embryonic later-of-origin. They do however, suggest 
enrichments of cardiac and neural functions when gene ontology analysis were performed. Here, we 
used missMethyl, a software which accounts for probe and genome represention per gene, specifically 
tailored for use on the Infinium450K array to calculate gene ontology enrichment p-values.  
Notwithstanding, primogeniture cannot be simplified into a limited nutrient deficiency model. In one 
of the first few DNA methylation studies within the Dutch Hunger Famine Cohort, individuals exposed 
to the Famine periconceptually had persistent hypomethylation within their IGF2 loci (Heijmans, Tobi 
et al. 2008). We find the same loci is hypermethylated in the GUSTO firstborns (ten significantly 
hypermethylated probes, all located on the promoter and first exon). Similarly, while observational 
validation of four gene promoters which were significantly differentially methylated in animal models 
within the same cohort did not replicate the methylation difference in the Famine cohort (Veenendaal, 
Costello et al. 2012), we observe hypermethylation in one of them – the promoter of LPL (lipoprotein 
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lipase, cg20435463, p-value = 8.34 x 10-3,  = -0.0864) but not the other four. Notably, the Famine 
studies employed techniques limiting methylation resolution to genomic regions rather than single 
nucleotide resolution, and that they used whole blood of their subjects at old age instead of umbilical 
cords at birth. Regardless, the high concordance of DNA methylation patterns within nearby genomic 
loci and persistence of DNA methylation patterns suggest prenatal nutrient restriction models might be 
insufficient to fully assess the effects of a nulliparous pregnancy despite the numerous similar 
epidemiological relationships between firstborns and periconceptually exposed individuals of the 




4.  GDM Study 
4.1 Biology of GDM (modifiable phenotype) 
Intuitively, pregnant women consume more food than their non-pregnant counterparts. While true in 
certain less privileged societies (Pena, Sanchez et al. 2003, Ojofeitimi, Ogunjuyigbe et al. 2008), this 
trend does not seem to hold true for more well-to-do communities. Surprisingly, comparing  total 
macronutrient intake between non-pregnant and healthy women in their first trimester, energy 
consumption only mildly increased (Lundqvist, Johansson et al. 2014), remained the same (Anderson, 
Campbell et al. 1993), or even remained significantly under recommended dietary intakes (Kubota, Itoh 
et al. 2013)1. Across the trimesters, most studies also reflect non-significant changes in nutrient caloric 
intake (reviewed in (Rad, Ritterath et al. 2011))2. This paradox can be explained by the marked 
reduction in physical activity during pregnancy (Prentice and Goldberg 2000), theoretical gestational 
energy costs (Durnin 1991)3 and differences in basal metabolic rates (BMR) between women in 
developed, high socioeconomic societies as compared to members of less affluent communities (Poppit, 
Prentice et al. 1994)4. Hormonal profiles of ghrelin and leptin in physiologically healthy pregnant 
women corroborates this suggestive non-significant increase in dietary intake – ghrelin (the hormone 
which is primarily responsible for feeling hunger) seems to be upregulated in pregnancy, peaking during 
mid-second trimester (Fuglsang, Skjærbæk et al. 2005); leptin (the hormone responsible for feeling 
satiated) follows a delayed ghrelin secretion profile, peaking late-second trimester (Henson and 
Castracane 2000). Given dietary norms do not experience significant changes, then becomes almost 
immediately obvious that significant increases in macronutrient dietary intake in pregnant, healthy 
women of affluent societies may potentially result in over-nutrition for both mother and fetus. 
 
1
 That said, maternal nutrient intakes seem to be very much underreported especially in the first trimester 
(McGowen and McAuffille 2012) – especially for methodologies relying on food diaries (forgotten entries), 
photo-taking food entries (underreporting), or weighing food intake (underestimating nutrient content). Hence, it 
might very well be that nutrient intake does not change significantly between non-pregnant and early-pregnant 
women. 
2
 Caveat being micronutrient intake and supplementation does indeed evolve during pregnancy. 
3
 Durnin suggests the extra energy requirements by healthy women during pregnancy can be obtained from minor 
increases in energy intake prior to pregnancy.  
4
 Poppit et al demonstrates pregnant women in developed countries exhibit significant elevation of BMR in the 




4.1.1 Modifying Maternal Metabolism 
Despite little evidence of the development of significant hyperphagia in physiologically healthy 
pregnant women5, changes are nevertheless observed in maternal metabolism. Notably, Norbert 
Freinkel hypothesized two major adaptations a pregnant mother experiences to provide adequate 
nutrition to the growing fetus: ‘accelerated starvation’ (Freinkel 1965) and ‘facilitated anabolism’ 
(Freinkel, Metzger et al. 1974). The first involves enhanced lipid metabolism upon a period of fasting6 
leading to significant decreases in free plasma glucose and amino acids and a concomitant increase in 
ketogenesis leading to more available free fatty acids and -hydroxybutyrate (Metzger, Ravnikar et al. 
1982). The latter refers to modified nutrient accumulation mechanisms upon consumption of food – 
amongst them, maternal fat accumulation (Hytten and Leitch 1971) and decreased insulin sensitivity 
(Catalano, Berstein et al. 1986). In concert, both pregnancy-related modifications ensure a continuous 
unbroken supply of nutrients to the growing fetus. 
Complementing the ‘accelerated starvation’ hypothesis is a striking drop in overall maternal plasma 
glucose levels during early pregnancy which continues to decrease as pregnancy progresses (Riskin-
Mashiah, Damti et al. 2011)7. Additionally, fasting plasma glucose levels significantly drop upon 
extended fasting durations (Metzger, Ravnikar et al. 1982)8. This initial fall in plasma glucose has been 
attributed to the increase in plasma volume (Metzger, Ravnikar et al. 1982). Incidentally, this 
significantly outpaces red blood cell production, leading to a significant decline in maternal 
haemoglobin and haematocrit concentrations (Bonica 1967) – resulting in increased propensities for the 
mother to develop anaemia during the first trimester. Given that glucose is the fetus’ principal metabolic 
fuel (Tsoulos, Colwell et al. 1971), the perpetuation of decline during pregnancy has been attributed to 
the increase in fetoplacental glucose utilisation.  
 
5
 Again many papers claim the converse, citing rat model studies or even claim human studies, but investigation 
into the primary sources reveal no such association. 
6
 He refers to sleeping, or overnight fasting. 
7
 This particular study had by far the highest sample sizes (n = 7946) across the most timepoints in pregnancy (8). 
Other studies with smaller sample sizes either also reflect a decrease in fasting plasma glucose levels, or non-
significant increases in the third trimester. 
8
 This may be a major concern in sampling fasting maternal plasma glucose levels. 
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Lipid metabolites (triacylglycerols, fatty acids, cholesterol) within the pregnant mother’s plasma also 
experience a decline during early gestation (Fahraeus, Larsson-Cohn et al. 1985). However, unlike 
maternal plasma glucose levels, maternal plasma lipid metabolite levels increase significantly until 
parturition (Alvarez, Montelongo et al. 1996)9, corresponding very nicely with the cumulating increase 
in maternal fat mass (Hytten and Leitch 1971). Whilst insulin resistance and estrogen activity have been 
speculated to be causal of increases in maternal plasma lipid metabolite levels (Silliman, Shore et al. 
1994), the latter (estrogen activity) is counter-intuitive considering its lipid (Terauchi, Honjo et al. 2012) 
and cholesterol (Gaspard, Wery et al. 1999) lowering effects. Other hormones such as human placental 
lactogen (Turtle and Kipnis 1967) and progesterone (Landau and Lugibihl 1967) are more likely 
candidates. Despite the reflexive fear associated with hyperlipidemia, significantly elevated plasma 
lipid profiles are the norm in pregnancy and does not adversely influence endothelial function nor long-
term maternal health (Saarelainen, Laitinen et al. 2006). This is attributed to the concomitant increase 
in both high density lipoproteins (HDLs) counteracting the oxidation of low density lipoproteins (LDLs) 
thereby protecting endothelial function. Nevertheless, pre-pregnancy obesity (Garduño-Alanís, Anda et 
al. 2015) and obstetric complications such as gestational diabetes and preeclampsia correlates with 
aggravated hyperlipidemia (both triglycerides and cholesterol, and up to a tripling of LDL levels) 




 More than triple as compared to the first trimester. 
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4.1.2 Pederson’s Hypothesis 
Also known as the hyperglycemia-hyperinsulinemia hypothesis (Pederson 1952), Jorgen Pederson 
hypothesized that the increase in maternal plasma glucose levels would be reflected in the fetal plasma 
and result in hypertrophy of fetal pancreatic -cells thereby resulting in fetal hyperinsulinemia. This 
translates to increased glucose utilization and altered physiological phenotypes in the offspring 
(Pederson 1967). Indeed to mimic maternal hyperglycemia, insulin in utero infusions were performed 
in rats (Ogata, Collins et al. 1988) and monkeys (Susa, Neave et al. 1984), resulting in increased body 
mass and hypertrophy in select organs such as the liver, heart and spleen without significant increases 
in blood lipid, protein, nucleic acids and glucose concentrations. Conversely, -cell destruction in sheep 
decreased fetal body weight without a decrease in fetal lipid accumulation (Philipps, Rosenkrantz et al. 
1991). This organ hypertrophy in antenatal hyperglycemia complements the organ hypotrophy (also in 
heart, liver, spleen, pancreas and muscle) observed in rats upon antenatal calorie restriction (Desai, 
Crowther et al. 1996). Moreover, overweight and obese gestationally diabetic women treated with 
insulin no longer exhibited significant risk of macrosomia when glucose levels were well controlled 
(Langer, Yogev et al. 2005)10, reinforcing the central role of insulin on physiologically development 
during pregnancy. 
Wherein plasma glucose concentrations arguably provide the strongest feedback insulin secretion, other 
macronutrients including free fatty acids and amino acids (which can also pass from the mother to the 
fetus) also can influence insulin levels. Notably, whereas maternal plasma triglyceride concentrations 
correlate with birthweight in healthy controls, glucose does not (Freinkel and Metzger 1979)11. This 
provided the impetus to expand the Pederson’s hypothesis to include other macronutrients within 
maternal pregnancy which may lead to an altered infant phenotype (Freinkel and Metzger 1979). 
Freinkel even went so far as to coin the phrase ‘fuel-mediated teratogenesis’ (Freinkel 1980) to describe 
 
10
 Overweight or obese gestationally diabetic women with well treated glucose levels on diet intervention 
nevertheless had a 50% increase in risk of macrosomia. Obesity itself presented a two-fold risk whereas insulin 
treated poorly controlled glucose levels had a three-fold increase in risk. 
11
 Glucose levels of gestationally diabetic mothers on the other hand, correlate strongly with birthweight. 
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the effects of overnutrition (fuel) in modification of insulin production and sensitivity – a concept 
embraced in heterokairy (section 1.3) and DOHaD (section 1.5). 
4.1.3 Consequences of Maternal Hyperglycemia 
Despite the decrease in fasting maternal plasma glucose levels during pregnancy, postprandial glucose 
levels increase during pregnancy (Siegmund, Rad et al. 2008), which is consistent with significantly 
larger diurnal ranges of maternal plasma glucose and insulin (Phelps, Metzger et al. 1981) and the 
‘facilitated anabolism’ hypothesis (Freinkel, Metzger et al. 1974). Intriguingly, decreased insulin 
sensitivity was worse12 in gestationally diabetic mothers, significantly lower than even obese but 
otherwise healthy pregnant mothers (Friedman, Ishizuka et al. 1999). Expectedly, any degree of insulin 
resistance would predispose an increased risk of developing GDM. These include mothers who were 
obese (Chu, Callaghan et al. 2007), themselves born with low birth weight (Innes, Byers et al. 2002), 
and suggestively13, even overexpression of insulin-modifying hormones such as human placental 
lactogen (Barbour, Shao et al. 2002). Given maternal hyperglycemia results in the fetus receiving 
excessive metabolic fuels (primarily glucose), the most prevalent obstetric complication expectedly is 
fetal macrosomia (Langer, Yogev et al. 2005). Consequently, this may lead to birth injuries such as 
shoulder dystocia (Jensen, Damm et al. 2001) or unplanned Caesareans (Vambergue, Nuttens et al. 
2000) as the fetus is too large to exit the mother. The abrupt removal from a high glucose environment 
coupled with the already high neonatal insulin production also predisposes the newborn infant to 
hypoglycaemia (Cianni, Miccoli et al. 2003). 
Unlike normal pregnancy, gestational diabetic mothers perpetuate an impaired insulin 
sensitivity/glucose tolerance postpartum, increasing their risk of developing GDM in subsequent 
pregnancies (Retnakaran, Austin et al. 2011) and overt type 2 diabetes later in life (Carr, Utzschneider 
et al. 2006). Notably, although insulin binding is not significantly different between a GDM and normal 
pregnancy (Hjollund, Pedersen et al. 1986), insulin receptor substrate-1 (IRS-1) is significantly 
 
12
 Measured as a function of insulin-stimulated glucose transport, GDM mothers had a 65% reduction compared 
to a 40% reduction norm. 
13
 Experiments done on transgenic mice 
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decreased in the skeletal muscles of both normal obese and GDM women as compared to obese 
nonpregnant controls (Friedman, Ishizuka et al. 1999). Such reduced IRS-1 expression recovers non-
significantly in most mothers affected with GDM, leading the authors to claim persistent insulin 
resistance up to a year postpartum (Friedman, Kirwan et al. 2008). GLUT4 glucose transporter proteins 
were also reduced in adipose cells14 more significantly in GDM mothers than healthy mothers (Okuno, 
Akazawa et al. 1995) potentially explaining the augmented lipidemic profiles unique to gestationally 
diabetic and obese mothers (section 4.1.1). Interestingly although postpartum GLUT4 expression and 
cellular location profiles have yet to be investigated, exercise has been shown to increase GLUT4 
translocation to the cell membrane in skeletal muscle, enhancing glucose uptake without altering overall 
expression levels (Kennedy, Hirshman et al. 1999). 
Apart from the increased risk of adverse obstetric outcomes, infants who have experienced antenatal 
maternal hyperglycemia also have increased risk of developing childhood obesity (Baptiste-Roberts, 
Nicholson et al. 2012), adult obesity and type 2 diabetes (Clausen, Mathiesen et al. 2009). This is 
unsurprising given even mild (20% more than control) hyperglycemia can result in significant 
hypertrophy of the fetal endocine pancreas and hyperplasia of islet -cells resulting in increased insulin 
production (Aerts, Holemans et al. 1990). Incidentally smaller organs resultant of maternal rodent 
antenatal calorie restriction also leads to a permanently altered metabolism (four-fold increase in 
gluconeogenesis in liver enzymatic activity) (Desai, Crowther et al. 1995). Intriguingly, the authors 
speculated the differential expansion of specific hepatic cells in relation to fetal fuel availability (Desai 
and Hales 1997) and since enzymatic activity is compartmentalized (glucokinase in the perivenous zone 
and phosphoenolpyruvate in the periportal zone), their differential cellular susceptibilities to insulin 
resistance and hormonal response could explain why human males are more insulin resistant than 




 But not in skeletal muscle cells (Garvey et al 1992) 
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4.1.4 Diagnosing GDM 










WHO 1999  7.0 75g OGTT Not required  7.8 
IADPSG  5.1 75g OGTT  10.0  8.5 
*Any one value above any categorical threshold is sufficient for diagnosing GDM 
Despite the apparent importance of identifying and treating pregnant mothers with impaired glucose 
tolerance or gestational diabetes, fixing a criteria for the diagnosis of GDM seems to be a Sisyphean 
task for both scientists and clinicians. The first attempt to differentiate GDM from overt type 2 diabetes 
was proposed in 1964 (O'Sullivan and Mahon 1964) based on a 3h 100g oral glucose tolerance test 
(OGTT) validated against the subsequent development of diabetes in the mother postpartum. A 2h 75g 
OGTT guideline followed in 1979 ‘based on contemporary knowledge of diabetes and also represents 
compromises of different points of views’ (Group 1979). Mind-blowingly, 75g was derived as it was 
‘midway between the dose of 50g widely used in Europe and the dose of 100g often used in the United 
States’, and the 2h OGTT thresholds extracted from O’Sullivan and Mahon, and rescaled by ‘certain 
members of the workgroup’15. Despite questionable origins, it was adopted by WHO the subsequent 
year (WHO 1980). Unsurprisingly, the nature of which thresholds were derived lead to multiple region-
specific guidelines (reviewed in (Donovan, Hartling et al. 2013)), most of which focuses on immediate 
adverse maternal outcomes during or immediately after parturition.  
In Singapore, most clinicians adopt the WHO 1999 guidelines in the diagnosis of women with 
gestational diabetes (WHO 1999). In particular, Singapore’s Health Promotion Board advocated OGTT 
testing only in women with high risk, ignoring WHO 1999’s statement that being of Asian ethnicity 
already made most women in Singapore in the high risk category of developing GDM16. Indeed we 
have found that there was no difference in the prevalence of GDM between high risk and non-high risk 
women in Singapore (Chong, Cai et al. 2014) and hence advocated universal screening of all pregnant 
women in Singapore. The latest revision of WHO GDM diagnostic criteria was in 2013, where the 
 
15
 Of whom neither O’Sullivan, Mahon nor Freinkel were included.  
16
 Singapore’s GDM guidelines were later retracted in 2013. 
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WHO panel recommends the use of the International Association of Diabetes and Pregnancy Study 
Groups’ (IADPSG) evaluation (IADPSG 2010) of the Hyperglycemia and Adverse Pregnancy Outcome 
(HAPO) Study17 (HAPO 2008) in establishing a criteria for GDM diagnosis (WHO 2013). These criteria 
are listed in Table 4.1. Like many of its predecessors, the HAPO diagnostic criteria for GDM was based 
primarily on adverse antenatal, parturition and immediate postpartum maternal and infant outcomes 
(1.75 risk of various outcomes). The HAPO criteria is exceptional over other criteria in that it had 
multiple cohorts spread globally (n = 25,505), and its thresholds were supported by clinical outcomes, 
thereby possessing superior statistical power and medical legitimacy to back its claims. 
Nevertheless, as with any diagnostic criteria, several issues are of concern. Firstly, a woman who was 
not previously diagnosed with type 2 diabetes can be diagnosed with GDM at any time within the 
duration of the pregnancy if her OGTT values cross the thresholds of whichever criteria adopted. 
Immediately women who were diabetic but merely not tested prior to pregnancy can be fallaciously 
classified as gestationally diabetic. Secondly, the fasting glucose levels falls (section 4.1.1) most 
significantly between the first and second trimesters (Riskin-Mashiah, Damti et al. 2011), hence testing 
prior to the recommended gestational window of 24-28 weeks potentially generates false positives 
especially during very early pregnancy. Thirdly, fasting glucose levels are usually tested in the morning, 
high diurnal variation in plasma glucose levels during pregnancy (Metzger, Ravnikar et al. 1982) may 
produce false negatives especially during extended clinic waiting times. Some researcher also note the 
importance of the 1h OGTT time point (most clinics use the fasting and 2h OGTT time points only) in 
diagnosing a sizable fraction of mothers with GDM which would otherwise be missed on the other two 
(Sacks, Hadden et al. 2012)18. It has also been argued that given the differences between WHO and 
HAPO, this translates to a differential proportion of mothers who will be left out when using one criteria 
over the other (Yew, Khoo et al. 2014). Nevertheless, the premise of such an argument cannot be 
 
17
 HAPO consortium encompasses several cohorts of Asian ethnicity, including two Singaporean cohorts, albeit 
separate from the GUSTO cohort. 
18
 Given diurnal glucose fluctuations exacerbates as pregnancy progresses, inconsistent gestational window 
sampling would most probably generate inconsistent GDM diagnoses. 
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substantiated unless the comparative guideline was derived from an evidence-based study19 (Donovan, 
Hartling et al. 2013).  
Notably, these factors are difficult to circumvent. Wherein undiagnosed diabetic mothers and clinic 
events present as systematic errors, narrowing OGTT gestational window survey can mitigate the 
natural variation in plasma glucose levels during gestation. Also, modelling OGTT results as a 
continuous rather than categorical variable circumvents the various controversies each diagnostic 
criteria possess. 
4.1.5 Potential Differences in Prognosis due to Hyperglycemia in Pregnancy 
Another aspect brought forth by the HAPO study is the suggestive differences between adverse maternal 
and fetal risk factors associated with fasting plasma glucose and glucose tolerance. While most adverse 
effects of maternal hyperglycemia are associated with both glucose measures20, risk factors associated 
with excess fetal nutrient compensation and altered fetal hormonal sensitivity21 are only found to be 
associated with glucose tolerance and not fasting glucose levels. Other risk factors associated with 
placental dysfunction such as pre-eclampsia was associated with both glucose measures – but the effect 
size was larger in glucose intolerance. Intriguingly, such differences suggestively extend well after 
pregnancy with elevated 2-h plasma glucose levels (glucose intolerance) associated with higher risk of 
the mother eventually developing Type 2 diabetes (O'Sullivan 1991).  
In line with Pederson’s hypothesis, impaired fasting glucose (IFG) projects a differential insulin 
sensitivity and secretion profile as compared to impaired glucose tolerance (IGT) – in IFG, the liver 
exhibits insulin resistance while the skeletal muscles have normal insulin sensitivities; in IGT, the liver 
has normal to slightly decreased insulin sensitivity while skeletal muscles exhibit moderate to severe 
insulin resistance. Pancreatic insulin secretion is decreased initially upon a glucose load in IFG but 
recovers later while remains severely repressed in IGT. Expectedly, in an IFG state, plasma glucose is 
 
19
 Which arguably, the 1999 WHO guidelines is not. 
20
 Macrosomia, large for gestational age, shoulder dystocia during parturition, increased risk of Caesarean 
delivery. 
21
 Infant hypoglycaemia and jaundice 
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initially high, becomes high after a glucose load, but drops back due to normal skeletal muscle insulin 
sensitivity. In the IGT state, although plasma glucose levels are lower at baseline, after a glucose load, 
plasma glucose levels remain high for prolonged periods (Abdul-Ghani, Jenkinson et al. 2006). This 
differential endocrine response between IFG and IGT states in a pre-diabetic state fits well with the 
differential prognostic outcomes observed within gestationally diabetic mothers when fasting glucose 
measures are separated from glucose intolerance measures. Thus, completing the picture would be the 
investigation of how these different glucose measures influence the metabolic trajectories in neonates 
post exposure – in which an interrogation of the DNA methylation landscape of the infant can provide.  
 
4.2 Materials and Methods 
As described in Section 2.4.1, 901 subjects with full phenotypic information with respect to the 
covariates adjusted for were selected to have the infant umbilical cord samples be surveyed via 
Infinium450K (Table 4.2). The -values (section 2.4.2) were batch-corrected using ComBat (Johnson, 
Rabinovic et al. 2007), analysed using linear regression (section 2.4.3), corrected for predominant 
covariates and cell types (section 2.4.4). 174,211 autosomal, non-hybridizing probes had data from at 
least 90% of the subjects, a 2xIQR DNA methylation range of above 10%. DNA methylation values of 
these probes were linearly regressed against the 26 week oral glucose tolerance test (OGTT) results of 
both fasting and after a 2-h 75g glucose challenge separately, correcting for birth order, infant gender, 
gestation, ethnicity and cell type. After the p-values of the probes were calculated, probes within 10bp 
of known SNPs, as well as those which were no longer significant after outlier correction (section 2.4.3) 
were removed from further analysis. Probes which were associated to genes previously found 
significant with diabetes or obesity-related Genome-Wide Association Studies (GWAS) were also 




Table 4.2. Characteristics of the study sample: N = 901 GUSTO Mother-infant dyads in GUSTO/GDM Study 




Maternal Age at 
birth (years) 31.3 (5.1) 28.0 901 2.27 x 10
-5 1.26 x 10-6 
Maternal BMI  
(26 week gestation) 22.7 (4.4) 26.3 836 3.20 x 10
-12 4.00 x 10-8 
Maternal Height 
(cm) 158.3 (5.6) 40.2 891 0.3041 1.70 x 10
-3 
Gestational Weight 
Gain (kg) 8.6 (4.5) 41.5 832 0.0239 0.1983 
Systolic Blood 
Pressure (mmHg) 113.6 (12.6) 94.0 746 6.00 x 10
-8 1.86 x 10-5 
Diastolic Blood 
Pressure (mmHg) 64.9 (8.4) 65.0 746 3.06 x 10
-3 3.32 x 10-5 
Gestation (days) 272.7 (6.9) 31.0 901 0.0127 0.0164 
Birthweight (g) 3153 (391) 3310 901 2.60 x 10-7 7.18 x 10-4 
 
 
OGTT (fasting) / mmol/L 
 
OGTT (2h) / mmol/L 







































































































































































































































*P-value of univariate analysis of OGTT(fasting) or OGTT(2h) with the corresponding covariate, adjusted for 
ethnicity. Mean, SD, Range and N reflect the corresponding OGTT values. 




 4.3 Results 
4.3.1 Diagnosing Gestational Diabetes 
 
Figure 4.1. Scatterplot of OGTT values (x-axis: fasting, y-axis: 2h) within the GUSTO GDM cohort. The lines 
represent the GDM thresholds as defined by WHO (yellow) and IADPSG (purple). Points above or to the right of 
the thresholds are deemed gestationally diabetic.  
 
Within the GUSTO cohort GDM study (n = 901), the average fasting plasma glucose levels is 4.3 
(standard deviation = 0.4) and average 2h plasma glucose levels is 6.5 (standard deviation = 1.4) with 
Pearson correlation coefficient = 0.3113 (p-value = 1.07 x 10-21). 
Testament to the variability of diagnostic criteria, there is indeed an observable and significant 
difference between the proportion of subjects who would have been diagnosed as gestationally diabetic 
using one criteria over the other (Using WHO, GDMproportion = 17.65%; using HAPO, GDMproportion = 
12.54%; p-value = 2.44 x 10-3). Interestingly, using only the 1999 WHO fasting plasma glucose criteria, 


0.10% of the cohort would be gestationally diabetic (only 1 subject), whereas the 1999 WHO 2h OGTT 
captures the entire 17.65% of the cohort who would be diagnosed as gestationally diabetic using both 
WHO indices. The individual HAPO GDM criteria on the other hand, would diagnose 4.77% (or 
38.05% of the cohort who would be diagnosed with GDM under HAPO) of the cohort as gestationally 
diabetic using fasting plasma glucose levels, and 9.77% (or 77.88% of the cohort who would be 
diagnosed with GDM under HAPO). 
 
4.3.2 Fasting Plasma Glucose Levels 
 
Figure 4.2 Distribution of Infinium450K probe p-values with respect to fasting plasma glucose levels. (A) 
Histogram; (B) Manhattan plot. The red line represents the threshold for significance using the Bonferroni-
corrected p-value (6.542). (C) Volcano plot of normalized regression  values (x-axis) against its negative 
logarithmic (base 10) p-values. Large black dots (n = 250) were randomly plotted to approximate the distribution 
within the scatterplot cloud. 
 
Out of a total of 174,211 autosomal, non-crosshybrid Infinium450K probes, 409 had significantly 
differentiated DNA methylation levels with respect to fasting glucose levels (p-value < 10-3) (Figure 
4.2A). These probes are represented in a Manhattan plot (Figure 4.2B) with none passing the 
Bonferroni-corrected p-value threshold of 2.870 x 10-7 (in red). After probes within 10bp of known 
SNPs were removed, 11,372 probes had p-value under 0.05 and also significant after outlier correction. 


The cloud density between the positive and negative ends of the normalized regression beta values are 
approximately of equal area and density, with a longer tailing on the left, suggesting slight 
hypomethylation in the umbilical cords of infants who experienced maternal hyperglycemia during 
fasting (Figure 4.2C; ratio of probes with positive normalized beta against negative normalized beta: all 




A) Fasting plasma glucose levels – Genomic Association 
 
B) Fasting plasma glucose levels – CGI 
 
 
Figure 4.3 Relative enrichment of probes significant within fasting plasma glucose levels with respect to 
methylation Interquartile Range (IQR), regression beta direction, p-value significance; segregated by (A) gene 
association and (B) CpG Island association. The left half of the figures represent probes which are hypomethylated 
with respect to fasting plasma glucose levels (i.e. negative beta values) whereas the right half represents probes 
which are hypermethylated (i.e. positive beta values). Each figure is further divided to represent probes which 
have relatively conserved methylation values (i.e. IQR  20%) and those which display large inter-individual 
variation (i.e. IQR > 20%). The significance of relative enrichments was calculated using a chi-square test and the 
p-values of the enrichment scores themselves is represented by asterisks (*). *: p-value < 0.05, **: p-value < 0.01, 




Significant enrichment of hypomethylated probes and significant under-representation of 
hypermethylated probes with low variability (IQR  20%) with respect to fasting plasma glucose levels 
in gene promoters suggest decreasing promoter methylation with increasing fasting plasma glucose 
levels (Figure 4.3A). Interestingly, there is also a significant under-representation of hypomethylated 
CGIs, and hypermethylated CG shores and shelves with a concominant enrichment of hypomethylated 
CG shores and hypermethylated CGIs in probes with low methylation variability (Figure 4.3B). 
Notably, there are very few probes with exhibit high methylated variation (n = 1,342) which could 
explain the lack of significance in enrichments for such regions – or suggestive of no specific genomic 
trend being influenced by fasting maternal plasma glucose levels. The inverse relationship between 
CGIs and promoters suggest other genomic regions (such as enhancers) may be subtly influenced by 




4.3.2.1 Most differentially methylated probes with respect to maternal fasting plasma glucose levels 
 
Figure 4.4 Heatmap of the differential methylation of infant umbilical cord DNA most significantly influenced by 
fasting plasma glucose. Infant CpGs associated with maternal pregnancy fasting plasma glucose are both 
hypomethylated and hypermethylated. Heatmap of regression coefficients for associations between the top 50 
most differentially methylated infant CpGs and maternal pregnancy FPG (left column) and corresponding 
associations for maternal pregnancy 2-h plasma glucose (2-hPG) (right column). Number of * represents the –
log10p-value for association between methylation and maternal PG. Colour represents the increasing magnitude 
of coefficients from red (most negative) to yellow (zero) to blue (most positive). Regression coefficients are 




Figure 4.5 Circos plot of infant genes associated with maternal pregnancy fasting plasma glucose (FPG). Circos 
plot illustrates the –log10p-values for associations between maternal pregnancy FPG and infant DNA methylation 
for the top 500 CpGs (red) and their neighbouring CpGs (black). Neighbouring CpGs are defined as CpGs within 
the gene for top CpGs located within the same gene or all CpGs within 50 kbp for CpGs located in intergenic 
regions. Gene names corresponding to the top 500, top 200 and top 50 CpGs are shown in the outermost, second 




The heatmap of the top FPG CpGs reflect approximately equal distributions of hypomethylation and 
hypermethylation in the infant DNA methylome (Figure 4.4). Notably, when the same CpG is regressed 
against 2-hPG instead of FPG, although the beta directionality is largely preserved, significance is lost 
by several orders of magnitude (Appendix III). This suggests that FPG influences specific genomic loci 
within the infant methylome differently from 2-hPG. The genes and neighbouring CpGs associated with 
the top 500 CpGs most differentially methylated with respect to FPG were also plotted on a circus plot 
to illustrate the distribution of probes across the genome (Figure 4.5). 
 
4.3.2.2 Diabetes and obesity-related genes  
Table 4.3 Significantly differentially methylated Infinium450K probes (top 500 with p < 0.001) with respect to 






No. of Probes,  
p-value < 0.001 
No. of probes  
p-value < 0.05  Reference 
ANK1 47 1 1 
(Imamura, Maeda et al. 2012, 
DIAGRAM, Consortium et al. 
2014) 
ARAP1 25 1 5 
(Voight, Scott et al. 2010, 
DIAGRAM, Consortium et al. 
2014) 
BRD2 29 1 3 (Houde, Ruchat et al. 2015) 
CDKN2B 4 1 2 (Zeggini, Weedon et al. 2007) 
DUSP8 14 1 3 (McCarthy 2010) 
KLF11 13 1 3 (Neve, Fernandez-Zapico et al. 2005) 
LHPP 18 1 4 (Binder, LaRocca et al. 2015) 
ZFAND3 23 1 2 (Cho, Chen et al. 2012) 
















Table 4.4 Significantly differentially methylated Infinium450K probes (top 500 with p < 0.001) with respect to 






No. of Probes,  
p-value < 0.001 
No. of probes  
p-value < 0.05  Reference 
C9orf171 13 1 1 (Comuzzie, Cole et al. 2012) 
EML6 13 1 1 (Cotsapas, Speliotes et al. 2009) 
FARS2 7 1 2 (Wheeler, Huang et al. 2013) 
GRIK2 35 2 18 (Comuzzie, Cole et al. 2012) 
ITPR2 13 1 2 (Heid, Jackson et al. 2010) 
KCNIP4 26 1 9 (Comuzzie, Cole et al. 2012) 
LHPP 18 1 4 (Comuzzie, Cole et al. 2012) 
LINC01101 43 2 7 (Wang, Zhang et al. 2011) 
MMD 12 1 1 (Comuzzie, Cole et al. 2012) 
MYO1B 13 1 2 (Comuzzie, Cole et al. 2012) 
NRXN3 34 1 6 (Berndt, Gustafsson et al. 2013) 
PHACTR2 14 1 2 (Comuzzie, Cole et al. 2012) 
PPARGC1B 11 1 3 (Comuzzie, Cole et al. 2012) 
RBFOX1 69 1 4 (Comuzzie, Cole et al. 2012) 
SAMD13 9 1 2 (Comuzzie, Cole et al. 2012) 
SHH 53 3 5 (Comuzzie, Cole et al. 2012) 
SLC22A11 25 1 1 (Comuzzie, Cole et al. 2012) 
SMYD3 23 1 3 (Comuzzie, Cole et al. 2012) 
SORBS1 24 2 5 (Comuzzie, Cole et al. 2012) 
TGFBRAP1 8 1 1 (Comuzzie, Cole et al. 2012) 
TRAPPC9 46 1 7 (Comuzzie, Cole et al. 2012) 
 
Since several GWAS related to diabetes, fasting/2h OGTT, insulin resistance and lipid metabolism have 
been conducted, differentiated methylated probes corresponding to these diabetes-associated (GWAS 
and EWAS, Table 4.3) and obesity-related (GWAS, Table 4.4) genes were extracted. Here, we used the 
top 500 differentially methylated CpGs with p < 0.001 which were associated with any gene reported 
to be correlated with any diabetes-related GWAS or EWAS. Eight diabetes-related genes each 





 BSCL2 was in the top 500 diabetes-related CpGs; Similarly, ESR1 and RASGEF1A were in the top 500 obesity-
related CpGs; CLEC16A was in both lists but all had p > 0.001. To prevent over-interpretation of results, they 
were removed from the final table. 
	

4.3.2.3 Gene Ontology Enrichment 
Genes associated to the top 500 probes were extracted and analysed for enrichment in gene ontological 
processes (312 genes) against a background gene list of genes associated with probes present in at least 
90% of all samples and possessing DNA methylation range of at least 10% (16,459 genes). Gene 
ontologies with p < 0.05 and their enrichment scores were then summarised using Revigo. 
 Table 4.5 Top 20 Gene Ontology Processes (Biological Processes) enriched within genes associated with 
genomic loci affected by fasting plasma glucose 












homophilic cell adhesion via 
plasma membrane adhesion 
molecules 
9.83E-05 0.342 0.715 1.000 1 3540 
GO:0006935 chemotaxis 1.20E-04 0.342 0.099 1.000 2 678 
GO:0042330 taxis 1.20E-04 0.342 0.099 1.000 3 679 
GO:0098742 cell-cell adhesion via plasma-
membrane adhesion molecules 1.68E-04 0.377 0.423 1.000 4 2486 
GO:0006909 phagocytosis 1.71E-04 0.377 0.880 1.000 5 3969 
GO:0016192 vesicle-mediated transport 5.16E-04 0.790 0.676 1.000 6 3437 
GO:1900274 regulation of phospholipase C 
activity 7.57E-04 0.794 0.587 1.000 7 3154 
GO:0048010 
vascular endothelial growth 
factor receptor signaling 
pathway 
8.04E-04 0.794 0.406 1.000 8 2417 
GO:0007411 axon guidance 8.11E-04 0.794 0.035 1.000 9 216 
GO:0097485 neuron projection guidance 8.11E-04 0.794 0.035 1.000 10 217 
GO:0038093 Fc receptor signaling pathway 8.39E-04 0.794 0.363 1.000 11 2198 
GO:0003420 
regulation of growth plate 
cartilage chondrocyte 
proliferation 
1.09E-03 0.902 1.000 1.000 12 4204 
GO:0010922 positive regulation of phosphatase activity 1.53E-03 1.000 0.089 1.000 13 604 
GO:0035306 positive regulation of dephosphorylation 1.57E-03 1.000 0.207 1.000 14 1402 
GO:0035307 positive regulation of protein dephosphorylation 1.57E-03 1.000 0.207 1.000 15 1403 
GO:0006893 Golgi to plasma membrane 
transport 1.64E-03 1.000 0.212 1.000 16 1429 
GO:0098609 cell-cell adhesion 1.77E-03 1.000 0.125 1.000 17 879 
GO:0051343 
positive regulation of cyclic-
nucleotide phosphodiesterase 
activity 
1.93E-03 1.000 1.000 1.000 18 4205 
GO:0061564 axon development 2.04E-03 1.000 0.048 1.000 19 290 







Table 4.6 Top* Representative Gene Ontology Processes (Biological Processes) as summarised by Revigo 






vascular endothelial growth factor receptor 
signaling pathway 73 50.13% -1.893 
regulation of phospholipase C activity 24 38.60% -2.122 
phagocytosis 20 6.83% -2.114 
chemotaxis 19 11.42% -2.036 
inositol phosphate metabolism 17 2.23% -1.791 
innate immune response 10 58.84% -1.951 
ion homeostasis 10 5.36% -1.853 
*Only representative ontologies with at least 10 gene ontology terms are presented. Cumulative frequency refers 
to the cumulative representation of the representative ontology as a function of the background (the higher, the 
larger representation) whereas the average log10p refers to the averaged p-value across the ontologies represented. 
  
None of the enriched ontological processes passed FDR q-value < 0.05, however, eleven least p-value 
< 10-3 (Table 4.5). When summarised into representative ontologies, maternal fasting glucose appears 
to impact genomic loci within gene regions associated with cell signalling, movement and immune 
pathways (Table 4.6). Surprisingly, processes which are associated with glucose energy metabolism do 




4.3.3. 2h Post 75g Glucose Challenge Plasma Glucose Levels 
 
Figure 4.6 Distribution of Infinium450K probe p-values with respect to 2h post glucose challenge plasma glucose 
levels. (A) Histogram; (B) Manhattan plot. The red line represents the threshold for significance using the 
Bonferroni-corrected p-value (6.690) whereas the blue line represents the threshold for the top 100 hits (3.585). 
(C) Volcano plot of normalized regression  values (x-axis) against its negative logarithmic (base 10) p-values. 
Large black dots (n = 250) were randomly plotted to approximate the distribution within the scatterplot cloud. 
 
Out of a total of 174,211 autosomal, non-crosshybrid Infinium450K probes, 625 had significantly 
differentiated DNA methylation levels with respect to fasting glucose levels (p-value < 10-3) (Figure 
4.6A). These probes are represented in a Manhattan plot (Figure 4.6B) with none passing the 
Bonferroni-corrected p-value threshold of 2.870 x 10-7 (in red). After probes within 10bp of known 
SNPs were removed, 16,837 probes had p-value under 0.05 and were also significant after outlier 
correction. Unlike the trend observed when analysing fasting plasma glucose levels, the cloud density 
on the negative end of the normalized regression beta values is slightly larger than that on the positive 
end, with a slightly longer tailing on the left, suggesting hypomethylation in the umbilical cords of 
infants who experienced elevated maternal glucose levels 2h post 75g glucose challenge (Figure 4.6C; 
ratio of probes with negative normalized beta against positive normalized beta: all probes – 2.046, 
probes with p-value <0.05 – 5.078). Notably, the difference in CpG density is greater at significance 
(p-value <0.05).  

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A) OGTT-2h – Genomic Association 
 
B) OGTT-2h – CGI  
 
 
Figure 4.7 Relative enrichment of probes significant within plasma glucose levels 2h post glucose challenge with 
respect to methylation Interquartile Range (IQR), regression beta direction, p-value significance; segregated by 
(A) gene association and (B) CpG Island association. The left half of the figures represent probes which are 
inversely correlated with fasting plasma glucose levels (i.e. negative beta values) whereas the right half represents 
probes which are positively correlated (i.e. positive beta values). Each figure is further divided to represent probes 
which have relatively conserved methylation values (i.e. IQR  20%) and those which display large inter-
individual variation (i.e. IQR > 20%). The significance of relative enrichments was calculated using a chi-square 
test and the p-values of the enrichment scores themselves is represented by asterisks (*). *: p-value < 0.05, **: p-
value < 0.01, ***: p-value < 0.001.  


Global differential methylation profile with respect to maternal plasma glucose levels 2h post 75g 
glucose challenge appears rather different from fasting plasma glucose levels. Significant depletion of 
probes significantly (low variability) differentially methylated, lying within gene promoters and 5’UTR, 
suggest conservation of DNA methylation patterns in such regions. Exons on the other hand, reflect 
small but significant enrichments on probes found to negatively correlate to 2h post glucose challenge 
plasma levels (Figure 4.7A). With respect to CpG islands, low variability probes appear to show 
significant under-representations suggesting conservation of methylation patterns in such regions. 
Conversely, regions not associated with CGIs (open seas) as well as hypomethylated CpG shelves are 
significantly enriched whereas hypermethylated CpG shelves reflect significant under-representation 
(Figure 4.7B). Probes which were most variable (IQR > 20%) were not significantly enriched for 




4.3.3.1 Most differentially methylated probes with respect to maternal plasma glucose levels 2h post 
75g glucose challenge 
 
Figure 4.8 Heatmap of the differential methylation of infant umbilical cord DNA most significantly influenced by 
2-h OGTT. Infant CpGs associated with maternal pregnancy 2-h plasma glucose is predominantly 
hypomethylated. Heatmap of regression coefficients for associations between the top 50 most differentially 
methylated infant CpGs and maternal pregnancy 2-h plasma glucose (2-hPG) (right column) and corresponding 
associations for maternal pregnancy FPG (left column). Number of * represents the –log10p-value for association 
between methylation and maternal PG. Colour represents the increasing magnitude of coefficients from red (most 
negative) to yellow (zero) to blue (most positive). Regression coefficients are reported as change in methylation 




Figure 4.9 Circos plot of infant genes associated with maternal pregnancy 2-h plasma glucose (2-hPG). Circos 
plot illustrates the –log10p-values for associations between maternal pregnancy 2-hPG and infant DNA 
methylation for the top 500 CpGs (red) and their neighbouring CpGs (black). Neighbouring CpGs are defined as 
CpGs within the gene for top CpGs located within the same gene or all CpGs within 50 kbp for CpGs located in 
intergenic regions. Gene names corresponding to the top 500, top 200 and top 50 CpGs are shown in the outermost, 
second outermost and third outmost tracks respectively. 
 
Unlike the heatmap of the top FPG CpGs, the top 2-hPG CpGs reflect globally hypomethylated infant 
DNA methylome (Figure 4.8). Taken together with the results of the top FPG CpGs, this global 
methylation difference strongly suggests FPG and 2-hPG influence the infant methylome in different 
specific regions. Nevertheless, when the same CpG is regressed against FPG, the beta directionality is 
largely preserved, and again, significance is lost by several orders of magnitude (Appendix IV). Since 

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FPG and 2-hPG are highly correlated with one other, despite the differential influence of the infant 
methylome by the two glucose measures, it is likely that similar regions can be affected by one measure 
and reflected in the other. The genes and neighbouring CpGs associated with the top 500 CpGs most 
differentially methylated with respect to 2-hPG were also plotted on a circus plot to illustrate the 
distribution of probes across the genome (Figure 4.9).  
 
4.3.3.2 Diabetes and Obesity-related genes   
Table 4.7 Significantly differentially methylated Infinium450K probes (top 500 with p < 0.001) with respect to 






No. of Probes, 
p-value < 0.001 
No. of Probes, 
p-value < 0.05 Reference 
ANK1 47 1 3 (Imamura, Maeda et al. 2012, DIAGRAM, Consortium et al. 2014) 
BCAR1 25 1 2 (Matsuba, Sakai et al. 2015) 
C18orf42 5 1 2 (Anderson, Cordell et al. 2015) 
DCD 5 1 4 (Zeggini, Scott et al. 2008) 
DLGAP2 97 2 25 (Ruchat, Houde et al. 2013, Houde, Ruchat et al. 2015) 
GPR45 19 1 2 (Salonen, Uimari et al. 2007) 
RBM38 14 1 2 (Saxonov, Berg et al. 2006) 
TXNIP 3 1 1 
(Chambers, Loh et al. 2015, Kulkarni, 
Kos et al. 2015, Florath, Butterbach et 
al. 2016) 
ZFAND3 23 1 2 (Cho, Chen et al. 2012) 





Table 4.8 Significantly differentially methylated Infinium450K probes (top 500 with p < 0.001) with respect to 





No. of Probes,  
p-value < 0.001 
No. of probes  
p-value < 0.05  Reference 
AGAP1 62 1 3 (Comuzzie, Cole et al. 2012)
ANKS1A 5 1 2 (Comuzzie, Cole et al. 2012)
ANKS1B 23 1 2 (Comuzzie, Cole et al. 2012)
ASZ1 8 1 2 (Liu, Monda et al. 2013) 
BMP2 4 1 1 
(Willer, Speliotes et al. 2009, 
Comuzzie, Cole et al. 2012, 
Graff, Ngwa et al. 2013) 
CDH4 16 1 8 (Comuzzie, Cole et al. 2012) 
CHL1 13 1 4 (Comuzzie, Cole et al. 2012) 
CPLX2 21 1 9 (Comuzzie, Cole et al. 2012)
DLG2 31 1 7 (Comuzzie, Cole et al. 2012)
EPHA6 11 1 3 (Comuzzie, Cole et al. 2012)
EXT1 39 1 4 (Comuzzie, Cole et al. 2012)
IL1RN 9 1 1 (Comuzzie, Cole et al. 2012)
KCNIP4 26 1 6 (Comuzzie, Cole et al. 2012)
LHX2 26 1 5 (Liu, Monda et al. 2013) 
LINC01101 43 1 4 (Comuzzie, Cole et al. 2012)
LOC101927587 5 1 1 (Comuzzie, Cole et al. 2012)
MATK 37 1 6 (Comuzzie, Cole et al. 2012)
NOS1AP 10 1 2 (Comuzzie, Cole et al. 2012, Bryan, Argos et al. 2014) 
OPCML 83 2 17 (Liu, Monda et al. 2013) 
PCSK1 5 1 1 (Liu, Monda et al. 2013, Wen, Zheng et al. 2014) 
PELI2 20 1 2 (Comuzzie, Cole et al. 2012) 
PLXNA4 23 1 4 (Fox, Heard-Costa et al. 2007) 
POLD1 4 1 2 (Comuzzie, Cole et al. 2012)
SHANK2 52 1 12 (Comuzzie, Cole et al. 2012)
SORBS1 24 1 9 (Comuzzie, Cole et al. 2012)
SPATA8 5 1 1 (Comuzzie, Cole et al. 2012)
TRHR 10 1 5 (Liu, Tan et al. 2009) 
UMODL1 8 1 4 (Comuzzie, Cole et al. 2012) 
 
 
Similar to Section 4.3.2.2, differentiated methylated probes corresponding to diabetes (Table 4.7) and 
obesity-related (Table 4.8) GWAS and EWAS were extracted. Using the top 500 most differentially 
methylated CpGs, nine genes had at least one CpG p < 0.001 which were associated with any reported 
gene correlated with any diabetes-related GWAS or EWAS, and 28 genes had at least one CpG p < 




4.3.3.3 Gene Ontology Enrichment 
Genes associated to the top 500 2-hPG probes were extracted and analysed for enrichment in gene 
ontological processes (316 genes) against a background gene list of genes associated with probes 
present in at least 90% of all samples and possessing DNA methylation range of at least 10% (16,459 
genes) 
 
Table 4.9 Gene Ontology (Biological Processes) Enriched within genes associated with genomic loci affected by 
OGTT (2h) 











GO:0050877 neurological system process 0.262 1.000 3.34E-04 1.000 1958 1 
GO:0048008 platelet-derived growth factor 
receptor signaling pathway 0.310 1.000 7.35E-04 1.000 2201 2 
GO:0003008 system process 0.149 1.000 1.12E-03 1.000 1234 3 
GO:0051055 negative regulation of lipid biosynthetic process 1.000 1.000 1.26E-03 1.000 4308 4 
GO:0050885 neuromuscular process 
controlling balance 0.029 1.000 1.54E-03 1.000 295 5 
GO:0071731 response to nitric oxide 1.000 1.000 1.56E-03 1.000 4309 6 
GO:0046686 response to cadmium ion 1.000 1.000 1.72E-03 1.000 4310 7 
GO:0050890 cognition 0.457 1.000 1.72E-03 1.000 2913 8 
GO:0061209 cell proliferation involved in 
mesonephros development 1.000 1.000 2.35E-03 1.000 4311 9 
GO:0030001 metal ion transport 0.165 1.000 2.84E-03 1.000 1349 10 
GO:0090045 positive regulation of deacetylase activity 1.000 1.000 3.04E-03 1.000 4312 11 
GO:2000664 positive regulation of interleukin-5 secretion 1.000 1.000 3.23E-03 1.000 4313 12 
GO:0007258 JUN phosphorylation 1.000 1.000 3.49E-03 1.000 4314 13 
GO:0021540 corpus callosum 
morphogenesis 0.101 1.000 3.74E-03 1.000 910 14 
GO:0036148 phosphatidylglycerol acyl-
chain remodeling 1.000 1.000 3.81E-03 1.000 4315 15 
GO:1990138 neuron projection extension 0.388 1.000 3.94E-03 1.000 2580 16 
GO:0007611 learning or memory 0.336 1.000 4.09E-03 1.000 2353 17 
GO:0097210 response to gonadotropin-
releasing hormone 1.000 1.000 4.23E-03 1.000 4316 18 
GO:0097211 
cellular response to 
gonadotropin-releasing 
hormone 
1.000 1.000 4.23E-03 1.000 4317 19 





Table 4.10 Top* Representative Gene Ontology Processes (Biological Processes) as summarised by Revigo 






negative regulation of lipid biosynthesis 32 13.78% -1.717 
metal ion transport 27 24.55% -1.745 
response to nitric oxide 26 1.21% -1.843 
neurological system process 25 11.14% -1.937 
regulation of cell size 22 3.87% -1.577 
*Only representative ontologies with at least 10 gene ontology terms are presented. Cumulative frequency refers 
to the cumulative representation of the representative ontology as a function of the background (the higher, the 
larger representation) whereas the average log10p refers to the averaged p-value across the ontologies represented.
  
None of the enriched ontological processes passed FDR q-value < 0.05, and only two at least p-value < 
10-3 (Table 4.9). Unlike fasting plasma glucose results, processes which are associated with glucose 
metabolism were enriched – polysaccharide metabolism had four ontologies represented (cumulative 
representation of 1.20%, average log10p-value = -1.545). Lipid metabolism was also clearly influenced 
in 2-hPG as the top representative ontology (Table 4.10). Neurological processes also feature 





4.3.4 Comparing Results from Two Separate GDM Indices 
 
Figure 4.10. Scatterplot of outlier-corrected significant probes. A) Common outlier-corrected probes significant 
with respect to fasting plasma glucose levels (x-axis) plotted against that of 2-h post glucose challenge. The 
numbers represent the number of point in each sector. B) Common outlier-corrected significant probes with 
respect to WHO GDM criteria (top row), HAPO GDM criteria (bottom row) plotted against those significant with 
OGTT (fasting) (left column) and OGTT (2h) (right column). 
 
In comparing the impact of both maternal antenatal fasting and 2h OGTT on the infant methylome, we 
attempt to uncover genomic loci which are most susceptible to the changing glucose tolerances a 
pregnant mother may experience. Intriguingly, since the diagnosis of gestational diabetes is primarily 
derived from the fasting plasma glucose as well as 2h OGTT, regardless of clinical thresholds actually 
employed, we expected a high concordance in the genomic loci significantly differentially methylated 
between both indices of GDM, as well as between the indices and established clinical diagnostic 
thresholds. However, from the scatterplots (Figure 4.10) between either index, compared against each 
other (Figure 4.10A) as well as compared against either GDM diagnostic criteria (Figure 4.10B), neither 
OGTT seems to be representative of findings using either the WHO or HAPO criteria for GDM. Since 
each OGTT is a representation of select maternal metabolic functions (fasting glucose – accelerated 
starvation; 2h OGTT – facilitated anabolism), the poor concordance between OGTTs suggest poor 




Table 4.11 List of Common CpGs which were most differentially methylated in FPG and 2-hPG 
CpG Gene FPG  FPG 95% C.I. FPG p 2-hPG 
 
2-hPG 95% C.I. 2-hPG p 
cg15160524 TNS1 -0.124 (-0.186, -0.062) 9.51E-05 -0.124 (-0.186, -0.063) 7.93E-05 
cg15683166 FAM24B -0.122 (-0.184, -0.061) 9.86E-05 -0.127 (-0.188, -0.067) 4.12E-05 
cg24016995 PTPRE -0.127 (-0.191, -0.063) 1.02E-04 -0.118 (-0.181, -0.054) 2.87E-04 
cg08096062 CCDC85A -0.125 (-0.188, -0.061) 1.31E-04 -0.115 (-0.178, -0.052) 3.77E-04 
cg10969919 TRPC7 -0.125 (-0.189, -0.060) 1.57E-04 -0.118 (-0.182, -0.055) 2.84E-04 
cg10567378 BTBD9 0.081 (0.039, 0.124) 1.90E-04 0.095 (0.053, 0.137) 9.64E-06 
cg20511797 ABL1 -0.115 (-0.175, -0.054) 2.09E-04 -0.117 (-0.177, -0.057) 1.28E-04 
cg11455444 LINC01101 0.108 (0.051, 0.166) 2.24E-04 0.106 (0.049, 0.163) 2.67E-04 
cg25915512 IL36B -0.108 (-0.167, -0.048) 3.94E-04 -0.115 (-0.174, -0.057) 1.20E-04 
cg07169660 LINC00910 -0.116 (-0.180, -0.052) 4.26E-04 -0.118 (-0.182, -0.055) 2.73E-04 
cg25046772 Intergenic -0.109 (-0.170, -0.048) 5.14E-04 -0.109 (-0.170, -0.049) 4.07E-04 
cg01547809 TUSC2 -0.104 (-0.164, -0.044) 7.28E-04 -0.117 (-0.176, -0.057) 1.28E-04 
cg00094412 GABBR1 0.087 (0.036, 0.137) 7.97E-04 0.098 (0.048, 0.148) 1.25E-04 
cg08938062 GPCPD1 -0.107 (-0.170, -0.043) 1.02E-03 -0.126 (-0.188, -0.063) 8.94E-05 
cg18530299 Intergenic -0.1 (-0.161, -0.040) 1.10E-03 -0.117 (-0.176, -0.057) 1.23E-04 
cg07790085 Intergenic -0.107 (-0.171, -0.042) 1.18E-03 -0.122 (-0.185, -0.058) 1.85E-04 
 
 
Table 4.12 List of Common Genes which contain CpGs most differentially methylated in FPG and 2-hPG 
Gene # CpGs in Top FPG CpG 
# CpGs in 
Top 2-hPG CpG 
ABL1 1 cg20511797 1 cg20511797 
ARL4D 1 cg01445163 1 cg06795960 
BBS1 1 cg12018863 1 cg04006266 
BTBD9 1 cg10567378 1 cg10567378 
C10orf11 1 cg09553982 1 cg03448754 
CCDC85A 1 cg08096062 1 cg08096062 
CD58 3 cg11574055, cg02974976, 
cg08478283 1 cg09584521 
ERICH1-AS1 1 cg23353046 1 cg06931523 
FAM24B 1 cg15683166 1 cg15683166 
GABBR1 2 cg09577455, cg00094412 2 cg00094412, cg17053201 
GPCPD1 1 cg08938062 1 cg08938062 
IL36B 1 cg25915512 1 cg25915512 
KCNIP4 1 cg23452289 1 cg07175433 
KIF26B 1 cg17888232 1 cg12448285 
LARP1 1 cg23613317 1 cg06442673 
LINC00910 1 cg07169660 1 cg07169660 
LINC01101 2 cg19102412, cg11455444 1 cg11455444 
OSBPL5 1 cg14722290 1 cg13421345 
PTPRE 1 cg24016995 1 cg24016995 
PTPRN2 1 cg25277638 4 cg07979652, cg21163617, 
cg08597719, cg16708264 
SMYD3 1 cg04798314 1 cg17971290 
SORBS1 2 cg18949056, cg04149179 1 cg10741308 
TMEM132D 1 cg24008358 2 cg18437033, cg24778576 
TNS1 1 cg15160524 1 cg15160524 
TNXB 1 cg05889186 1 cg04076535 
TRAPPC3 1 cg01747664 1 cg19822229 
TRPC7 1 cg10969919 1 cg10969919 





Figure 4.11 Gene ontologies differ between FPG and 2-hPG CpGs. Barplot illustrates the top 20 most significant gene 
ontologies enriched for within the top 500 Fasting (dark blue) and 2-hPG (light blue) CpGs as calculated by missMethyl. 
 
From Sections 4.3.2.1, 4.3.3.1 and 4.3.4.1, we clearly observe that the same CpGs differentiated 
methylated in one glucose measure would likely be much less significant in the other. Taking the top 
500 CpGs on both sides, we note only 16 CpGs overlap between FPG and 2-hPG (3.3%, Table 4.9). 
This overlap increases to about 8.5% if we consider the corresponding gene to individual CpGs – FPG 
corresponds to 312 unique genes and 2-hPG corresponds to 316 genes – 27 genes overlap between the 
two (Table 4.11). Gene ontology enrichments were also different between FPG and 2-hPG – with little 
overlap between any of the specific ontologies derived from missMethyl (Figure 4.12). However, when 
these ontologies were summarised using Revigo, we observe some similarities between FPG and 2-hPG 
– in certain immunological processes and general cell signalling. Nevertheless, whereas FPG is clearly 
enriched mostly in vascular endothelial growth factor receptor signalling pathway (37.5% of all 
biological processes) with little evidence of glucose or lipid metabolic regulation, 2-hPG not only 






Gestational diabetes as a pathology is diagnosed upon one or more clinically determined plasma glucose 
thresholds (Section 4.1.4). The colinearity of these two clinical measurements probably lead to the use 
of their combinatory results in diagnosing gestational diabetes. These thresholds however, can be 
classified into two categories – fasting and a fixed amount of time after a fixed quantity glucose 
ingestion challenge. Wherein fasting plasma levels is associated with metabolic changes under the 
‘accelerated starvation’ hypothesis such as lipid catabolism and protein ketogenesis (Freinkel 1965); 
postprandial plasma glucose levels associate with different metabolic pathways such as lipogenesis and 
decreased insulin sensitivity (Freinkel, Metzger et al. 1974). Here, although both fasting plasma glucose 
and 2h OGTT are indicative of involvement of genes previously identified to be associated with type 2 
diabetes, our results suggest that the resulting DNA methylation profile at birth is significantly different 
between the both of them. Wherein increasing fasting plasma glucose levels is suggestive of increasing 
DNA methylation (Section 4.3.1), increasing glucose levels 2-h post glucose challenge is suggestive of 
decreasing DNA methylation (Section 4.3.2). The scatterplot distributions between the two studies also 
corroborate that each phenotype influences the DNA methylome in a direction antagonistic to the other. 
Expectedly, results derived from using either standards of GDM diagnosis also do not correlate well to 
either plasma measurement – this suggests that either current diagnostic standards do not accurately 
predict molecular influences of an altered metabolism within gestational diabetes, or gestational 
diabetes is actually an amalgamation of two separate pathologies. 
In this study, we observe several unique covariates associated with one glucose measure but not the 
other. For example, while Malays are tolerant of glucose loading as opposed to Chinese (p = 2.71 x 10-
5), Indians on the other hand possess naturally elevated fasting plasma glucose levels (p = 3.52 x 10-4). 
This observation is concordant with recent trends in GDM diagnosis. Since GDM diagnosis is primarily 
based on the WHO (1999) guidelines in Singapore, which we observe to over-represent elevated 2-hPG 
patients, we note that Malays have the lowest rates of GDM as opposed to Chinese and Indians. This 
reduced glucose tolerance in Chinese also nicely explains why the prevalence of GDM among the 
Chinese was observed to experience the greatest decline (followed by Indians) when the GDM criteria 
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shifts from WHO (1999) to IADPSG (2013) (Yew, Khoo et al. 2014). Other demographic/socio-
economic differences include maternal education (p = 1.94 x 10-4), height (p  = 1.70 x 10-3) and reduced 
glucose tolerance, smoking (p = 3.34 x 10-3) and alcohol exposures (p = 8.88 x 10-3) on increased glucose 
tolerance. Expectedly, obesity measures such as prepregnancy BMI and blood pressures impact both 
glucose measures – except gestational weight gain, which is associated with higher fasting plasma 
glucose (p = 0.024) but not 2-hPG. 
Maternal fasting plasma glucose appears to influence different infant DNA methylation loci as 
compared to maternal 2-hPG. With increasing fasting plasma glucose concentrations, we observe a 
slight increase in genome methylation (1.286 significantly hypermethylated per significantly 
hypomethylated CpG) in an otherwise approximately centred differential methylation environment. 
This is remarkably different from the extensive hypomethylation observed across all significant 2-hPG 
CpGs (5.078 significantly hypomethylated per significantly hypermethylated CpG). Furthermore, 
whereas in FPG, CpGs with borderline significances (not passing Bonferroni) were largely 
hypomethylated in promoter regions, as well as CG shores, while those in exons and CGIs were mostly 
hypermethylated; in 2h-PG, gene-centric regions appear to have an inverse relationship – promoters, 
5’UTRs are more hypermethylated, and CG shelves and genomic regions of open sea were also enriched 
for hypomethylated regions. Comparing the most differentially methylated CpGs between FPG and 2-
hPG, we also note that if a CpG is found to be significant in one, it is very unlikely to have significance 
in the other23.  
These two glucose measures also appear to influence the DNA methylation across different genes. Here, 
we note that our original comparison pitted the two glucose measures against the same pool of CpGs – 
hence a relatively unbiased genomic comparison. In order to increase the rate of overlap, many EWAS 
choose to pool the methylation values across one entire gene for comparison. This is not advisable as 
the methylation patterns across an entire gene is highly varied depending on its functional control and 
response elements to other epigenetic phenomena (Section 1.4.1). Averaging methylation across the 
 
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 Assume random chance ( = 0.05), given a pool of 500 CpGs, 25 should be found in common with another pool 
of 500 CpGs. In our case, only 16 were found common between the top 500 CpGs of FPG and 2-hPG. 
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gene typically reduces the sensitivity of the analysis – which may lead to false conclusions due to 
genomic biases which are not easily addressed. Hence, here we compared the rate of overlap between 
genes but did not compare the methylation levels directly as the absolute number of CpGs that overlap 
exactly is small (13).  
To identify gene ontologies which may be common between the two glucose measures, we compared 
whether there were significant overlaps in the top CpG genes with known diabetes or obesity-related 
genes. Although literature pertaining to diabetes GWAS are prevalent, relevant literature on GDM 
GWAS or diabetes-related EWAS on the other hand remains an emerging field. Unsurprisingly, while 
383 genes were compiled from various diabetes-related GWAS24, only 30 additional genes were found 
among the latest EWAS. Obesity-related GWAS are much more extensive, encompassing a total of 
1,423 obesity-related genes25 for comparison. Two diabetes-related genes (ANK1 and ZFAND3) as 
well as three obesity-related genes (LINC01101, KCNIP4 and SORBS1) lie in common between the 
genes associated with the top 500 CpGs of each glucose measure. These genes remain significant for 
both glucose measures even after additionally adjusting for maternal obesity measures – prepregnancy 
BMI and gestational weight gain. Notably, while the SNP on ANK1 has been shown to be significantly 
associated to Type 2 diabetes in both Japanese and European populations (Imamura, Maeda et al. 2012), 
ZFAND3 is specific to East Asians only (Cho, Chen et al. 2012). This ethnic-specific observation is not 
unique to SNPs and potentially impacts epigenetic markers to a larger degree. We note that although 
we did not find evidence to show significant ethnicity (or infant gender26) interactions with both glucose 
measures, like in the parity study, wherein CpGs significant in the entire cohort would be likely to 
remain significant among the Chinese, a smaller proportion remain significant in the Malays and 
Indians. Hence, to further validate the potential influence of genotype on the epigenome27, one could 
follow up with a gene-environment interaction model – first investigating the genetic contribution of 
 
24
 347 genes from the National Human Genome Research Institute (NHGRI) database, 36 additional genes from 
other GWAS papers not in the database. 
25
 1,401 genes from NHGRI and 22 additional genes from other GWAS papers. 
26
 No significant interactions was found between infant genders on DNA methylation. However, the effect sizes 
are suggestively larger in female infants with respect to 2-hPG. 
27
 This is motivated by the lack of CpGs passing Bonferroni significance – which does not strongly suggest specific 
loci differentially methylated in context of either glucose measure. Gene-environment interactions may shed more 
light on potential genetic heterogeneity not investigated within this thesis. 
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potential SNPs in these candidate genes within the cohort, and then determine whether the candidate 
CpGs uncovered here are driven by genotype (methylation Quantitative Trait Loci, methQTLs) or more 
associated with gene-environment interactions.  
In context of diabetes-related EWAS, we compiled the genes from significant CpGs reported across 
four large Type II diabetes (Hidalgo, Irvin et al. 2014, Chambers, Loh et al. 2015, Kulkarni, Kos et al. 
2015, Florath, Butterbach et al. 2016) and three known GDM EWAS studies (Ruchat, Houde et al. 
2013, Binder, LaRocca et al. 2015, Houde, Ruchat et al. 2015). A list of 34 CpGs were reported from 
these seven studies, seven of which were filtered during initial quality control checks and five had low 
inter-individual variability. Among the 22 CpGs remaining, five were significant (p < 0.05) with one 
(cg19693031) passing multiple testing correction (p < 0.05/22). This CpG is found to be associated with 
three Type 2 diabetes EWAS cohorts (Table 4.7) but not any of the GDM EWAS cohorts and located 
in TXNIP terminal exon and hypomethylated in both FPG and 2-hPG (FPG p = 0.0200, 2-hPG p = 3.50 
x 10-4). Thioredoxin-interaction protein (TXNIP) has multiple cellular functions, regulating redox 
homeostasis (Yoshihara, Masaki et al. 2014). In pancreatic -cells, it is upregulated in response to 
hyperglycemia, which can lead to -cell apoptosis (Minn, Hafele et al. 2005). Upregulation of TXNIP 
also leads to inhibition of glucose uptake by fat and muscle cells (Parikh, Carlsson et al. 2007).  
Understandably, despite the suggested genomic implications provided by this study, some obvious 
limitations are apparent. As with the parity study, both fasting plasma glucose as well as 2-h post 
glucose challenge did not uncover any genomic loci significant beyond the Bonferroni-corrected p-
value threshold. Despite actual pathologies involved, it is worth noting that mothers who were 
diagnosed with gestational diabetes were treated upon diagnosis (early second trimester); and that 
mothers who were overtly diabetic were excluded from analysis.  Hence, the lack of significantly 
differentially methylated loci may not be unexpected – as were the magnitude of effect sizes (maximum 
mod beta value observed in fasting plasma is 0.0756 and that of 2-h post glucose challenge is 0.0261). 
This could also suggest that immediate treatment of gestational diabetes could mitigate epigenetic 
perturbations from dysfunctional glucose regulation. Moreover, given that changes in obesity related 
metabolisms have been shown to result in large effect sizes in DNA methylation (Benton, Johnstone et 
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al. 2015)28, as well as the health outcomes associated with maternal hyperglycemia, it seems unlikely 
that the infant is protected by prolonged perturbations in maternal glucose metabolism bordering on the 
clinical definitions of impaired glucose tolerance. Lastly, as with any preliminary screening study, both 





 On the same Infinium450K platform, these authors achieved beta values of 0.232 in adipose tissue methylation 
on women after weight loss. 
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5. Milestones  
5.1 Parity Study  
Parity is an amalgamation of many pre-pregnancy and antenatal environments which may influence 
fetal development and metabolic trajectories. Expectedly, we have found several associations which 
can be broadly categorised as socio-economic status, diet/lifestyle preferences and maternal physiology 
– which significantly associate with firstborn status. Furthermore, the Parity Study presents, to our 
knowledge, the first single nucleotide-resolution, Epigenome-Wide Association Study (EWAS) 
between a non-modifiable environmental influence (primogeniture) and the DNA methylome of the 
infant’s umbilical cord at birth, on the Infinium450K platform.  
We have shown that firstborn infants have significantly hypermethylated intergenic regions and 
hypomethylation in CGIs and 3’UTR regions of genes. Despite no individual CpG passing a strict 
Bonferroni cutoff of 2.870 x 10-7, 5 CpGs had p-values under 10-5. Majority of the most differentially 
methylated CpGs within primogenicity also reflect significance when analysed against birth order. We 
have also found several genomic regions with clusters of significantly differentially methylated probes, 
some clustered around promoter regions of genes with unknown function – likely to play regulatory 
roles as non-coding RNA. The relative enrichment of significantly differentially methylated CpGs 
within intergenic regions also suggest epigenetic regulation beyond gene expression – characteristic of 
interaction between other elements such as histone modifications and proteins regulating genome 
architecture within the nucleus.  
The influence of parity on infant DNA methylation also appears to be independent of maternal age and 
ethnicity. Functional annotation of the top CpGs found in the study reveals hypomethylation patterns 
which do not seem to aggregate according to embryonic tissue of origin, suggesting global changes 
across all tissue types. Gene onotology analysis and summaries of the genes associated with the most 
differentially methylated CpGs reveal cardiac and neural biological processes being the most affected 
pathways. This is concordant with some of the epidemiological associations associated with firstborns, 
such as elevated obesity risks (Section 3.1.2). Notably, such associations do not appear to be 
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transgenerationally inherited – suggesting the potential for further comparisons in future offspring to 
refine the exact epigenetic markers which may predispose the affected individual to negative growth 
outcomes. 
Despite the small absolute DNA methylation differences observed between the CpGs, the ontology 
enrichments revealed in this analysis provides useful insight as to the pathways to look out for in the 
developing child. As GUSTO is a longitudinal study, these initial DNA methylation differences 
observed at birth can be further interrogated in different tissues (buccal and eventually when the child 
is old enough, blood) to observe how they evolve in relation to childhood development and growth. As 
these markers may also be representative of how the maternal environment evolves, similar 
comparisons can be done on maternal blood (against how many times she has been previously pregnant) 
– potentially addressing not only methylome changes with respect to parity, but also the relationship 





 5.2 GDM Study 
The GDM Study presents, to our knowledge, the first single nucleotide-resolution, Epigenome-Wide 
Association Study (EWAS) between indices of a modifiable environmental influence (Oral Glucose 
Tolerance Test (OGTT) as an indicator for glucose regulation) and the DNA methylome of the infant’s 
umbilical cord at birth, on the Infinium450K platform. The comparison of the DNA methylome against 
both fasting and 2h post 75g glucose challenge is significant as it not only presents this prenatal 
influence as a continuum rather than an arbitrary defined dichotomy, but also by testing these highly 
correlated influences separately, we can observe that they indeed impact the fetal DNA methylome 
quite uniquely from each other. Our results also suggest that despite the collinearity of the two glucose 
indices, they reflect different mechanisms within the pathology of gestational diabetes – adding weight 
to the argument that either index is insufficient to prescribe a positive diagnosis of this pathology.  
Despite the similarities in methodology between Parity and GDM, they are distinct studies with 
different outcomes. While parity aims to identify the contribution of various pre-pregnancy and 
antenatal environments to firstborn status, here, the GDM study aims to identify the different etiologies 
contributing to the diabetic state by interrogating two distinct glucose profiles. With respect to fasting 
plasma glucose, we have shown hypomethylation in promoters, CG shores and hypomethylation in 
CGIs. While no individual CpG passed the Bonferroni threshold of 2.870 x 10-7, nine CpGs had p-
values < 10-5. Eight genes with previous associations to diabetes-related GWAS also had CpGs with 
differential DNA methylation of p-value < 10-3. Concordant with the different etiologies of FPG and 2-
hPG, less than half of the most differentially methylated CpGs within fasting plasma glucose do not 
reflect significance when analysed against 2h OGTT.  
With respect to 2-h plasma glucose levels, we have shown significant global hypomethylation, 
especially in CG shelves and open seas. Like in the other studies, we find no individual CpG passing 
Bonferroni cutoff of 2.870 x 10-7, but seven CpGs had p-values under 10-5. Also, similar to fasting 
plasma glucose study, less than half of the most differentially methylated CpGs within 2h OGTT were 
not significant in the fasting glucose study. Here, nine diabetes-related GWAS genes had CpGs with 
differential DNA methylation of p-value under 10-3. Such differentially methylated loci may act in 
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concert with the diabetes-related GWAS SNP loci through genomic architecture, moderated by other 
epigenetic elements – however, this would prove more challenging to experimentally verify.  
In context of diabetes-related pathologies, many genome-wide studies have previously been conducted. 
However, gestational diabetes and epigenome-wide analysis of diabetes-related pathologies remain an 
emerging trend. Here, we have summarised the results from various diabetes-related EWAS and 
managed to replicate significance in five out of 22 CpGs previously found significant. In particular, the 
strongest significance was found in a CpG significantly associated to both FPG and 2-hPG. Intriguingly, 
this CpG possesses a larger effect size (and statistical significance) in 2-hPG than FPG (Section 4.4). 
Notably, it was found to be significant in three of the four Type 2 diabetes EWAS we compiled – the 
fourth did not use 2-hPG but instead looked at the continuous effect of FPG on adult blood DNA 
methylation.  
Moreover, between the two glucose measures, we note that while FPG is associated to altered DNA 
methylation marks in CpGs associated with genes linked to angiogentic, signal transduction and 
immune responses, 2-hPG CpGs’ representative ontology encompasses lipid and carbohydrate 
metabolic processes, and neural cell signalling and growth pathways. This provides useful insight as to 
how these two different glucose measures contribute to the pathogenesis of the diabetic condition. 
 
 5.3 Limitations  
5.3.1 Bisufite Conversion  
One obvious limitation within all bisulfite-based DNA methylation studies is that bisulfite-conversions 
do not discriminate between 5-methylcytosine (5mC) and 5-hydroxy-methylcytosine (5hmC). As such, 
a CpG loci flagged as methylated by such technologies could be either 5mC or 5hmC. Currently, this 
can only be resolved through Tet-assisted bisulfite sequencing (Yu, Hon et al. 2012) – a technique 
which first protects the 5-hydroxymethyl group on the cytosine, and Tet1 conversion of 5mC to 5-
carboxyl-cytosine (5caC) before subsequent bisufite treatment and PCR, which converts both cytosine 
and 5caC to thymine, leaving only 5hmC nucleotides as cytosines post PCR; or the use of 5hmC-specific 
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antibodies in a fashion similar to MeDIP (HMeDIP)1 (Cingolani, Cao et al. 2013). Fortunately, while 
5hmC is found in the highest concentrations within brain cells such as Purkinje and granule cells 
(Kriaucionis and Heintz 2009)2, it does not seem to be found in observable quantities in human T cells 
(Tahiliani, Koh et al. 2009)3 or cancer cell lines (Kriaucionis and Heintz 2009). Moreover, in cells 
where a high proportion of 5hmC is found, the proportion of 5mC over 5hmC is still largely over-
representative of 5mC by more than tenfold. It is worth noting however, that no study to date has 
investigated the proportion of 5hmC within the whole umbilical cord, or cell types within cord itself. 
5.3.2 Cellular Heterogeneity 
Another limitation in context of umbilical cords would be cellular heterogeneity. The measured 
epigenome varies tissue-specifically, hence a homogeneous biological sample (such as that from a cell 
culture) would exhibit less DNA methylation variability over the same genomic loci as compared to 
one from a clinical sample. However, the obvious limitation would be sample preparation – conducting 
cell sorting on hundreds of clinical samples to obtain a homogeneous cell type would not only be 
economically and chronologically expensive, the eventual cellular fraction might not possess sufficient 
biological material for subsequent downstream analysis. In this regard, cell type composition is factored 
into the analysis within the thesis. Granted however the DNA methylation profiles were obtained from 
GEO accession databases of most closely related cell types, this can be better refined through targeted 
DNA methylation profiling of major cell types which are found within umbilical cords. In such context, 
given that mast cells is one of the cell types present within the cord, gene enrichments related to mast 
cell metabolism (Parity study) would have to be further validated before substantial claims can be made 
with respect to it.  
 
1
 Another variant would be Pvu-Seq – after the enzyme PvuRts1I, which cleaves near single 5hmC sites, allowing 
for enrichment of 5hmC DNA fragments. 
2
 0.6% of all nucleotides in Purkinje, 0.2% granule. 
3
 Recently, there was a paper which describes changes within the 5hmC landscape in human embryonic stem cells 
and cord blood using HMeDIP technology (Sen et al. 2015, Epigenetics, 10, 607-621.). However, they failed to 
quantify the proportion of 5hmC within their samples. Moreover, wherein the group’s validation of 5hmC-ome 
was >89% in their first paper, in this paper, it dropped to <44%. This could be due to fickle antibody specificity. 
Regardless, it would seem more prudent to assume poor 5hmC-ylation in blood. 
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One confounder that is relatively difficult to adjust in this regard would be the potential presence of 
hypoblastic reminants – the yolk sac and allantois – cell types which exhibit drastically different DNA 
methylation profiles as compared to their epiblastic counterparts (Smith, Chan et al. 2012). Despite the 
relatively small proportion of such tissue-types within the cord, because they possess significantly 
different DNA methylation profiles, even a small proportion of such could change the overall sample 
DNA methylome profile. In this regard, clinical sampling protocol clearly dictates the collection of the 
mid-region of the umbilical cord – such tissue is normally located in close proximity to the infant. Given 
that an umbilical cord is approximately 50cm in length, the harvesting of a 5cm segment midway would 
potentially avoid hypoblastic tissue contamination. Notably the use of umbilical cords as a proxy for 
infant DNA methylome representation would most probably be less heterogeneous as compared to the 
placenta (which, on top of multiple cell types, also is divided into the maternal and fetal side), and 
provide more abundant biological material than cord blood or buccal swabs.  
5.3.3 Investigative Platform 
The Infinium450K array was primarily designed for cancer-related studies. This poses two unique 
challenges: (i) genomic loci represented by the Infinium450K would be biased towards oncogenic 
representation. This could explain the enrichments of differentially methylated regions having similar 
profiles to certain oncogenic pathologies. (ii) The microarray only surveys approximately 1.7% of 
genomic CpGs – limiting novel discovery of genomic loci which may be unique to metabolic disease 
but different from known oncogenic pathways. This is addressed in Section 5.4.1. 
5.3.4 Within the Parity Study 
Inherent within the Singapore clinical definition of parity, firstborn status beguiles the passive reader 
with respect to the obstetric history of the mother. Given the difference in health outcomes of a truly 
first-time mother (primigravida) as opposed to a mother who has previously experienced 
miscarriage/abortion but delivers her first successful child (nulliparous), one naturally expects the 
physiology of the maternal uterine environment to be somewhat different between the two groups. In 
this regard, one has to collect more in depth obstetric data to perform sub-group analysis. 
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5.3.5 Within the GDM study 
An obvious limitation within the GDM study is an ethnical one – mothers who have attained the 
threshold for clinically diagnosed GDM were treated for the pathology4. In this case, the criteria used 
for the clinical diagnosis was the WHO 1999. Wherein the OGTT data was obtained 26 weeks into 
gestation, the DNA methylome of the infant was obtained at birth. Moreover, mothers who were 
diagnosed as overtly diabetic (Type 2 diabetes) were excluded from the analysis. We do not discount 
the possibility that in the last trimester, the DNA methylome was altered by GDM treatment to reflect 
a more normative state, or that non-GDM mothers experienced a glucose dysfunction due to certain 
lifestyle factors. Nevertheless, we do note however, that most pregnancy-related hormones pass the 
point of inflexion5 by the start of the third trimester (exception being CRH), and that glucose levels 
(both fasting and postprandial) are more stable6. One possible concern is the lack of variation within 
the fasting plasma glucose concentrations of the GUSTO subjects as opposed to the 2h OGTT 
measurements – regardless of criteria employed, most mothers would have been diagnosed as GDM or 
not based on their 2h OGTT results. This could have resulted in lower genomic loci flagged as 
significantly differentially methylated as opposed to the 2h OGTT measurements. Nevertheless, we 
note that the inclusion of overtly diabetic subjects would not increase the fasting glucose measurements 
much. Moreover, the small sample sizes of extreme clinical measurements may introduce outliers which 
potentially skew results, introducing unwanted false positive signals. Notably, outside pregnancy, 
individuals possessing typical plasma glucose profiles that would have been diagnosed with GDM are 
typically classified as impaired glucose tolerance (WHO 1999). It is within the scope of impaired 




 Most through diet intervention. A small group were treated with insulin. 
5
 Greatest rate of change 
6
 In the case of postprandial glucose levels, there seems to be insignificant difference between the fluctuations 
within the second and third trimester – both are equally high. 


5.4 Project Prognosis 
To address the various limitations within GUSTO in her entirety, several projects are on-going. Firstly, 
various tissue-specific DNA methylation profiles are being established by a partner laboratory from 
clinical samples. Moreover, to increase interrogative depth and potential success of functional 
validation, we can adopt a Gene-Epigenome (GxE) analysis, incorporate other NGS technologies to 
survey the epigenome, as well as survey other biological samples to construct a comparative epigenomic 
profile within the same subject (such as the cord blood, cord and buccal swab of one infant) or within 
familial groups (such as comparing the epigenome of mother, father and child). Other projects I am 
currently involved in are briefly described below. 
5.4.1 NGS-based Technologies 
 
Figure 5.1: Boxplot representation of how the number of CpGs detected (Frequency) declines as a function of 
increasing minimum coverage (x-axis). The box plot whiskers represent the 97.5th and 2.5th percentile, the black 
diamond represent the average and the yellow line plots the average trend. 63 RRBS GUSTO samples were used 
in this plot. 
 
The main advantage of most NGS-based technologies over Illumina450K is their greatly enhanced 
genomic discovery potential. In particular, GUSTO has adopted RRBS to survey limited samples and 
is looking into methylC-seq to expand the interrogation of DNA methylome within the cohort. RRBS 
allows the surveying of CpG dense regions spanning several promoters and repeat regions, covering 
approximately 1% of the entire genome. Preliminary analysis reflected good correlation between RRBS 
and Infinium450K (Pan et al. 2012). However, we note that within the Parity and GDM studies, the 
effect sizes expected is typically very small. Hence, the sequencing depth required of NGS-based 


technologies would be necessarily very high to acquire sufficient resolution in order to make an accurate 
DNA methylation call. Due to the chemistry of Infinium450K microarrays, it is able to achieve 
resolutions typically within the range of under 5%. However, in RRBS, the higher the genomic coverage 
requirements, the number of CpGs with meaningful DNA methylation information exponentially 
decreases (Figure 5.1). This is inherent within RRBS technology itself, as there is much higher DNA 
sample library representation over the number of probes, the random sampling of DNA sample libraries 
would also result in reduced sample reproducibility. Testament to this, none of the most differentially 
methylated genomic loci within an initial discovery cohort based on RRBS-technology was achieved 
using Sequenom MassARRAY. 
The use of methylC-seq would be able to circumvent many limitations within RRBS. The selectivity of 
methylC-seq probes enables targeted genomic region investigation – such regions can be selected for 
known genomic regions of interest, or algorithmically selected based on certain genomic characteristics. 
Moreover, methylC-seq technology allows for >3million probes to be surveyed (as compared to 
<500,000 of Infinium450K). Notably, the sequencing nature of methylC-seq would still limit DNA 
methylation resolution calls based on sequencing depth, however, the targeted nature of this technology 
reduces the “random selection” nature of RRBS (and WGBS), thus provides more meaningful data over 





Methylome analysis of the Parity and GDM studies revealed potential mechanisms in which 
primogeniture and glucose dysregulation may impact future health of the offspring through methylation 
markers within the umbilical cord. These findings however are confounded by several limitations 
including lack of numerical population size due to small effect sizes, insufficient obstetric background 
(parity), and the cross-sectional nature of the study which did not allow the correlation of glucose 
readings to the evolving methylome (GDM). Nevertheless, they have highlighted several metabolic 
pathways in which the prenatal environment may impact on the developing fetus. In addition, the GDM 
study revealed significant areas of concern with respect to how GDM is diagnosed and the physiological 
mechanisms in which it effects. Given the rich phenotypic information available postpartum and the 
intended follow-up investigation of various DNA methylomes – this potentially could resolve causality 
between epigenetic marks and environmental influences, as well as provide substantial insight into 
mechanisms hypothesized within DOHaD. GUSTO is truly an exciting place and time to be conducting 
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Appendix I. Most Significantly Differentially Methylated CpGs in Firstborn Umbilical Cord DNA 
Table I. Top 50 most significantly differentially methylated CpGs with respect to firstborn status 
Probe ID Chr Position Annotation Gene CGI   95% C. I. P-value 
cg24125648 15 44092606 promoter  HYPK Shore -0.881 0.320 (0.197, 0.442) 3.61E-07 
cg27380292 13 20964888 Intergenic Intergenic Shore -0.683 0.241 (0.137, 0.344) 5.59E-06 
cg06666376 19 3480596 promoter  SMIM24 Shore -1.594 0.241 (0.137, 0.346) 6.58E-06 
cg13863764 1 11561908 exon  PTCHD2 Island -1.436 0.284 (0.160, 0.408) 8.09E-06 
cg03314013 15 60394017 Intergenic Intergenic Sea 3.319 -0.281 (-0.405, -0.157) 9.05E-06 
cg16530382 17 37123671 promoter  FBXO47 Sea -1.896 0.264 (0.146, 0.381) 1.20E-05 
cg06044662 16 30386144 promoter  MYLPF Shelf -0.565 0.239 (0.132, 0.346) 1.29E-05 
cg14120476 17 5988176 intron  WSCD1 Sea 1.785 -0.285 (-0.412, -0.157) 1.39E-05 
cg23263641 19 44128109 intron  CADM4 Shelf -1.546 0.278 (0.153, 0.404) 1.53E-05 
cg08923594 1 7462176 intron  CAMTA1 Sea -0.509 0.199 (0.109, 0.289) 1.53E-05 
cg00292312 1 7318138 intron  CAMTA1 Sea 1.229 -0.272 (-0.396, -0.148) 1.87E-05 
cg10262997 11 18654886 intron  SPTY2D1 Shore -1.026 0.275 (0.149, 0.401) 1.96E-05 
cg01081737 8 142238752 promoter  SLC45A4 Shore -1.390 0.272 (0.146, 0.398) 2.60E-05 
cg10837383 6 9096296 Intergenic Intergenic Sea 1.727 -0.275 (-0.402, -0.147) 2.62E-05 
cg20539816 17 5988249 intron  WSCD1 Sea 1.598 -0.273 (-0.400, -0.146) 2.76E-05 
cg23465650 5 158522899 intron  EBF1 Shore -0.838 0.256 (0.136, 0.375) 3.05E-05 
cg26898099 5 95192949 intron  C5orf27 Sea -1.589 0.253 (0.134, 0.371) 3.07E-05 
cg26032417 2 241185226 Intergenic Intergenic Island -0.900 0.271 (0.143, 0.399) 3.38E-05 
cg00235442 7 157408294 intron  PTPRN2 Shore -0.754 0.263 (0.139, 0.387) 3.39E-05 
cg26013975 4 74965755 promoter  CXCL2 Shore -0.877 0.253 (0.133, 0.372) 3.52E-05 
cg26740942 17 37123711 promoter  FBXO47 Sea -0.852 0.238 (0.125, 0.350) 3.62E-05 
cg20648501 8 61626832 intron  CHD7 Island -0.732 0.239 (0.126, 0.352) 3.69E-05 
cg19970086 13 113474413 intron  ATP11A Shore -0.356 0.235 (0.124, 0.346) 3.79E-05 
cg11924452 2 241185198 Intergenic Intergenic Island -1.114 0.272 (0.143, 0.401) 3.80E-05 
cg19397885 7 12444115 promoter  VWDE Shore -1.837 0.265 (0.139, 0.391) 3.81E-05 
	

cg24371425 1 11561497 exon  PTCHD2 Island -1.669 0.266 (0.140, 0.393) 4.09E-05 
cg01546563 8 11567189 intron  GATA4 Island 2.310 -0.236 (-0.350, -0.123) 4.47E-05 
cg01156295 5 138211184 promoter  LRRTM2 Sea -1.231 0.237 (0.123, 0.351) 4.65E-05 
cg10600889 17 37123767 promoter  FBXO47 Sea -1.358 0.237 (0.123, 0.350) 4.68E-05 
cg20119532 20 749581 promoter  SLC52A3 Sea 0.878 -0.267 (-0.396, -0.139) 4.75E-05 
cg16815157 10 80893922 intron  ZMIZ1 Sea 1.102 -0.255 (-0.377, -0.132) 4.83E-05 
cg09395562 3 123501051 intron  MYLK Sea -0.496 0.249 (0.129, 0.369) 4.93E-05 
cg11685843 4 176349171 Intergenic Intergenic Sea -2.823 0.265 (0.137, 0.393) 5.23E-05 
cg04120272 17 37123843 promoter  FBXO47 Sea -1.525 0.244 (0.126, 0.363) 5.42E-05 
cg02051688 11 111568985 intron  SIK2 Sea 1.087 -0.260 (-0.386, -0.134) 5.51E-05 
cg17328716 7 56516243 promoter  LOC650226 Shore -2.925 0.256 (0.132, 0.380) 5.53E-05 
cg09238000 8 142238452 5' UTR  SLC45A4 Shore -0.511 0.247 (0.127, 0.368) 6.10E-05 
cg23483799 11 18659383 Intergenic Intergenic Shelf 1.834 -0.260 (-0.388, -0.133) 6.53E-05 
cg15080361 2 134841337 Intergenic Intergenic Sea 1.123 -0.258 (-0.384, -0.131) 6.77E-05 
cg12088773 19 44128330 exon  CADM4 Sea -0.857 0.252 (0.128, 0.375) 6.92E-05 
cg13073302 17 637000 intron  FAM57A Shore 1.000 -0.251 (-0.374, -0.128) 7.00E-05 
cg06704518 8 11565530 5' UTR  GATA4 Island 2.439 -0.232 (-0.346, -0.118) 7.11E-05 
cg01224393 12 124272266 intron  DNAH10 Island -0.747 0.215 (0.109, 0.320) 7.12E-05 
cg10032599 16 51560612 Intergenic Intergenic Sea 1.684 -0.250 (-0.374, -0.126) 8.05E-05 
cg14203218 7 144107540 promoter  NOBOX Sea 2.533 -0.262 (-0.392, -0.131) 8.54E-05 
cg12058390 7 4885521 intron  RADIL Sea -1.100 0.231 (0.116, 0.345) 8.62E-05 
cg16844941 8 11555178 Intergenic Intergenic Island 2.316 -0.248 (-0.371, -0.124) 8.82E-05 
cg21579107 12 49783192 non-coding  LOC100335030 Island -0.753 0.248 (0.124, 0.372) 8.95E-05 
cg08847856 2 106184698 Intergenic Intergenic Sea 2.031 -0.251 (-0.377, -0.126) 9.05E-05 
cg01107240 16 74054182 Intergenic Intergenic Sea -0.937 0.251 (0.125, 0.377) 9.56E-05 
Legend: Chr – chromosome, CGI – Association of CpG with respect to CGIs,  – Mean DNA methylation of probe in firstborns subtracted by the mean DNA methylation of probe in non-
firstborns (value in absolute percentage),  – beta coefficient of regression term, 95% C.I. – 95% confidence interval of beta coefficient.. 
	

Appendix II. Differentially methylated Genomic Regions within the Parity Study  
Clusters of Significant Probes 
Several of the most differentially methylated Infinium450K probes with respect to firstborn status were 
clustered in small regions across the genome. A small subset of regions with high probe density and/or 
epigenetic mark annotations with a significant probe ( = 10-4) is represented below. 
ELL3/SERINC4/HYPK 
 
Figure II. Summary of the (A) genomic distribution, (B) methylation distribution and (C) inter-correlation of 
Infinium450K probes near the inter-junction of ELL3, SERINC4 and HYPK. Only probes significant ( = 0.05) 
after outlier correction are shown in (A). Cg24125648 has a p-value = 2.47 x 10-7. DNA methylation of firstborns 
are represented in yellow and non-firstborns in green. (C) Correlationship between all five outlier-corrected 
significant probes within the HYPK promoter/exon with respect to firstborn status. Squares on the diagonal right 
represent scatterplots of the methylation values; coloured circles on the diagonal left represent the magnitude of 
Pearson correlation coefficient from blue (correlation = 1) to white (correlation = 0). All correlations have p-value 




Cg24125648 is the most significant differentially methylated probe (p-value = 3.61 x 10-7) with respect 
to firstborn status, every standard deviation increase in DNA methylation of this CpG increases the odds 
of not being a firstborn by 0.320. Cg24125648 resides within the promoter/exon of Huntington 
Interacting Protein K (HYPK), 311bp upstream the Serine Incorporator 4 (SERINC4) transcription start 
site as well as 1,271bp upstream the Elongation Factor RNA Polymerase II-Like 3 (ELL3) transcription 
start site (Figure II.A). Four CpGs surveyed 1kbp downstream of cg24125648 (further down the HYPK 
gene) are not significantly differentially methylated with respect to firstborn status (data not shown) 
however four out of five CpGs surveyed 1kbp upstream of cg24125648 are significant even after outlier 
correction (Figure II.B; cg02556940, filtered; cg13793048,  = 0.1256, p-value = 0.0358; cg26552774, 
 = 0.1510, p-value = 0.0153; cg02394812,  = 0.1662, p-value = 4.52 x 10-3). Intriguingly, the 
correlation between these five CpGs suggest good correlation between the first four CpGs (Figure II.C; 
rmax = 0.555, rmin = 0.138, all 6 intercorrelations amongst the first four CpGs p < 0.001), but not so much 
with the most significantly methylated CpG with respect to firstborn status. Suggestively, cg02556940 
is the only probe located after the transcription start site of SERINC4 out of the five – thus it could be 
that the first three/four probes are more closely associated with the regulation of SERINC4 and the latter 
two/singular probe that of HYPK. All five probes also suggest hypomethylation in the firstborn (as well 




Appendix III. Gene Ontology Enrichments (Parity Study) with respect to tissue-specific 
functionality  
CpGs with p < 10-3 were categorised into nine general tissue/cell types based on their GenoSkyline 
tissue-specific functionality scores and analysed for gene ontology enrichments using missMethyl – an 
R package specifically designed for Infinium450K microarrays. The gene ontology enrichment output 
was then channelled into Revigo – an ontology visualizer, which summarises the ontology enrichment 
results into representative ontologies.  
Blood  
167 out of 417 CpGs with p < 10-3 were classified as possessing blood-related functionality. 
Table III.I Gene Onotology Summary of significant Blood-related CpGs  
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195 out of 417 CpGs with p < 10-3 were classified as possessing brain tissue-related functionality. 
Table III.II Gene Onotology Summary of significant Brain-related CpGs   
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204 out of 417 CpGs with p < 10-3 were classified as possessing epithelium-related functionality. 
Table III.III Gene Onotology Summary of significant Epithelium-related CpGs   
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Embryonic Stem Cells (ESC) 
187 out of 417 CpGs with p < 10-3 were classified as possessing ESC-related functionality. 
Table III.IV Gene Onotology Summary of significant ESC-related CpGs   
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309 out of 417 CpGs with p < 10-3 were classified as possessing fetal tissue-related functionality. 
Table III.V Gene Onotology Summary of significant Fetal tissue-related CpGs   
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228 out of 417 CpGs with p < 10-3 were classified as possessing GI tissue-related functionality. 
Table III.VI Gene Onotology Summary of significant GI-related CpGs   
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186 out of 417 CpGs with p < 10-3 were classified as possessing heart tissue-related functionality. 
Table III.VII Gene Onotology Summary of significant Heart-related CpGs   
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150 out of 417 CpGs with p < 10-3 were classified as possessing pulmonary tissue-related 
functionality. 
Table III.VIII Gene Onotology Summary of significant Lung-related CpGs   
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188 out of 417 CpGs with p < 10-3 were classified as possessing muscle tissue-related functionality. 
Table III.IX Gene Onotology Summary of significant Muscle-related CpGs   
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Appendix IV. Top 50 most significantly differentiated CpGs with respect to fasting plasma glucose levels with complementary p-values with respect 
to 2h post glucose challenge plasma glucose levels  
Table IV. Top 50 most significantly differentially methylated CpGs with respect to FPG 




95% C.I. 2-hPG P 
cg26549330 22 46471442 Intergenic Intergenic Shelf 0.0612 0.399 -0.133 (-0.182, -0.083) 1.75E-07 -0.082 
(-0.131, -
0.033) 1.16E-03 
cg05033701 2 127904972 Intergenic Intergenic Sea 0.0685 0.379 0.099 (0.061, 0.137) 3.66E-07 0.050 
(0.012, 
0.088) 1.07E-02 
cg20342079 12 25055381 promoter BCAT1 Shore 0.0583 0.336 0.122 (0.073, 0.171) 1.46E-06 0.034 
(-0.015, 
0.083) 1.77E-01 
cg11574055 1 117077116 intron CD58 Island 0.0511 0.235 0.149 (0.088, 0.210) 1.89E-06 0.073 
(0.012, 
0.134) 1.85E-02 
cg02974976 1 117077219 intron CD58 Island 0.0552 0.282 0.140 (0.081, 0.199) 3.20E-06 0.060 
(0.002, 
0.119) 4.44E-02 
cg05753799 20 3746315 intron C20orf27 Shore 0.0482 0.265 0.123 (0.070, 0.177) 5.98E-06 0.091 
(0.038, 
0.144) 7.94E-04 
cg00830767 16 19098198 Intergenic Intergenic Island 0.0521 0.243 -0.148 (-0.211, -0.084) 6.07E-06 -0.056 
(-0.120, 
0.007) 8.31E-02 
cg17638213 13 114164151 intron TMCO3 Shore 0.0301 0.205 0.123 (0.070, 0.176) 6.12E-06 -0.005 
(-0.058, 
0.048) 8.60E-01 
cg19374752 12 52404151 promoter GRASP Shelf 0.0449 0.330 0.076 (0.042, 0.109) 1.22E-05 0.053 
(0.019, 
0.086) 2.09E-03 
cg04846203 1 167690438 promoter MPZL1 Shore 0.0283 0.204 -0.137 (-0.198, -0.076) 1.26E-05 -0.055 
(-0.116, 
0.006) 7.79E-02 
cg25953417 6 30690712 exon TUBB Shore 0.0513 0.359 -0.123 (-0.178, -0.068) 1.29E-05 -0.031 
(-0.086, 
0.024) 2.67E-01 
cg23584087 13 33626629 intron KL Sea 0.0747 0.493 -0.135 (-0.197, -0.074) 1.88E-05 -0.059 
(-0.120, 
0.003) 6.14E-02 
cg23703079 12 113016393 Intergenic Intergenic Shelf 0.0462 0.253 -0.136 (-0.199, -0.074) 2.15E-05 -0.087 
(-0.149, -
0.025) 6.32E-03 
cg01494454 12 25055214 5' UTR BCAT1 Shore 0.0585 0.305 0.124 (0.067, 0.182) 2.54E-05 0.066 
(0.009, 
0.123) 2.44E-02 
cg08111857 17 40840012 intron CNTNAP1 Island 0.0498 0.277 0.131 (0.070, 0.193) 2.64E-05 0.072 
(0.011, 
0.133) 2.08E-02 






cg23462305 5 536783 promoter MIR4456 Shore 0.0988 0.319 -0.143 (-0.209, -0.076) 2.81E-05 -0.085 
(-0.151, -
0.019) 1.22E-02 
cg06738786 20 19265058 non-coding LOC100130264 Sea 0.0818 0.481 -0.121 (-0.177, -0.064) 3.12E-05 -0.070 
(-0.126, -
0.013) 1.58E-02 
cg08849095 9 97846048 intron C9orf3 Shelf 0.0468 0.290 -0.129 (-0.189, -0.068) 3.31E-05 -0.087 
(-0.147, -
0.026) 4.85E-03 
cg08724310 12 25055304 promoter BCAT1 Shore 0.0655 0.358 0.110 (0.058, 0.162) 3.59E-05 0.013 
(-0.039, 
0.065) 6.14E-01 
cg17039022 1 203595145 promoter ATP2B4 Shelf 0.299 0.721 0.138 (0.073, 0.204) 3.81E-05 0.009 
(-0.057, 
0.074) 7.90E-01 
cg15328703 12 126142896 3' UTR TMEM132B Sea 0.0451 0.362 -0.124 (-0.183, -0.065) 4.03E-05 -0.034 
(-0.093, 
0.025) 2.57E-01 
cg25685359 22 46473721 Intergenic Intergenic Sea 0.0881 0.493 -0.122 (-0.180, -0.064) 4.22E-05 -0.094 
(-0.152, -
0.036) 1.49E-03 
cg12217625 1 159825628 promoter C1orf204 Shore 0.0713 0.349 0.121 (0.063, 0.179) 4.42E-05 0.067 
(0.009, 
0.124) 2.31E-02 
cg20687940 11 63753228 promoter OTUB1 Shore 0.0494 0.260 -0.120 (-0.178, -0.062) 4.96E-05 -0.090 
(-0.148, -
0.033) 2.04E-03 
cg11360546 7 1094263 intron C7orf50 Shelf 0.0693 0.347 0.114 (0.059, 0.169) 5.05E-05 0.050 
(-0.005, 
0.105) 7.43E-02 
cg14780084 1 28096753 Intergenic Intergenic Shelf 0.0255 0.134 0.123 (0.063, 0.183) 5.98E-05 0.022 
(-0.038, 
0.082) 4.75E-01 
cg18280126 11 57235389 exon RTN4RL2 Shelf 0.0844 0.404 0.105 (0.054, 0.156) 6.24E-05 0.080 
(0.030, 
0.131) 1.97E-03 
cg03938043 1 212207851 intron INTS7 Shore 0.0643 0.332 -0.117 (-0.174, -0.060) 6.27E-05 -0.078 
(-0.134, -
0.021) 7.47E-03 
cg22383874 17 48670670 intron CACNA1G Sea 0.0485 0.244 0.118 (0.061, 0.176) 6.31E-05 0.080 
(0.023, 
0.138) 6.37E-03 
cg04404304 8 141248921 intron TRAPPC9 Sea 0.0717 0.432 0.100 (0.051, 0.150) 6.43E-05 0.037 
(-0.012, 
0.086) 1.36E-01 
cg24092253 20 61848099 promoter YTHDF1 Island 0.0401 0.235 -0.108 (-0.162, -0.055) 6.70E-05 -0.051 
(-0.104, 
0.002) 5.70E-02 
cg12675571 5 148808721 TTS MIR143 Sea 0.064 0.352 -0.105 (-0.156, -0.054) 6.72E-05 -0.082 
(-0.133, -
0.031) 1.59E-03 
cg09577455 6 29593382 intron GABBR1 Shore 0.055 0.245 0.130 (0.066, 0.194) 7.25E-05 0.092 
(0.028, 
0.155) 4.65E-03 
cg13101330 14 79799891 intron NRXN3 Sea 0.0621 0.323 0.126 (0.064, 0.188) 7.65E-05 0.040 
(-0.022, 
0.101) 2.10E-01 
cg06473363 6 31631797 exon GPANK1 Shore 0.0493 0.303 -0.105 (-0.157, -0.053) 7.66E-05 -0.071 
(-0.122, -
0.019) 7.28E-03 






cg02245467 8 20112813 promoter LZTS1 Sea 0.0452 0.218 0.115 (0.058, 0.172) 8.68E-05 0.033 
(-0.024, 
0.090) 2.57E-01 
cg08170911 3 53202324 intron PRKCD Sea 0.0401 0.219 0.120 (0.060, 0.179) 8.73E-05 0.040 
(-0.019, 
0.099) 1.86E-01 
cg14861570 17 53499954 promoter MMD Shore 0.0416 0.246 -0.129 (-0.193, -0.065) 8.80E-05 -0.088 
(-0.151, -
0.024) 7.14E-03 
cg14601621 9 97848457 promoter MIR3074 Island 0.075 0.330 -0.130 (-0.196, -0.065) 8.87E-05 -0.082 
(-0.147, -
0.017) 1.30E-02 
cg21246872 17 38295894 promoter CASC3 Sea 0.0517 0.287 -0.122 (-0.183, -0.061) 8.89E-05 -0.088 
(-0.148, -
0.027) 4.49E-03 
cg00211661 11 72433619 promoter ARAP1 Sea 0.0281 0.148 -0.124 (-0.186, -0.062) 9.19E-05 -0.081 
(-0.142, -
0.019) 0.010164 
cg00016439 18 55018650 Intergenic Intergenic Shore 0.0461 0.230 -0.118 (-0.177, -0.059) 9.32E-05 -0.081 
(-0.140, -
0.022) 0.006806 
cg10012623 14 65441407 intron CHURC1-FNTB Shelf 0.0792 0.433 0.092 
(0.046, 
0.138) 9.46E-05 0.014 
(-0.032, 
0.060) 0.546971 
cg15160524 2 218771426 intron TNS1 Sea 0.0352 0.180 -0.124 (-0.186, -0.062) 9.51E-05 -0.124 
(-0.186, -
0.063) 7.93E-05 
cg06962684 18 34839039 intron CELF4 Sea 0.0682 0.421 0.124 (0.062, 0.186) 9.65E-05 0.003 
(-0.059, 
0.065) 0.920335 
cg14722290 11 3144774 intron OSBPL5 Shelf 0.0269 0.152 -0.123 (-0.184, -0.061) 9.83E-05 -0.069 
(-0.130, -
0.008) 0.027157 
cg15683166 10 124611000 intron FAM24B Sea 0.0481 0.398 -0.122 (-0.184, -0.061) 9.86E-05 -0.127 
(-0.188, -
0.067) 4.12E-05 
cg03825810 3 38888170 3' UTR SCN11A Sea 0.0407 0.211 -0.122 (-0.183, -0.061) 0.0001 -0.082 
(-0.142, -
0.021) 0.008539 
Legend: Chr – chromosome, CGI – Association of CpG with respect to CGIs, IQR – Interquartile range of DNA methylation of all CpGs in this probe, Range – maximum DNA methylation 




Appendix V. Significantly differentiated DMRs with respect to fasting plasma glucose levels (p-
value < 10-4)  
ARAP1 Promoter 
 
Figure V.I. ARAP1 promoter DMR. (A) Genomic location of the DMR with respect to the ARAP1 gene. (B) 
Inter-correlationship of individual Infinium450K probes within the DMR. 
 
The ARAP1 promoter-associated DMR comprises of five Infinium probes (cg18769818, cg01381367, 
cg0021661, cg10589860 and cg00350448) spanning 808bp (p-value = 2.75 x 10-5) (Figure V.I.A). This 
DMR also overlapping rs1552224, the SNP significantly associated with type 2 diabetes and fasting 
plasma glucose levels. All five individual probes show high intercorrelation (Pearson correlation = 




Figure V.II. YTHDF1 promoter DMR. (A) Genomic location of the DMR with respect to the YTHDF1 gene. (B) 
Inter-correlationship of individual Infinium450K probes within the DMR. 
 
The YTH Domain-containing Family protein 1 (YTHDF1) promoter-associated DMR comprises of six 





spanning 1375bp (p-value = 4.19 x 10-5) (Figure V.II.A). Wherein the last two individual probes show 





Figure V.III. BCKDK promoter DMR. (A) Genomic location of the DMR with respect to the BCKDK gene. (B) 
Inter-correlationship of individual Infinium450K probes within the DMR. 
 
The Branched Chain Ketoacid Dehydrogenase Kinase (BCKDK) promoter-associated DMR comprises 
of three Infinium probes (cg08374890, cg20527168 and cg03984055) spanning 252bp (p-value = 4.32 
x 10-5) (Figure V.III.A). All three individual probes show high intercorrelation (Pearson correlation = 
0.336-0.556) (Figure V.III.B). 
 
Intergenic region downstream of COQ7 
 
Figure V.IV. Intergenic region downstream of COQ7 DMR. (A) Genomic location of the DMR with respect to 
the COQ7 gene. (B) Inter-correlationship of individual Infinium450K probes within the DMR. 
 
This DMR, located 5619bp downstream the Coenzyme Q biosynthesis protein 7 (COQ7) gene, 




5.10 x 10-5) (Figure V.IV.A). All three individual probes are weakly intercorrelated (Pearson correlation 
= 0.082-0.302) (Figure V.IV.B). 
 
TMCO3 exon  
 
Figure V.V. TMCO3 exon DMR. (A) Genomic location of the DMR with respect to the TMCO3 gene. (B) Inter-
correlationship of individual Infinium450K probes within the DMR. 
 
The Transmembrane and Coiled-coil Domains 3 (TMCO3) exon 7-associated DMR comprises of five 
Infinium probes (cg26715170, cg17638213, cg20022454, cg22448360 and cg12030328) spanning 
2784bp (p-value = 5.95 x 10-5) (Figure V.V.A). All five probes were weakly intercorrelated (Pearson 




Figure V.VI. MIRLET7BHG intron DMR. (A) Genomic location of the DMR with respect to the MIRLET7BHG 
gene. (B) Inter-correlationship of individual Infinium450K probes within the DMR. 
 
The MircoRNA Let-7B Host Gene (MIRLET7BHG) intron-associated DMR comprises of five 




2352bp (p-value = 6.25 x 10-5) (Figure V.VI.A). All five individual probes show relatively high 




Figure V.VII. TGFBR3 intron DMR. (A) Genomic location of the DMR with respect to the TGFBR3 gene. (B) 
Inter-correlationship of individual Infinium450K probes within the DMR. 
 
The Transforming Growth Factor, Beta Receptor III (TGFBR3) intron 1-associated DMR comprises of 
four Infinium probes (cg00342358, cg01336162, cg17074704 and cg26542412) spanning 457bp (p-
value = 7.56 x 10-5) (Figure V.VII.A). Intercorrelation was highest amongst the individual probes 




Figure V.VIII. MYO1A promoter DMR. (A) Genomic location of the DMR with respect to the MYO1A gene. 





The Myosin 1A (MYO1A) promoter-associated DMR comprises of three Infinium probes 
(cg22614532, cg09541248 and cg01514487) spanning 691bp (p-value = 8.85 x 10-5) (Figure V.VIII.A). 




Figure V.XI. KCNIP4 promoter DMR. (A) Genomic location of the DMR with respect to the KCNIP4 gene. (B) 
Inter-correlationship of individual Infinium450K probes within the DMR. 
 
The Kv Channel Interacting Protein 4 (KCNIP4) promoter-associated DMR comprises of eight Infinium 
probes (cg0327161, cg08125031, cg23452289, cg18308184, cg26748440, cg27526346, cg11612852 
and cg23330788) spanning 780bp (p-value = 9.68 x 10-5) (Figure V.XI.A). Save the weakly 
intercorrelated terminal probe, all seven other probes show high inter-correlationship (Pearson 
coefficient = 0.605-0.835) (Figure V.XI.B).

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Appendix VI. Top 50 most significantly differentiated CpGs with respect to 2h post glucose challenge plasma glucose levels with complementary p-
values with respect to fasting plasma glucose levels 
Table VI. Top 50 most significantly differentially methylated CpGs with respect to 2-hPG 
Probe ID Chr Position Annotation Gene CGI IQR Range 2-hPG  2-hPG 95% C.I. 2-hPG P FPG  
FPG 95% 
C.I. FPG P 
cg11669606 5 36741478 Intergenic Intergenic Shelf 0.0302 0.150 -0.158 (-0.220, -0.096) 6.35E-07 -0.028 
(-0.092, 
0.036) 3.88E-01 
cg16133500 10 133357247 Intergenic Intergenic Sea 0.0328 0.145 -0.157 (-0.221, -0.093) 2.01E-06 -0.075 
(-0.141, -
0.009) 2.52E-02 
cg25092764 11 70912368 intron SHANK2 Sea 0.0256 0.136 -0.145 (-0.208, -0.082) 6.60E-06 -0.027 
(-0.091, 
0.037) 4.08E-01 
cg14354820 8 41691767 intron ANK1 Sea 0.0265 0.134 -0.147 (-0.211, -0.083) 7.71E-06 0.005 
(-0.060, 
0.071) 8.70E-01 
cg01140985 16 71843559 promoter AP1G1 Shore 0.0484 0.347 -0.090 (-0.129, -0.051) 8.60E-06 -0.023 
(-0.064, 
0.017) 2.54E-01 
cg10567378 6 38145232 intron BTBD9 Sea 0.0722 0.421 0.095 (0.053, 0.137) 9.64E-06 0.081 
(0.039, 
0.124) 1.90E-04 
cg14228614 8 58909645 intron FAM110B Shore 0.0920 0.430 -0.133 (-0.192, -0.074) 1.13E-05 -0.063 
(-0.123, -
0.003) 4.08E-02 
cg10034808 8 99380162 Intergenic Intergenic Sea 0.0810 0.450 0.115 (0.064, 0.165) 1.16E-05 0.071 
(0.019, 
0.123) 7.13E-03 
cg17510567 8 47171826 Intergenic Intergenic Sea 0.0400 0.245 -0.138 (-0.200, -0.077) 1.19E-05 -0.007 
(-0.070, 
0.056) 8.31E-01 
cg27142530 4 187266705 intron F11-AS1 Sea 0.0537 0.275 -0.140 (-0.202, -0.077) 1.20E-05 -0.065 
(-0.128, -
0.001) 4.64E-02 
cg14981819 7 96597711 TTS DLX6-AS1 Sea 0.0507 0.269 -0.136 (-0.198, -0.074) 1.80E-05 -0.064 
(-0.127, -
0.001) 4.78E-02 
cg11515095 11 132949437 intron OPCML Shelf 0.0273 0.142 -0.139 (-0.203, -0.075) 2.13E-05 -0.029 
(-0.094, 
0.036) 3.88E-01 
cg19296520 15 42067443 non-coding MAPKBP1 Shore 0.0547 0.296 -0.096 (-0.141, -0.052) 2.26E-05 -0.046 
(-0.091, -
0.001) 4.67E-02 
cg26838787 12 132842005 intron GALNT9 Shore 0.0362 0.191 -0.134 (-0.195, -0.072) 2.37E-05 -0.043 
(-0.106, 
0.020) 1.84E-01 
cg23542533 3 126500809 intron CHCHD6 Sea 0.0603 0.422 0.089 (0.048, 0.130) 2.47E-05 0.059 
(0.018, 
0.101) 5.30E-03 





cg23959474 17 40195832 Intergenic Intergenic Shelf 0.0299 0.158 -0.134 (-0.196, -0.071) 2.87E-05 -0.034 
(-0.097, 
0.030) 2.99E-01 
cg20724690 2 231584368 intron CAB39 Sea 0.0375 0.185 -0.136 (-0.199, -0.072) 2.90E-05 -0.095 
(-0.160, -
0.031) 3.82E-03 
cg02006082 7 7111826 Intergenic Intergenic Sea 0.0362 0.312 -0.128 (-0.188, -0.068) 2.93E-05 -0.044 
(-0.105, 
0.017) 1.58E-01 
cg06945634 8 30413794 intron RBPMS Sea 0.0288 0.134 -0.133 (-0.196, -0.071) 3.11E-05 -0.079 
(-0.142, -
0.015) 1.57E-02 
cg01759112 17 5980904 intron WSCD1 Sea 0.0423 0.184 -0.135 (-0.199, -0.072) 3.25E-05 -0.069 
(-0.134, -
0.004) 3.65E-02 
cg19735804 7 142421812 Intergenic Intergenic Sea 0.0903 0.467 -0.127 (-0.186, -0.067) 3.26E-05 -0.042 
(-0.103, 
0.019) 1.73E-01 
cg19775718 7 117065034 intron ASZ1 Shelf 0.0377 0.243 -0.129 (-0.190, -0.068) 3.29E-05 -0.016 
(-0.078, 
0.046) 6.07E-01 
cg09585333 11 65340843 exon FAM89B Shore 0.0633 0.395 -0.108 (-0.159, -0.057) 3.33E-05 -0.062 
(-0.114, -
0.010) 1.90E-02 
cg07912020 2 2713385 Intergenic Intergenic Sea 0.0261 0.136 -0.132 (-0.194, -0.070) 3.42E-05 -0.037 
(-0.100, 
0.027) 2.55E-01 
cg21482290 17 77395837 intron RBFOX3 Sea 0.0453 0.246 -0.122 (-0.179, -0.064) 3.48E-05 -0.060 
(-0.119, -
0.001) 4.45E-02 
cg05846798 10 131142538 Intergenic Intergenic Sea 0.0281 0.155 -0.131 (-0.193, -0.069) 3.62E-05 -0.022 
(-0.085, 
0.041) 5.01E-01 
cg10336935 20 55969282 intron RBM38 Shelf 0.0428 0.212 -0.125 (-0.184, -0.066) 3.91E-05 -0.073 
(-0.134, -
0.013) 1.73E-02 
cg08116408 6 30112776 intron TRIM40 Sea 0.0623 0.312 -0.128 (-0.189, -0.067) 3.93E-05 -0.031 
(-0.093, 
0.031) 3.23E-01 
cg15683166 10 124611000 intron FAM24B Sea 0.0481 0.398 -0.127 (-0.188, -0.067) 4.12E-05 -0.122 
(-0.184, -
0.061) 9.86E-05 
cg25457064 19 3825390 exon ZFR2 Island 0.0389 0.199 -0.133 (-0.196, -0.069) 4.22E-05 -0.050 
(-0.115, 
0.014) 1.26E-01 
cg03803861 5 41511150 promoter PLCXD3 Shore 0.0488 0.319 -0.131 (-0.194, -0.069) 4.24E-05 -0.063 
(-0.126, 
0.001) 5.40E-02 
cg02397205 12 117796245 intron NOS1 Shore 0.0358 0.179 -0.132 (-0.195, -0.069) 4.30E-05 -0.022 
(-0.087, 
0.042) 4.93E-01 
cg21382382 4 174452961 intron HAND2-AS1 Island 0.0633 0.339 0.137 (0.071, 0.202) 4.39E-05 0.100 
(0.034, 
0.166) 3.20E-03 
cg22963629 7 31147341 3' UTR ADCYAP1R1 Sea 0.0425 0.398 -0.127 (-0.187, -0.066) 4.62E-05 -0.063 
(-0.125, -
0.001) 4.66E-02 
cg08978092 5 108023428 Intergenic Intergenic Sea 0.1020 0.635 -0.126 (-0.186, -0.065) 4.67E-05 -0.060 
(-0.124, 
0.004) 6.81E-02 





cg11942603 2 69969794 intron ANXA4 Shore 0.0714 0.512 -0.114 (-0.168, -0.059) 4.79E-05 -0.085 
(-0.140, -
0.029) 2.72E-03 
cg16405768 20 61290066 exon SLCO4A1 Island 0.0305 0.143 -0.126 (-0.187, -0.065) 4.92E-05 0.019 
(-0.043, 
0.081) 5.44E-01 
cg18042043 19 44147545 Intergenic Intergenic Shelf 0.0552 0.303 -0.121 (-0.180, -0.063) 4.97E-05 -0.072 
(-0.132, -
0.013) 1.71E-02 
cg17153382 8 59570327 intron NSMAF Shore 0.0320 0.145 -0.134 (-0.199, -0.070) 5.03E-05 -0.063 
(-0.129, 
0.002) 5.88E-02 
cg11985116 2 1567042 Intergenic Intergenic Sea 0.0264 0.170 -0.129 (-0.192, -0.067) 5.10E-05 -0.003 
(-0.067, 
0.061) 9.26E-01 
cg17971290 1 245915294 intron SMYD3 Sea 0.0765 0.393 0.109 (0.056, 0.161) 5.11E-05 0.072 
(0.019, 
0.126) 7.93E-03 
cg11306735 19 49943812 intron SLC17A7 Shore 0.0371 0.202 -0.131 (-0.194, -0.068) 5.30E-05 -0.030 
(-0.094, 
0.035) 3.63E-01 
cg18100753 8 1356513 Intergenic Intergenic Shore 0.0455 0.351 -0.128 (-0.190, -0.066) 5.30E-05 -0.041 
(-0.104, 
0.022) 1.99E-01 
cg18467922 13 112837161 Intergenic Intergenic Sea 0.0314 0.159 -0.125 (-0.186, -0.065) 5.39E-05 -0.072 
(-0.134, -
0.010) 2.23E-02 
cg26477169 17 75196864 intron SEC14L1 Sea 0.0724 0.462 -0.106 (-0.158, -0.055) 5.50E-05 -0.015 
(-0.068, 
0.038) 5.78E-01 
cg09925075 14 60098793 intron RTN1 Shore 0.0476 0.220 -0.133 (-0.198, -0.069) 5.59E-05 -0.020 
(-0.086, 
0.046) 5.61E-01 
cg04599158 7 142363376 Intergenic Intergenic Sea 0.0535 0.384 -0.127 (-0.189, -0.066) 5.64E-05 -0.084 
(-0.147, -
0.021) 8.87E-03 
cg21512950 12 121057469 Intergenic Intergenic Sea 0.0368 0.248 -0.128 (-0.190, -0.066) 5.79E-05 -0.097 
(-0.160, -
0.034) 2.61E-03 
Legend: Chr – chromosome, CGI – Association of CpG with respect to CGIs, IQR – Interquartile range of DNA methylation of all CpGs in this probe, Range – maximum DNA methylation 
value subtracted by the minimum value, 2-hPG – 2-h plasma glucose,  – beta regression coefficient, 95% C.I. – 95% confidence interval, P – p-value, FPG – Fasting Plasma Glucose. 
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Appendix VII. Significantly differentiated DMRs with respect to 2h post glucose challenge 
plasma glucose levels (p-value < 10-4)  
 
ADCYAP1R1 terminal exon 
 
Figure VII.I. ADCYAP1R1 terminal exon DMR. (A) Genomic location of the DMR with respect to the 
ADCAP1R1 gene. (B) Inter-correlationship of individual Infinium450K probes within the DMR. 
 
The Adenylate Cyclase Activating Polypeptide 1 (Pituitary) Receptor Type 1 (ADCYAP1R1) 
promoter-associated DMR comprises of three Infinium probes (cg10000602, cg09327253 and 
cg22963629) spanning 49bp (p-value = 7.74 x 10-6) (Figure VII.I.A). All three probes appear to be 




Figure VII.II. IRX4 promoter/exon DMR. (A) Genomic location of the DMR with respect to the IRX4 gene. (B) 
Inter-correlationship of individual Infinium450K probes within the DMR. 
 
The Iroquois Homeobox 4 (IRX4) promoter/exon-associated DMR (promoter for two transcripts, 2nd 
exon for four transcripts) comprises of five Infinium probes (cg13974394, cg07733257, cg24937747, 
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
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cg02641288 and cg23121993) spanning 1767bp (p-value = 1.21 x 10-5) (Figure VII.II.A). These 
individual probes either do not appear to be or are weakly intercorrelated (highest Pearson correlation 




Figure VII.III. AP1G1 promoter DMR. (A) Genomic location of the DMR with respect to the AP1G1 gene. (B) 
Inter-correlationship of individual Infinium450K probes within the DMR. 
 
The Adapter-Related Protein Complex 1, Gamma 1 Subunit (AP1G1) promoter-associated DMR 
comprises of three Infinium probes (cg03865041, cg01140985 and cg10407113) spanning 982bp (p-
value = 1.80 x 10-5) (Figure VII.III.A). Individually, cg01140985 and cg10407113 are weakly 
intercorrelated (Pearson correlation = 0.209) but cg03865041 does not seem to be correlated with the 
other two probes (Figure VII.III.B). 
 
BTBD9 terminal intron 
 
Figure VII.IV. BTBD9 terminal intron DMR. (A) Genomic location of the DMR with respect to the BTBD9 gene. 




The BTB (POZ) Domain Containing 9 (BTBD9) terminal intron-associated DMR comprises of three 
Infinium probes (cg13442386, cg10567378 and cg11599864) spanning 340bp (p-value = 2.30 x 10-5) 
(Figure 4.9.4A). All three individual probes are highly intercorrelated (Pearson correlation = 0.749-
0.779) (Figure VII.IV.B). 
 
OPCML first intron 
 
Figure VII.V. OPCML first intron DMR. (A) Genomic location of the DMR with respect to the OPCML gene. 
(B) Inter-correlationship of individual Infinium450K probes within the DMR. 
 
The Opioid Binding Protein/Cell Adhesion Molecule-Like (OPCML) intron 1-associated DMR 
comprises of eight Infinium probes (cg14535138, cg24437089, cg17142091, cg26626251, 
cg08357627, cg11515095, cg15702349 and cg07214967) spanning 3087bp (p-value = 3.65 x 10-5) 
(Figure VII.V.A). All eight probes appear to be intercorrelated (Pearson correlation = 0.122-0.392) 
(Figure VII.V.B). 
 
SNED1 first intron 
 
Figure VII.VI. SNED1 first intron DMR. (A) Genomic location of the DMR with respect to the SNED1 gene. (B) 





The Sushi, Nidogen And EGF-Like Domains 1 (SNED1) intron 1-associated DMR comprises of three 
Infinium probes (cg11046579, cg24401641 and cg18467041) spanning 157bp (p-value = 4.50 x 10-5) 
(Figure VII.VI.A). All three probes appear to be weakly intercorrelated (Pearson correlation = 0.221-
0.391) (Figure VII.VI.B). 
 
NR1H2 terminal exon 
 
Figure VII.VII. NR1H2 terminal exon DMR. (A) Genomic location of the DMR with respect to the NR1H2 gene. 
(B) Inter-correlationship of individual Infinium450K probes within the DMR. 
 
The Nuclear Receptor Subfamily 1, Group H, Member 2 (NR1H2) terminal exon-associated DMR 
comprises of three Infinium probes (cg06965177, cg19438699 and cg13476044) spanning 1537bp (p-
value = 6.12 x 10-5) (Figure VII.VII.A). All three probes appear to be intercorrelated (Pearson 
correlation = 0.276-0.383) (Figure VII.VII.B). 
 
Intergenic region downstream of AX747408 
 
Figure VII.VIII. Intergenic region downstream of AX747408 DMR. (A) Genomic location of the DMR with 





This DMR, 27,014bp downstream of the putative mRNA AX747408 (Homo sapiens cDNA FLJ34886 
fis, clone NT2NE2016766, weakly similar to Mus musculus nuclear localization signal binding protein 
(spot-1) mRNA), comprises of three Infinium probes (cg05563662, cg22704845 and cg18800771) 
spanning 1002bp (p-value = 9.96 x 10-5) (Figure VII.VIII.A). The first two probes are correlated 
(Pearson correlation = 0.658) but the third is not (Figure VII.VIII.B). 
